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Abstract
Interventions to reduce the risk of surgically transmitted
Creutzfeldt–Jakob disease: a cost-effective modelling review
Matt Stevensono ,1* Lesley Uttleyo ,1 Jeremy E Oakleyo ,2
Christopher Carrollo ,1 Stephen E Chicko 3 and Ruth Wongo 1
1School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK
2School of Mathematics and Statistics, University of Sheffield, Sheffield, UK
3INSEAD, Fontainebleau, France
*Corresponding author m.d.stevenson@sheffield.ac.uk
Background: Creutzfeldt–Jakob disease is a fatal neurological disease caused by abnormal infectious
proteins called prions. Prions that are present on surgical instruments cannot be completely deactivated;
therefore, patients who are subsequently operated on using these instruments may become infected.
This can result in surgically transmitted Creutzfeldt–Jakob disease.
Objective: To update literature reviews, consultation with experts and economic modelling published
in 2006, and to provide the cost-effectiveness of strategies to reduce the risk of surgically transmitted
Creutzfeldt–Jakob disease.
Methods: Eight systematic reviews were undertaken for clinical parameters. One review of
cost-effectiveness was undertaken. Electronic databases including MEDLINE and EMBASE were
searched from 2005 to 2017. Expert elicitation sessions were undertaken. An advisory committee,
convened by the National Institute for Health and Care Excellence to produce guidance, provided an
additional source of information. A mathematical model was updated focusing on brain and posterior
eye surgery and neuroendoscopy. The model simulated both patients and instrument sets. Assuming that
there were potentially 15 cases of surgically transmitted Creutzfeldt–Jakob disease between 2005 and
2018, approximate Bayesian computation was used to obtain samples from the posterior distribution
of the model parameters to generate results. Heuristics were used to improve computational efficiency.
The modelling conformed to the National Institute for Health and Care Excellence reference case. The
strategies evaluated included neither keeping instruments moist nor prohibiting set migration; ensuring
that instruments were kept moist; prohibiting instrument migration between sets; and employing
single-use instruments. Threshold analyses were undertaken to establish prices at which single-use
sets or completely effective decontamination solutions would be cost-effective.
Results: A total of 169 papers were identified for the clinical review. The evidence from published literature
was not deemed sufficiently strong to take precedence over the distributions obtained from expert
elicitation. Forty-eight papers were identified in the review of cost-effectiveness. The previous modelling
structure was revised to add the possibility of misclassifying surgically transmitted Creutzfeldt–Jakob
disease as another neurodegenerative disease, and assuming that all patients were susceptible to infection.
Keeping instruments moist was estimated to reduce the risk of surgically transmitted Creutzfeldt–Jakob
disease cases and associated costs. Based on probabilistic sensitivity analyses, keeping instruments moist
was estimated to on average result in 2.36 (range 0–47) surgically transmitted Creutzfeldt–Jakob disease
cases (across England) caused by infection occurring between 2019 and 2023. Prohibiting set migration or
employing single-use instruments reduced the estimated risk of surgically transmitted Creutzfeldt–Jakob
disease cases further, but at considerable cost. The estimated costs per quality-adjusted life-year gained of
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these strategies in addition to keeping instruments moist were in excess of £1M. It was estimated that
single-use instrument sets (currently £350–500) or completely effective cleaning solutions would need
to cost approximately £12 per patient to be cost-effective using a £30,000 per quality-adjusted life-year
gained value.
Limitations: As no direct published evidence to implicate surgery as a cause of Creutzfeldt–Jakob
disease has been found since 2005, the estimations of potential cases from elicitation are still
speculative. A particular source of uncertainty was in the number of potential surgically transmitted
Creutzfeldt–Jakob disease cases that may have occurred between 2005 and 2018.
Conclusions: Keeping instruments moist is estimated to reduce the risk of surgically transmitted
Creutzfeldt–Jakob disease cases and associated costs. Further surgical management strategies can reduce
the risks of surgically transmitted Creutzfeldt–Jakob disease but have considerable associated costs.
Study registration: This study is registered as PROSPERO CRD42017071807.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 11. See the NIHR Journals Library website for further project information.
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Plain English summary
The aims of this report were to summarise evidence relating to surgically transmitted Creutzfeldt–Jakobdisease and to explore the value for money of strategies to reduce the chance of any future surgically
transmitted Creutzfeldt–Jakob disease cases. Current recommendations include keeping sets of surgical
instruments together for high-risk operations and using separate instruments for people born after 1996.
The project involved reviewing published papers, speaking with experts and building a computer model.
The literature reviews found that Creutzfeldt–Jakob disease occurs in around 1–2 per million people
and that no definite cases of surgically transmitted Creutzfeldt–Jakob disease have been observed
since the 1970s. The reviews also looked for information on the possibility of patients being infected
with Creutzfeldt–Jakob disease after having surgery on high-risk tissues, such as the brain and the
back of the eye. They found that there was a great deal of uncertainty regarding who might have
Creutzfeldt–Jakob disease, but not yet have symptoms, as well as the risk of transmission and the
ability of strategies to reduce this risk.
The computer model aimed to estimate value for money of different strategies to reduce the risks of
surgically transmitted Creutzfeldt–Jakob disease. However, the reviews found that some of the numbers
needed for the model were not known, so experts were asked to estimate this information instead along
with the range of possible values. This information included the effectiveness of different cleaning practices
and the chances of infected tissue being transmitted between patients undergoing high-risk surgery.
The model found that keeping surgical instruments moist prior to cleaning was likely to save money
and reduce the chance of future surgically transmitted Creutzfeldt–Jakob disease cases. However,
additional measures, such as using only sets of single-use instruments, ensuring that instruments were
kept together in their sets or using separate instruments for those born after 1996, appeared to be
poor value for money.
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Scientific summary
Background
Creutzfeldt–Jakob disease is a progressive, fatal disease affecting the brain. Creutzfeldt–Jakob disease is
caused by an abnormal infectious protein called a prion. Surgical instruments can become contaminated
with prions when a person who has Creutzfeldt–Jakob disease, but does not exhibit clinical symptoms,
undergoes surgery on ‘high-risk’ tissues. Such surgery includes intradural neurosurgical operations on
the brain (excluding operations on the spine and peripheral nerves), neuroendoscopy and posterior eye
procedures that involve the retina or optic nerve. These prions are unlikely to be completely deactivated
by conventional hospital cleansing and sterilisation techniques; therefore, subsequent patients may be
infected iatrogenically with Creutzfeldt–Jakob disease by surgical instruments, resulting in surgically
transmitted Creutzfeldt–Jakob disease. Previous work involving authors of this report assessed the cost-
effectiveness of sets of single-use instruments and other strategies to reduce future surgically transmitted
Creutzfeldt–Jakob disease cases, evidence from which was considered by the National Institute for Health
and Care Excellence in establishing Interventional Procedures Guideline 196 [National Institute for Health
and Care Excellence (NICE). NICE Interventional Procedure Guidance 196. Patient Safety and Reduction of Risk
of Transmission of Creutzfeldt–Jakob Disease (CJD) Via Interventional Procedures. London: NICE; 2008].
Interventional Procedures Guideline 196 includes recommendations on decontamination methods and
guidance for set-keeping to ensure that instruments that are in contact with potentially high-risk tissues
do not move from one set to another. Furthermore, supplementary instruments used during high-risk
procedures were recommended either to be single-use or to remain with the set to which they were
introduced. An age split was also recommended, with separate instruments used for people born before
1997 (and at risk of variant Creutzfeldt–Jakob disease because of dietary exposure to bovine spongiform
encephalopathy) and those born after 1996 (who were believed, at the time of writing Interventional
Procedures Guideline 196, to be at zero risk of dietary exposure to bovine spongiform encephalopathy).
Objectives
To evaluate the expected risk of surgically transmitted Creutzfeldt–Jakob disease cases under present
surgical conditions and to estimate the cost-effectiveness of strategies that may alter the anticipated
risks of surgically transmitted Creutzfeldt–Jakob disease.
Methods
Review methods
Eight systematic reviews were conducted. Four questions were fundamental to understanding
Creutzfeldt–Jakob disease and four were undertaken to understand the risks of transmission via surgery.
Broadly, the reviews investigated Creutzfeldt–Jakob disease with regards to (1) prevalence and incidence,
(2) risk of transmission via surgery, (3) incubation periods and (4) infectivity, (5) efficacy of current
decontamination procedures, (6) adherence to the National Institute for Health and Care Excellence
guidance by keeping surgical instrument sets together, (7) evidence of complications from single-use
instruments and (8) likelihood of patients who have undergone high-risk surgery returning for further
surgery. Literature searches were conducted in major electronic bibliographic databases [MEDLINE,
EMBASE, Science Citation Index, Conference Proceedings Citation Index and Web of Science™ (Clarivate
Analytics, Philadelphia, PA, USA)] from 2005 to 2017. Titles and abstracts were examined by one reviewer
and 10% of randomly selected excluded citations were double-checked by a second reviewer. At full-paper
stage, all citations excluded from a particular review question were double-checked by the second reviewer.
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A systematic review of cost-effectiveness was undertaken to identify cost and utility data and to
ensure that methods used in previous potentially relevant papers could be incorporated. Titles and
abstracts were examined by one reviewer, and 10% of randomly selected excluded citations were
double-checked checked by a second reviewer. Where appropriate, full papers were reviewed for
pertinent information.
Elicitation methods
To provide plausible distributions on key parameters where there were no direct published data,
elicitation was undertaken. This process used four experts and asked the group to answer eight
questions relating to the decision problem. The elicitation was conducted using the Sheffield Elicitation
Framework. A face-to-face meeting between the experts and the facilitator was convened. For each
uncertainty quantity, the experts were asked to independently make their probability judgements,
without conferring. These individual judgements were then presented to all of the experts. Following
discussion between the experts and the facilitator, a single set of probability judgements was proposed,
from which a probability distribution could be constructed. The probability distribution was presented
to the experts at the meeting for comment and, if necessary, revised. Following the meeting, a report
with all the elicited distributions was sent to the experts, with the experts given a further opportunity
to suggest modifications.
Evaluation of cost-effectiveness
The mathematical model used previously to assess the cost-effectiveness of strategies to reduce
surgically transmitted Creutzfeldt–Jakob disease was updated in this report. This model simulated a
surgical centre assuming that there were 27 such centres in England. All assumptions were agreed
with a National Institute for Health and Care Excellence committee convened to provide national
guidance, and conformed to the National Institute for Health and Care Excellence reference case,
using a NHS and personal social services perspective. Key changes between the earlier modelling work
and this work include re-eliciting key parameters; assuming that all patients, irrespective of genotype,
were susceptible to surgically transmitted Creutzfeldt–Jakob disease infection; taking into account the
possibility that patients with surgically transmitted Creutzfeldt–Jakob disease could be misdiagnosed
with an alternative neurodegenerative disease; and setting a calibration target of these number of
possible surgically transmitted Creutzfeldt–Jakob disease cases observed between 2005 and 2018.
To reduce the impact of sampling error, 27 random number streams were used for each probabilistic
sensitivity analysis configuration. Calibrating the model was complex and required the use of heuristics
to initially rule out parameter configurations that were incompatible with the observed data, and then
estimating likelihoods for the remaining parameter configurations. These were used to calculate the
cost-effectiveness of each strategy considering infections estimated to occur between 2019 and 2023.
In consultation with the National Institute for Health and Care Excellence committee, the following
strategies were run:
l Do nothing, assuming that the current situation is maintained with respect to surgical centres’
adherence to Interventional Procedures Guideline 196.
l Full adherence to Interventional Procedures Guideline 196, and guidance on keeping instruments
moist for those units where this is not followed, with the exception of single-use neuroendoscopes.
l Full adherence to guidance on keeping instruments moist for those units where Interventional
Procedures Guideline 196 is not followed.
l Removal of the requirements to have separate instrument sets for patients born after 1996.
l Modelling interventions that prohibit the possibility of surgically transmitted Creutzfeldt–Jakob
disease. These are likely to take the form of the introduction of sets of single-use instruments or a
completely effective decontamination product.
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Threshold analyses were undertaken to observe at what price per operation sets of single-use instruments,
or a completely effective cleaning solution, would need to be to reach cost per quality-adjusted life-year
gained values of £30,000 (a typical threshold for cost-effectiveness used by the National Institute for
Health and Care Excellence) and £300,000 (the maximum value used by the National Institute for Health
and Care Excellence for highly specialised technologies). Further threshold analyses were undertaken to
look at the maximum costs associated with following Interventional Procedures Guideline 196 to be at,
or below, thresholds of £30,000 and £300,000 per quality-adjusted life-year gained. Additional analyses
explored the affect of removing current regulations that patients born after 1996 should be operated on
with separate instruments to the rest of the population.
Based on advice provided by the National Institute for Health and Care Excellence committee, modelling
of decontamination products was not conducted other than that contained in strategy 5 (see Review
methods). The reasons for this include the heterogeneity of the studies of decontamination products
for Creutzfeldt–Jakob disease prions across several domains, which precluded accurate estimates of
effectiveness; problems of commercial availability; and additional steps potentially required in the
decontamination process.
Results
Literature searches for the clinical reviews yielded 8549 citations from which 169 papers were relevant
to the eight review questions. The incidence of any type of Creutzfeldt–Jakob disease case is reported
to be between 1 and 2 per million worldwide, but the rate of sporadic Creutzfeldt–Jakob disease cases
is noted to be increasing in some countries. The prevalence of non-clinical Creutzfeldt–Jakob disease
prions in tissues in the general population is estimated to be 240 per million, based on analyses of
appendix specimens. Published evidence indicates that there have been no surgically transmitted
Creutzfeldt–Jakob disease cases since the 1970s and that the risk of iatrogenic Creutzfeldt–Jakob
disease is presently very low, with no cases reported between 2005 and 2017. However, there remains
a possibility that undetected cases have been mistaken for alternative neurodegenerative diseases.
The incubation period of Creutzfeldt–Jakob disease ranges between 1 and 42 years. The infectivity of
Creutzfeldt–Jakob disease is likely to be moderated by a number of factors including the recipient’s
genotype, the infecting prion strain and the route of transmission. Some agents appear to be completely
effective in deactivating certain prions, but there are major issues with the agents and the evidence
base; however, the reduction of residual mass to ≤ 5 µg of residual protein per instrument and
keeping instruments in moist conditions prior to autoclaving and sterilisation enhances the efficacy of
decontamination strategies. A paucity of direct evidence exists on whether or not surgical instruments
for high-risk procedures stay in their original sets, and on the risks and benefits of reusable versus
single-use instruments. Evidence on the risk of future surgery for patients undergoing high-risk
procedures is limited.
Although no data from the literature were directly used in the model, apart from a paper co-written by
authors of this report that detailed, and updated, the evidence considered for Interventional Procedures
Guideline 196, selected papers were used in discussion with clinical experts to inform the model parameters.
A key result from the cost-effectiveness analyses was that keeping instruments moist was expected to save
money and to reduce the estimated number of surgically transmitted Creutzfeldt–Jakob disease cases;
however, there was still a risk of Creutzfeldt–Jakob disease transmission. Based on probabilistic sensitivity
analyses, keeping instruments moist was estimated to produce on average 2.36 surgically transmitted
Creutzfeldt–Jakob disease cases between 2019 and 2023, with a maximum value of 47 surgically
transmitted Creutzfeldt–Jakob disease cases across the 27 assumed surgical centres. From a position of
keeping instruments moist, the cost per quality-adjusted life-year of introducing single-use instruments
was in excess of £1.0M in all scenarios. From a position of implementing Interventional Procedures
Guideline 196 and keeping instruments moist, the cost per quality-adjusted life-year of introducing
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single-use instruments was in excess of £4.5M in all scenarios. From a position of keeping instruments
moist, the cost per quality-adjusted life-year of implementing Interventional Procedures Guideline 196
was estimated to be in excess of £1.6M.
The threshold analyses indicated that with a cost-effectiveness threshold of £300,000 per quality-
adjusted life-year, a single-use set (or completely effective detergent) would need to be ≤ £50 per
operation, assuming that instruments were kept moist. At a cost-effectiveness threshold of £30,000
per quality-adjusted life-year, this value reduced to £15 per operation. Threshold analyses exploring
the maximum cost associated with implementing Interventional Procedures Guideline 196 indicated
that this value was approximately £140,000 (assuming a cost-effectiveness threshold of £300,000)
and £15,000 (assuming a cost-effectiveness threshold of £30,000) per surgical unit over a 5-year
period. Analyses undertaken indicated that there would not be a large change in the numbers of
quality-adjusted life-years lost because of surgically transmitted Creutzfeldt–Jakob disease (< 0.20)
if guidance that patients born after 1996 should have different instrument sets was removed.
Discussion
Direct evidence to answer the literature review questions was limited because of the rare nature of
Creutzfeldt–Jakob disease and the reliance on historical cases of surgically transmitted Creutzfeldt–Jakob
disease, the lack of observational data, the case–control study designs and the use of animal data. The
apparent increase in sporadic Creutzfeldt–Jakob disease cases noted in several papers is most probably
because of improved case ascertainment, population increases and an ageing population. Recent studies
of prior accumulation in human lymphoid tissue raise the possibility of either a low background prevalence
of abnormal prion proteins or an extended period of bovine spongiform encephalopathy-related infection
[see Public Health England. Summary Results of the Third National Survey of Abnormal Prion Prevalence
in Archived Appendix Specimens. London: Public Health England; 2016; and Advisory Committee on
Dangerous Pathogens TSE Subgroup. Updated Position Statement on Occurrence of vCJD and Prevalence
of Infection in the UK. 2016. URL: www.clinicalvirology.org/news/acdp-tse-subgroup-updated-position-
statement-on-occurrence-of-vcjd-and-prevalenceof-infection-in-the-uk/ (accessed 8 January 2020)]. The
possibility of underdiagnosis of variant Creutzfeldt–Jakob disease also exists. Data on the likely incubation
periods of Creutzfeldt–Jakob disease are limited to retrospective data from iatrogenic Creutzfeldt–Jakob
disease, variant Creutzfeldt–Jakob disease or kuru cases. As Creutzfeldt–Jakob disease detection
methods advance, more accurate confirmation of Creutzfeldt–Jakob disease pathology will be possible
from autopsy and excised tissue samples. Evidence on decontamination of surgical instruments is highly
heterogeneous, with limited external validity to the clinical setting. As published data on instrument
set-keeping and single-use instruments were not identified, no evidence to substantiate or refute
anecdotal claims about the drawbacks and merits of reusable versus single-use instruments is available.
Data on the risk of future surgery was limited and lacked control data for those who had not undergone
an index high-risk procedure.
As with any mathematical model attempting to replicate a complex decision problem, simplifications
were made. The model structure and the parameterisation of the variables were discussed with the
National Institute for Health and Care Excellence committee and amended accordingly; it is thus
believed that key facets of the decision problem have been incorporated although it is possible that
some relevant aspects were omitted. Although running a greater number of probabilistic sensitivity
analysis configurations would increase the accuracy in the incremental cost-effectiveness ratio related
to uncertainty in parameter estimates, and running more random number streams would increase the
accuracy for a given probabilistic sensitivity analysis configuration, the results appear sufficiently robust
for decision-making. Keeping instruments moist is predicted to both save money and reduce the risk
of future surgically transmitted Creutzfeldt–Jakob disease cases. All other strategies evaluated have
incremental cost-effectiveness ratios in excess of £1M per quality-adjusted life-year gained. The removal
of the need for patients born after 1996 to be operated on using separate instruments did not show a
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marked increase in the number of predicted surgically transmitted Creutzfeldt–Jakob disease cases.
Throughout the modelling there was a conscious decision to be pessimistic if a choice needed to be
made, and, thus, the cost per quality-adjusted life-year estimates are likely to be underestimates rather
than overestimates.
It is possible that a completely effective cleaning solution may be cost-effective. Further research
would be required to prove the efficacy and the commercial viability of such agents.
Conclusions
The systematic reviews were comprehensive and inclusive and retrieved studies providing indirect,
observational and speculative data to inform about the likelihood of a rare disease being transmitted
via surgery. The limited evidence identified indicates that there have been no observed cases of
surgically transmitted Creutzfeldt–Jakob disease since the 1970s. Evidence implicating surgery as a
risk factor for Creutzfeldt–Jakob disease is restricted to case–control designs, and the evidence on
decontamination agents and processes has limited applicability. Owing to the rarity of the disease and
the difficulties in conducting externally valid studies to provide robust evidence for the clinical setting,
direct evidence to answer the review questions was limited.
The modelling undertaken indicates that keeping surgical instruments moist is a dominant strategy.
Additional strategies aimed at reducing the future risk of surgically transmitted Creutzfeldt–Jakob
disease cases do not appear to be cost-effective as they have cost per quality-adjusted life-year gained
estimates in excess of £1M. It is estimated that removing the requirement to operate on people born
after 1996 with different instruments would not markedly increase the risk of surgically transmitted
Creutzfeldt–Jakob disease cases.
The modelling indicates that a number of surgically transmitted Creutzfeldt–Jakob disease cases
that could occur despite keeping instruments moist. In the event of multiple surgically transmitted
Creutzfeldt–Jakob disease cases being identified, performing an urgent update of this review, with an
amended calibration target is likely to be informative.
Study registration
This study is registered as PROSPERO CRD42017071807.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 11.
See the NIHR Journals Library website for further project information.
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Chapter 1 Introduction
Creutzfeldt–Jakob disease (CJD) is a progressive, fatal disease affecting the brain. CJD is caused byan abnormal transmissible protein called a prion. Once CJD is transmitted, the concentration of CJD
prions varies throughout the body, but reaches high levels in the brain and posterior eye, resulting in
neurological symptoms including rapidly progressive dementia, extrapyramidal signs and visual symptoms.
Most people with clinically diagnosed CJD will die within 1 year of the symptoms appearing.
Four classifications of CJD exist: sporadic CJD (sCJD), variant CJD (vCJD), genetic CJD (gCJD) and
iatrogenic CJD (iCJD). Referrals of suspected CJD and values for death definitely related (with
neuropathological confirmation) or probably related (without neuropathological confirmation) to CJD
are recorded by the National CJD Research and Surveillance Unit (NCJDRSU) in Edinburgh.1 This
source estimates that since 1990 there have been 3746 referrals for investigation and 2370 deaths
from definite or probable CJD (as of 8 January 2018).
Sporadic CJD has historically been the most common type of CJD, accounting for around 85% of CJD
cases. The cause of sCJD is thought to be the spontaneous generation of an abnormal isoform of prion
protein (PrP). sCJD generally occurs later in life (in those with a mean age of 67 years) and has a short
survival post diagnosis of around 4 months.2 Although there is evidence of a genetic predisposition to
sCJD, the precise cause of the disorder is unknown.
Genetic CJD, also known as familial or inherited CJD, is associated with a pathogenic mutation in
the prion protein gene (PRNP) and includes conditions known as fatal familial insomnia (FFI) and
Gerstmann–Schäussler–Scheinker (GSS) syndrome. Overall, gCJD accounts for between 5% and 15%
of CJD cases or approximately 10 CJD deaths in the UK, per year.
Variant CJD was observed following the exposure of the UK population during the late 1980s and early
1990s to bovine spongiform encephalopathy (BSE), which was presumed to be transmitted to humans by
eating food contaminated with the brain, spinal cord or digestive tract of infected carcasses. The vCJD
epidemic peaked in 2000 with 28 deaths and has since declined, with only two ‘definite or probable’ vCJD
deaths reported since 2012. The majority of cases have occurred in a younger population compared with
that observed in sCJD, with a mean age of 26 years. The median disease duration post diagnosis is longer
in vCJD (14 months) than that observed in sCJD. All people who have contracted clinically observed vCJD
have died.
Incidences of iCJD, which is the transmission of prion disease through medical procedures or equipment,
have been recorded for procedures such as dura mater grafts, electroencephalography (EEG) needles
and neurosurgery, and from receipt of corneal grafts, growth hormones, gonadotrophin or packed red
blood cells.3
The current decision problem focuses on the risk of transmission of CJD (of all forms) via surgical
instruments. Prions are unlikely to be completely deactivated on surgical instruments by conventional
hospital cleansing and sterilisation techniques4 and, therefore, patients may be infected iatrogenically
with CJD by surgical instruments resulting in a surgically transmitted CJD (stCJD) case. Iatrogenic
transmission can occur when surgical instruments, endoscopes or laryngoscopes are used during high-risk
neurosurgical procedures in patients who have asymptomatic CJD but who are infectious because neural
tissue in particular has a high infectious load.5 Four cases of iCJD transmitted via neurosurgery were
observed between 1952 and 1974 from three sporadic index cases of CJD.6 Stringent public health
requirements are in place to limit the risk of iCJD being spread from people with an increased risk of
developing CJD, or with CJD, or for whom a diagnosis of CJD is being considered or cannot be excluded.
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Immediately following the recognition of vCJD, as a consequence of the BSE outbreak, the potential
scale of the number of infections was uncertain; estimations incorporated potential subclinical vCJD
infections identified from a histopathological survey of lymphoreticular tissue to be 237 per million
[95% confidence interval (CI) 49 to 692 per million].7–9 Surgical transmission of CJD in this scenario was
considered to pose a potential risk to public health by virtue of a self-sustaining iatrogenic epidemic.
Therefore, in 2005 the National Institute for Health and Care Excellence (NICE) commissioned the
School of Health and Related Research (ScHARR) at the University of Sheffield to conduct a systematic
review and perform cost-effectiveness modelling of evidence on patient safety and reduction of risks of
transmission of CJD.10 This evidence, together with data collected from experts, was used to populate a
mathematical model assessing the cost-effectiveness of single-use surgical instruments.11,12 The outputs
from the model and a separate risk assessment conducted by the Department of Health Economics,
Statistics and Operational Research Division13 were used to inform the NICE Interventional Procedures
Guidance 196 (IPG196) Patient Safety and Reduction of Risk of Transmission of Creutzfeldt–Jakob Disease
(CJD) Via Interventional Procedures.14 The existing guidance includes recommendations on decontamination
methods and guidance for set-keeping to ensure that instruments in contact with potentially high-risk
tissues do not move from one set to another. Furthermore, supplementary instruments (SIs) used during
high-risk procedures were recommended to either be single-use or to remain with the set with which they
were introduced. An age split was also recommended with separate instruments used for people born
before 1997 (and at risk of dietary exposure to BSE) and those born after 1996 (who were believed,
at the time of writing IPG196, to be not infected with vCJD). High-risk procedures are regarded as
intradural neurosurgical operations on the brain (excluding operations on the spine and peripheral
nerves), neuroendoscopy, and posterior eye procedures that involve the retina or optic nerve.14 Although
the cost-effectiveness analysis indicated that the introduction of single-use instruments for all high-risk
procedures was not cost-effective, there was great uncertainty in these results and a recommendation
was made by the study authors that policy might need to be revised if new relevant data become available.
An epidemic of CJD has not occurred since the publication of IPG196 and no conclusive evidence of
transmission by surgery has transpired to date. However, a number of developments have occurred
since 2006 that include:
l a finding of abnormal prion accumulation in the appendixes of low-risk cohorts (i.e. those born
after 1996)15,16
l continued evolution of high quality and less expensive single-use instruments
l anecdotal reports of difficulties implementing the recommendation from IPG196 related to keeping
instruments in their original sets across a number of units
l anecdotal reports of problems in maintaining quarantined instruments for patients born after 1996.
A recent study has also implicated neurosurgery as a possible iatrogenic source for amyloid beta
accumulation in the brain, a peptide that is associated with Alzheimer’s disease.17 This finding
underlines the potential risk associated with high-risk procedures and the importance of assessing
evidence relevant to decontamination or disposal of neurosurgical equipment.
Purpose of the research
The objective of the current research is to update selected evidence from the research project
conducted in 2005 (project number IP1553)18,19 that informed NICE guidance IPG19611 for the
NICE Interventional Procedures (IPs) committee to review the decision problem in 2018. The aim is
to review the evidence base for the current risk of transmission of CJD (any form) related to surgery
in order to provide up-to-date relevant evidence to NICE, and to inform the cost-effectiveness of
potential management strategies.
INTRODUCTION
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Research objectives
1. To perform updates of the systematic reviews completed in 2005 on the clinical evidence on patient
safety and risks of transmission of CJD via surgery.
2. To update the economic model and, where necessary, seek new input from expert elicitation to
make the model relevant for the decision problem today.
3. To undertake modelling to estimate the cost-effectiveness of strategies to reduce the risk of
transmission of CJD via surgical procedures.
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Chapter 2 Clinical evidence
Methods for systematic reviews
The protocol for this project was developed in consultation with the NICE Interventional Procedures
Advisory Committee and was registered on the Centre for Reviews and Dissemination (CRD)
systematic review database (PROSPERO registration number CRD42017071807). The project aimed
first to update the evidence for the following eight research questions:
1. What is the incidence of CJD and what is the prevalence of CJD-related prions in humans in the UK?
2. What is the risk of secondary transmission of CJD by surgical procedure?
3. What are the incubation periods of acquired transmissible spongiform encephalopathies (TSEs)?
4. What is the infectivity of CJD?
5. What is the evidence on the efficacy of decontamination techniques for instruments infected with prions?
6. What is the evidence that instruments used for high-risk procedures remain in their original sets?
7. What is the evidence for complication rates of single-use compared with reusable instruments for
high-risk procedures?
8. What is the evidence for likelihood of future surgery for a patient undergoing high-risk procedures?
Eight systematic reviews have been completed to address these research questions. These reviews
adhered to best practice systematic review methodology in accordance with Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) 200920 standards.
Eligibility criteria
The inclusion and exclusion criteria differ for each review question. These are broadly summarised
in Table 1.
TABLE 1 Eligibility criteria for each review question
Review question Eligibility criteria for inclusion into the review
What is the incidence of CJD and what is the prevalence
of CJD-related prions in humans in the UK?
l Population: humans with CJD or CJD-related prions
in tissue
l Outcome: incidence or prevalence data
l Study designs: national surveillance reports, registry
data, epidemiological studies or pathological surveys
that provide empirical estimates of prevalence
What is the risk of secondary transmission of CJD by
surgical procedure?
l Population: humans who have acquired CJD via
iatrogenic transmission via surgery
l Outcome: incidence data
l Study design: observational studies such as case series
and case reports
What are the incubation periods of acquired TSEs? l Population: humans with CJD or related prion disease
(e.g. kuru) as a result of primary or secondary transmission
l Outcome: incubation data
l Study designs: empirical or epidemiological studies,
reviews/guidance documents for reference checking
What is the infectivity of CJD? l Phenomenon of interest: the infectiousness of CJD in
terms of CJD type, subtype or strain, genotype of the
recipient, infectivity of infectious tissue and the
infectious mass required to transmit CJD
l Outcome: trends or themes in CJD infectivity
l Study designs: empirical in vivo or in vitro studies
continued
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5
Search strategy
Literature searches were conducted to retrieve relevant evidence. Electronic databases were searched
on 14 August 2017:
l MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations – via Ovid®
(Wolters Kluwer, Alphen aan den Rijn, the Netherlands), 1946 to 2017
l EMBASE – via Ovid, 1974 to 2017
l Science Citation Index and Conference Proceedings Citation Index– Web of Science™
(Clarivate Analytics, Philadelphia, PA, USA), 1990 to 2017.
A date restriction from 2005 to 2017 was applied for the first seven review questions. For the final
review question regarding the risk of future surgery in patients who have had high-risk procedures,
because no relevant evidence was found in the previous review, the search strategy was revised and
searches were performed from database inception to 2017. No language or study design limits were
applied to the searches. The search strategies are presented in Appendix 1.
TABLE 1 Eligibility criteria for each review question (continued )
Review question Eligibility criteria for inclusion into the review
What is the evidence on the efficacy of decontamination
techniques for instruments infected with CJD/TSE/prions?
l Phenomenon of interest: the binding of prions to steel
surfaces. The restriction to steel (e.g. steel wires), despite
limitations, is because prions adhering to steel better
simulate the real-world scenario of surgical instruments
than inactivation of prions in brain homogenate or tissue
l Intervention: autoclaving with/without an additional
decontamination process, decontamination processes
other than autoclaving
l Outcome: log-reductions in the infectious titre, that is
a reduction in the load of infectivity on steel (wires)
after decontamination processes
l Study designs: empirical in vivo or in vitro studies,
reviews/guidance documents for reference checking
What is the evidence that instruments used for high-risk
procedures remain in their original sets?
l Intervention: instruments used for specified
high-risk surgeries
l Outcomes: set integrity, migration of instruments
between sets
l Study designs: empirical or epidemiological studies,
reviews/guidance documents for reference checking
What is the evidence for complication rates of single-use
compared with reusable instruments for high-risk
procedures?
l Intervention: single-use instruments for specified
high-risk surgeries
l Comparator: reusable instruments for specified
high-risk surgeries
l Outcomes: complications
l Study designs: comparative studies, reviews/guidance
documents for reference checking
What is the evidence for risk of future surgery for a
patient undergoing high-risk procedures?
l Population: patients undergoing neurosurgery or
specified high-risk surgeries
l Outcomes: risk of future neurosurgery or additional
high-risk surgeries after undergoing a high-risk procedure
l Study designs: empirical or epidemiological studies,
reviews/guidance documents for reference checking
The following citations were excluded from all review questions:
l Studies concerning detection of CJD involving laboratory parameters only.
l Animal studies without relevant discussion of implications to humans.
l Discussion papers or papers providing guidance that do not provide relevant empirical data.
l Papers that are superseded by later or more complete published data.
l Papers relating only to treatment or care of patients with CJD.
l Papers relating to filtering blood for transfusion or other blood products from CJD-related prions.
l Papers relating only to prion diseases without specific mention of CJD or decontamination of prions.
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Members of the NICE IP’s committee were consulted as content experts for potentially relevant papers
for all review questions. Papers recommended by experts were subject to bibliography checking.
The searches combined terms that would be relevant for more than one review question. Therefore,
five targeted literature searches, instead of eight, for all review questions were conducted, which
combined terms for:
1. Searches for the UK incidence and prevalence of CJD and the incubation period of acquired human TSEs.
Electronic literature searches were performed to identify relevant articles. Terms for ‘incidence and
prevalence’ or ‘incubation’ (see Appendix 1, search strategy lines 10–15) were combined with ‘CJD’
population terms (see Appendix 1, search strategy lines 1–9). The terms applied were identical to
those used in appendices 1 and 3 in the original systematic review.10
2. Searches for the secondary transmission of CJD by invasive diagnostic or surgical procedures;
infectious mass required to transmit CJD; and the decontamination of surgical, anaesthetic and
diagnostic instruments, scopes and implantable devices.
Electronic literature searches were performed to identify relevant articles. Terms for ‘transmission’ and
‘transfer’ (see Appendix 1, search strategy line 27) and ‘instrument decontamination’ (see Appendix 1,
search strategy lines 28–33) were combined with ‘CJD’ population terms in humans or non-human
mammals (see Appendix 1, search strategy lines 18–25).
3. Searches for the extent to which surgical instruments remain in their original sets following use
and decontamination.
Electronic literature searches were performed to identify articles that report on the extent to which
surgical instruments remain in their original sets following use and decontamination. Terms for
‘instrument decontamination’ (see Appendix 1, search strategy lines 36–41) were combined with
‘high-risk surgical procedures’ (see Appendix 1, search strategy lines 42–56). A list of high-risk
surgical procedures were taken from appendix C of NICE IPG196.14
4. Searches for the complication rates associated with the use of single-use versus reusable anaesthetic,
diagnostic or surgical instruments.
Electronic literature searches were performed to identify articles that report on complication rates
associated with the use of single-use versus reusable anaesthetic, diagnostic or surgical instruments.
Terms for ‘disposable’ or single-use’ instruments (see Appendix 1, search strategy lines 60–63), including
specifically named instruments recommended at the NICE committee meeting in June 2017 (see
Appendix 1, search strategy line 63), were combined with ‘high-risk surgical procedures’ (see Appendix 1,
search strategy lines 65–79) or ‘complications’ (see Appendix 1, search strategy lines 81–84).
5. Searches for the risk of future surgery following surgery.
Electronic literature searches were performed to identify articles that report on the risk of future
surgery following surgery. Terms for ‘reoperation’ or ‘repeat surgery’ were combined (see Appendix 1,
search strategy lines 88–90) with ‘high-risk surgical procedures’ (see Appendix 1, search strategy lines
92–106). As the review question was reconceptualised to be more sensitive to potentially relevant
studies than the previous review undertaken in 2006, no date restrictions were applied.
Cost-effectiveness searches
A literature search was undertaken to identify evidence relevant to the cost-effectiveness model such
as relevant economic evaluations in CJD.
Four electronic databases were searched on 7 June 2017 from 2004 to present:
l MEDLINE, MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations – via Ovid,
1946 to 2017
l EMBASE – via Ovid, 1974 to 2017
l The Cochrane Library (Wiley Online Library) Cochrane Database of Systematic Reviews, 1996 to
2017; Health Technology Assessment Database, 1995 to 2016; NHS Economic Evaluation Database,
1995 to 2015
l Science Citation Index and Conference Proceedings Citation Index – Web of Science, 1990 to 2017.
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The search strategy comprised Medical Subject Headings or Emtree thesaurus terms and free-text
synonyms for ‘CJD’. Searches were translated across databases and were not limited by language.
The search strategies are presented in Appendix 2. Search filters designed to identify economic
evaluations were used on MEDLINE and EMBASE.
Study selection
Results from the electronic bibliographic searches were imported into reference management software,
EndNote Version 8 [Clarivate Analytics (formerly Thomson Reuters), Philadelphia, PA, USA], and
duplicates were removed. Titles and abstracts of retrieved records were examined by one reviewer
(LU) and irrelevant citations were excluded. A proportion (10%) of randomly selected excluded
citations were double-checked by a second reviewer (CC) and any disagreements were resolved by
discussion between the reviewers. Consultation with the third designated team member (MS) was
not required for any citation. At the full-paper stage, all citations excluded from a particular review
question by the reviewer were double-checked by the second reviewer. Lists of these citations, with
the principal reason for exclusion, are reported for each review in Appendix 3. Data identified from
countries outside the UK were incorporated if deemed relevant.
Literature identified within the cost-effectiveness review was processed in a similar manner. Titles
and abstracts of retrieved records were examined by one reviewer (MS) and irrelevant citations
were excluded. A proportion (10%) of randomly selected excluded citations were double-checked by a
second reviewer (LU). All full-text articles were independently assessed for inclusion by two reviewers
(MS, and LU). No disagreements were required to be resolved through discussion or with involvement
of the third designated team member (CC).
Data extraction
Bespoke data extraction forms were developed for each review question in Microsoft Excel® (Microsoft
Corporation, Redmond, WA, USA) to record relevant outcome data for the review question in hand.
All data were extracted by one systematic reviewer (LU for reviews 1, 2 and 4; CC for reviews 3, 5, 6,
7 and 8) and independently checked by a second reviewer (LU for reviews 3, 5, 6, 7 and 8; CC for
reviews 1, 2 and 4). Any disagreements were resolved by discussion and consensus or by consulting
with a third member of the project team (MS).
Quality assessment
Formal quality assessment using standard checklists, such as the Cochrane risk-of-bias tool, was
considered for these systematic reviews. The value of conducting quality assessment is to assess how
a study has been conducted in order to balance the numerical findings (or the statistical strength of
effects) against the methodological quality. There are a range of quality assessment tools available
depending on the study type included; quality assessment is not only amenable to a review of RCTs.
However, none of the review questions sought data that were estimating treatment effects; therefore,
the typical domains of quality assessment, such as randomisation, performance bias, detection bias and
attrition bias, are less relevant. Furthermore, in many cases, the included ‘studies’ in this review were
not amenable to quality assessment because (1) they are surveillance reports, thereby not constituting
the traditional definition of a study or (2) they are laboratory studies using highly specific scientific
methods that are not amenable to the quality assessment for clinical trials. As these included studies
were mainly observational in nature, the data of interest were less vulnerable to author conflicts of
interest or systematic bias. Assessment of study heterogeneity is most important when performing
formal synthesis to estimate treatment effects, which is not the objective of this review. Indeed,
limitations to review inclusion criteria based on study design, scientific discipline, setting or context
would potentially have restricted the external validity of the review. Therefore, no formal quality
assessment has been undertaken and the protocol for the systematic review, registered on the
PROSPERO database (CRD42017071807), was updated accordingly.21 The purpose of the reviews was
primarily to describe the relevant literature rather than to aggregate data or rank individual studies.
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Data analysis/synthesis
Data were tabulated, synthesised and discussed narratively for each review question. Meta-analyses
were planned to be conducted by an experienced statistician using appropriate software, and
heterogeneity was to be explored using meta-regression where comparable data were available.
However, no suitable data were identified for formal aggregation using meta-analysis.
Meta-biases and assessment of external validity
Owing to the complex nature of the clinical topic, the number of review questions and the diverse
information required to inform the economic model, the systematic reviews were methodologically
challenging. To obtain high-quality, trustworthy data and to maintain the external validity of the
reviews, the inclusion criteria were kept broad until full text retrieval. After discussion within the
project team and with the NICE committee experts, a decision was made to take a broad approach
during the assessment of study relevance, rather than applying stringent inclusion criteria.
The risk of this approach was that the evidence generated from the reviews was less amenable to
replication. However, the purpose the clinical reviews was to inform commissioners about potential
risks of CJD transmission via surgery rather than estimating treatment effect. Therefore, a more
inclusive methodological approach by the evidence review group in this complex clinical topic was
deemed justifiable.
Literature search results
The literature searches of bibliographic databases were performed on 14 August 2017 and yielded
8466 citations. During the screening process, a citation of potential relevance to review question 2 was
identified that had not been picked up by the literature searches. Therefore, the information specialist
in consultation with the project team revised the search terms for review 2 to perform an additional
search on 2 October 2017, resulting in a further 310 citations. A total of 41 further citations were
obtained and assessed for eligibility either from recommendations from NICE’s committee members
(n = 16) or through checking the reference lists of relevant citations (n = 25). After duplicates were
removed, the 8549 titles and abstracts were reviewed by one reviewer (LU). In total, 10% of excluded
citations were independently assessed by a second reviewer (CC) with very good agreement (κ = 0.98).
Any disagreements were carried forward for further discussion but none was ultimately deemed
eligible for full text inspection by either reviewer (see Appendix 3 for the table of excluded studies).
A PRISMA flow diagram illustrating the process of identifying citations through to final study selection
for each review question is shown in Figure 1.
The incidence of Creutzfeldt–Jakob disease and the prevalence of
Creutzfeldt–Jakob disease-related prions in humans in the UK
The purpose of this review was to identify published and unpublished evidence for:
l the incidence of CJD (sporadic, genetic, variant and iatrogenic)
l the prevalence of CJD-related prions in humans in the UK.
The NCJDRSU provides the most comprehensive and regularly updated figures for the UK. Globally,
figures are gathered by the CJD International Surveillance Network (EuroCJD);22 however, this source
was last updated in May 2015 and is therefore less up to date than the NCJDRSU. The literature
searches were also used to retrieve the most recent or complete figures, incidence trends or studies
regarding subclinical prevalence of CJD prions in tissue. A total of 69 published citations were
identified as being relevant to the incidence of clinical CJD or the prevalence of subclinical CJD around
the world.
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The incidence of Creutzfeldt–Jakob disease
The global incidence of CJD is typically reported to be around 1 to 2 cases per million per year,22 based
on surveillance studies published around the world from 2005 (Table 2). Higher incidence rates may be
more likely to occur in areas with access to established surveillance units for referring suspected cases
of prion disease. In the UK since 1990, the NCJDRSU has been mandated to actively monitor and
identify all CJD cases. By contrast, a paper by Jeon et al.28 described that CJD surveillance did not begin
in Korea until 2001, and iCJD was not studied in Korea prior to 2011. This indicates geographical
variation in how CJD may have been detected and reported in time globally.
A study by Gao et al.29 does not report an incidence rate per million for CJD in China, but does report
that during the period from 2006 to 2010, 261 patients were diagnosed with sCJD and 23 patients
were diagnosed with genetic human prion diseases out of a group of 624 suspected patients who were
referred to China CJD surveillance.29
Increase in the UK sporadic Creutzfeldt–Jakob disease incidence over time
Between 1990 and 2017, the NCJDRSU recorded figures of iCJD [from receipt of human
gonadotrophin (hGN), human-derived growth hormone or dura mater) and vCJD, which were relatively
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FIGURE 1 The PRISMA flow diagram of studies included in systematic reviews.
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low compared with sCJD. Figure 2 plots the number of deaths in the UK that have been attributed to
definite or probable CJD between 1996 and 2017 (as of 2 May 2018) as reported by the NCJDRSU.
An increase in sCJD cases is noted over the 27-year period, whereas iatrogenic, genetic and variant
forms remain rare.
TABLE 2 Global estimations of CJD incidence from studies published in 2005 or after (ordered by date, then alphabetically)
Country
Time period of
estimation
CJD incidence or mortality
rate per million CJD types included Study author/source
Austria 1993–2017 1.49 Sporadic EuroCJD22
Australia 1993–2016 1.20 Sporadic EuroCJD22
Belgium 1997–2017 1.19 Sporadic EuroCJD22
Canada 1994–2017 1.03 Sporadic EuroCJD22
Czech Republic 2000–17 1.16 Sporadic EuroCJD22
Denmark 1993–2017 1.45 Sporadic EuroCJD22
Estonia 2004–17 0.32 Sporadic EuroCJD22
France 1993–2017 1.53 Sporadic EuroCJD22
Germany 1993–2017 1.36 Sporadic EuroCJD22
Hungary 1997–2017 1.07 Sporadic EuroCJD22
Italy 1993–2017 1.44 Sporadic EuroCJD22
Netherlands 1993–2017 1.21 Sporadic EuroCJD22
Norway 1995–2017 0.96 Sporadic EuroCJD22
Slovakia 1993–2017 0.85 Sporadic EuroCJD22
Slovenia 1993–2017 1.38 Sporadic EuroCJD22
Spain 1993–2017 1.30 Sporadic EuroCJD22
UK 1993–2017 1.19 Sporadic NCJDRSU 20161
USA 2016 1.22 Excludes vCJD US Centers for Disease
Control and Prevention23
Japan 1999–2015 1.3 All types Yamada et al.24
Australia 1993–2014 1.2 All types Klug et al.25
Finland 1997–2013 1.45 Sporadic EuroCJD22
Cyprus 1995–2013 0.70 Sporadic EuroCJD22
Germany 1993–2013 1.33 Excludes vCJD EuroCJD22
Holland 1993–2013 1.21 Excludes vCJD EuroCJD22
Hungary 1997–2013 1.65 Excludes vCJD EuroCJD22
Sweden 1997–2013 1.44 Excludes vCJD EuroCJD22
Switzerland 1993–2013 1.72 Sporadic EuroCJD22
Argentina 2008 0.85 All types Begué et al.26
Greece 1997–2008 0.62 Sporadic EuroCJD22
Taiwan 1998–2007 0.55 Sporadic Lu et al.27
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Possible reasons for the increase in the detection of sCJD cases in the UK are speculated to include:
l improved case ascertainment because of clinician awareness and/or improvements in
diagnostic testing
l population increases
l an ageing population
l changes to the sporadic case definition to include cerebrospinal fluid and magnetic resonance
imaging (MRI) diagnostic tests.
An upwards trajectory of CJD cases may be attributable to the way that data are collected for the
surveillance of CJD. Case ascertainment is likely to improve in areas where CJD surveillance is strong,
where there is greater awareness among health-care professionals of CJD and where there are more
neurologists who are able to diagnose CJD. As the national surveillance programme for CJD has
been operating since May 1990, and is a prospective surveillance programme, there are likely to be
improvements over time with respect to how this rare condition is detected, referred, investigated
and reported when compared with retrospective surveillance studies. Moreover, owing to the potential
for iatrogenic transmission, there has been a focused collaborative effort to examine the evidence of
transmission through different exposures by examining the links to confirmed CJD cases through
retrospective ‘lookback’ studies.31
The gradual increase in sCJD but not gCJD, adds support to the ‘ageing population’ theory over merely
population increase and improved case ascertainment.
Increase in sporadic Creutzfeldt–Jakob disease incidence globally
Reports of increased rates of sCJD were noted from other countries. In Finland, an increased incidence
of sCJD was noted between 1974 and 1989 of 0.6 per million to 1.36–1.44 per million in 2007–13, as
reported in an abstract by Isotalo et al.32 An abstract by Chen33 reports that sCJD incidence rates in
Taiwan doubled between 2008 and 2015. They also report that age at onset became younger. Chen33
speculates that the reasons for the increase in CJD cases include physician’s sensitivity in recognising
CJD; improved reporting systems; concerns around vCJD, and high media coverage. A published
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FIGURE 2 Deaths attributed to definite or probable CJD in the UK, using data from the NCJDRSU, between 1996 and 2017.30
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study34 from Belgium noted a relevant trend of significantly increased age-specific incidence of sCJD
patients between the age of 70 and 90 years in the period 2002–04 compared with 1998–2001, using
retrospectively obtained data (1990–1997; p < 0.01). The authors conducted a clinical and biochemical
analysis to investigate this increase, but could not identify any reason other than an increased vigilance
for the diagnosis. Similarly, in Japan, Ae et al.35 report in a study abstract that the annual incidence of
human prion diseases has increased since 1999, particularly so in older patients (aged ≥ 70 years),
with cases of rapidly developing dementia increasingly being identified by domestic physicians.
One study from Slovenia reported an apparent fluctuation of sCJD cases in 2015, with seven definite
and two probable sCJD cases resulting in an incidence of 4.36 per million for the country that year.36
Autopsy and biopsy in Creutzfeldt–Jakob disease
In the UK, confirmation of CJD from neuropathological (via autopsy or brain biopsy), immunocytochemical
or biochemical examination is required for obtaining a definitive sCJD diagnosis. For vCJD, confirmation
must be from neuropathology.1 Despite the observed increase in sCJD cases over the last twenty years,
autopsy is not performed routinely on sCJD cases. In the UK, almost 50% of all cases referred to the
NCJDRSU undergo autopsy.2 The most recent case of vCJD appeared in its clinical presentation and
neuroimaging to be sCJD, but as the age of the patient was atypically young (aged 36 years), a pathological
examination after death in February 2016 confirmed it to be vCJD despite the absence of clinical
epidemiologic diagnostic criteria for probable or possible vCJD.37 On the basis of this recent vCJD case,
pathological examination of every sCJD case would be required to know the true figures of autopsy-proven
sCJD and vCJD. Given this, an alternative explanation for the increasing number of sCJD cases over the last
20 years could be attributable to an altered incubation and clinical presentation of acquired CJD (variant or
iatrogenic CJD) that mimics sCJD or another neurological condition. Indeed, surgery has been posited as a
risk factor the transmission of sCJD by a number of epidemiological studies; a retrospective study by Urwin
et al.,38 described as ongoing, is seeking to investigate this risk factor further by reviewing UK sCJD cases.
Cursory analysis of published literature from studies on CJD around the world generates potential
reasons for why autopsy is not always routinely completed in sCJD patients. Brain biopsy and autopsy
of suspected CJD cases carry the risk of iatrogenic transmission to medical or pathology staff, meaning
that there is an extra burden of duty to ensure that stringent infection control protocols are followed.
Protocols for instrument decontamination are required for brain biopsy. For example, Shi et al.39 state
that although an intracranial biopsy procedure is invasive and carries risk of cerebral infection or
hematoma, it is generally a safe and well-tolerated procedure; however, special precautions to prevent
the spread of prions must be taken. Medical instruments and equipment supplies must be either
destroyed by incineration or autoclaved and sterilised. Similarly, Baig and Phillips.40 state that getting a
biopsy in a timely manner is often not possible given the costly and aggressive nature of the diagnostic
test and that the rigorous decontamination and sterilisation techniques for handling tissue at biopsy
may make it impractical in a community setting.
Ethnic and geographical differences
Variations in CJD incidence according to ethnicity by Maddox et al.41 and Holman et al.42 were noted in the
literature. In the USA, the age-adjusted CJD incidence for white people was reported as being 2.7 times
higher than that for black people (1.04 and 0.40 per million, respectively). Similarly, the estimated
incidence of CJD (0.7 per million) among Asians and Pacific Islanders in the USA between 2003 and 2009
was reported by Maddox et al.43 as being significantly lower than that for white people (p < 0.001).
Nakatani et al.44 noted that the occurrence of sCJD appeared to have regional variations in Japan,
suggesting that the existence of genetic or region-specific factors may affect the incidence of the
disease, such as hereditary background or other local factors. In this study, geographical clusters of
sCJD were scattered in the western half of Japan. However, no direct evidence to support theories
about the causative factors underlying this trend are presented and, therefore, this particular
phenomenon remains to be explored. Klug et al.45 conducted a spatial and epidemiological analysis of
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sCJD case-clusters in Australia. The authors concluded that the observed increase of sCJD cases in a
geographic area is more likely to be related to better awareness of the disease by local neurologists
rather than to an increase in risk factors.
Genetic forms of CJD are most often associated with a mutation at codon 200.46 Mitrova et al.47 report
that although gCJD represents approximately 10–15% of all CJD patients in the majority of countries,
in Slovakia the rate of gCJD has been higher than 65% since 1975 owing to an accumulation of gCJD
incidence in two clusters in central Slovakia. The authors state that all but one of the 202 patients who
had gCJD in Slovakia carried the mutation form E200K and highlight that asymptomatic carriers of this
gene could contribute to iatrogenic transmission of CJD. A voluntary genetic testing study conducted by
the authors showed positivity for the E200K mutation in 9 out of 2662 subjects who were unrelated to
the gCJD cases both inside and outside the focal cluster. This finding indicates an unusual phenomenon
of an increased prevalence of the E200K mutation linked to gCJD in the Slovak region. A study by
Ladogana et al.48 reported similar prevalence of sCJD across the UK, France, Germany, Italy, the
Netherlands and Slovakia, but also reported an excess of genetic cases in Italy and Slovakia.
Geographical differences in CJD incidence are likely to be influenced by ascertainment bias in countries
where access to health care is free and, moreover, when active national CJD surveillance is in place.
Diagnosis of Creutzfeldt–Jakob disease
Global differences in the culture of pursuing autopsy to confirm CJD diagnosis and subtype are likely
to exist depending on national CJD surveillance protocols. For example, Tuskan–Mohar et al.49 report
that post-mortem examination was not performed in any of the five cases of CJD occurring in Croatia
between 2001 and 2011 owing to patient families’ refusal of the procedure. More generally, Kosier50
state anecdotally in a US case report that the diagnosis of CJD is often delayed because of clinician bias
towards more obvious possible medical or psychiatric causes. Litzroth et al.51 highlight that in Belgium,
between 1998 and 2012, on average 60% of hospitalised patients who died with suspected CJD were
captured by the surveillance system. The authors also report that 11% of surveyed neurologists would
not refer suspect vCJD cases for autopsy, nor contact a reference centre for diagnostic support and that
61% of surveyed neurologists were not familiar with the surveillance system.
Two studies from Ireland describe a relatively sensitive surveillance system for CJD detection but less
accuracy in obtaining a final confirmatory CJD diagnosis. From a review of 21 referrals to the National
CJD Centre in Ireland, Brett et al.52 found that only five referrals were positive for CJD, with 12 being
referred as part of their differential diagnosis. Brett et al.52 cautioned that, more often than not, the
clinical suspicion of CJD was not borne from the final neuropathological diagnosis and that failure
by clinicians to adhere to the recommended CJD investigation algorithm impacts adversely on the
neuropathology workload and causes unnecessary concern among operating theatre, laboratory and
nursing personnel. Loftus et al.53 also raised the issue that the terms ‘probable CJD’ and ‘definite CJD’
might be used indiscriminately. They highlight from an analysis of 100 cases of CJD in Ireland, that
approximately half of cases (50/96 referrals) were confirmed as definite CJD via tissue samples
through biopsy or autopsy.53 The authors proposed an algorithm for CJD referrals to reduce infection
control and diagnostic difficulties encountered in CJD surveillance.
Despite the fact that sCJD is a condition known to affect older people, its detection may have
improved in the last 6 years. Figure 3 is taken from the 25th Annual Report of the NCJDRSU2 and
shows a steep increase in the detection of CJD mortality in the UK,2 particularly in the age category
of 65–69 years. However, incidence using age-adjusted data of CJD-related deaths per million will be
influenced by the assumed population in each band. The mortality rates for 1995–2004 use the same
census data as those for 2005–9. However, if there are proportionately more older people in the more
recent age band, the incidence will be inflated.
CLINICAL EVIDENCE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
Owing to the median age at onset of sCJD symptoms, it is possible that CJD and prion disease cases
may be concealed among cases of more commonly encountered but similarly rapidly deteriorating
neurological conditions affecting older people, such as Alzheimer’s disease. In the published literature,
there are numerous reports of CJD mimicking other conditions including stroke,54,55 acute neuropathy,56
hyperparathyroidism,57 dementia,51,58–61 Lewy body dementia,51 encephalitis,51 aphasia,62 Alzheimer’s
disease,51,60 psychiatric decompensation50 and movement disorder.63 The potential for CJD cases
to be misdiagnosed was first demonstrated in a study in 1995 which found from an analysis of
dementia autopsies that only about 60% of prion disease cases with pathologically typical spongiform
encephalopathy were identified clinically during life.64 Therefore, the observed rates of any type of
CJD could still be an underestimate of the actual rate of CJD deaths in the absence of definitive
pathological examination of all cases. It is also plausible that numerous cases of CJD that occur later
in life, particularly where access to clinicians with experience of diagnosing CJD is limited, may result
in some cases of misclassification of CJD, despite potentially improved detection. However, given the
rarity of CJD presentation worldwide and consequent clinical expertise, a degree of caution should be
exercised in the interpretation of the limited available data.
Disease duration
Disease duration is regarded as the time between the onset of clinical CJD symptoms and death. sCJD is
commonly reported to have a disease duration of 4–7 months;2,22,65–67 however, Nagoshi et al.68 report
that duration of disease was longer for sCJD in Japan than in Western countries. The authors state that
sCJD, which represented 77.0% of cases of prion disease in their surveillance network between 1999
and 2008, had a mean disease duration of 15.7 months. This longer disease duration in Japan is more
akin to the median observed in the UK for vCJD, which is 14 months from the onset of symptoms to
death (NCJDRSU’s 2016 annual report2) or indeed iCJD via human growth hormone (hGH), the median
of which is reported as 16 months (mean 14 months) for 22 iCJD patients.69 Nagoshi et al.68 also report
that disease duration was longer in females (19.7 months) than males (14.5 months) for sCJD and that
this tendency was also true for dura mater iCJD and types of gCJD including human GSS syndrome
and FFI. Nagoshi et al.68 also report that younger onset of disease was associated with longer disease
duration for all types of CJD.
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FIGURE 3 Age-specific mortality rates from sCJD in the UK 1970–2016: reproduced from NCJDRSU Annual Report
2016.2 1970–1984 mortality rates calculated using mid-1981 England and Wales population estimates based on the 1981
Census. 1985–1994 mortality rates calculated using mid-1991 UK population estimates based on the 1991 Census.
1995–2004 mortality rates calculated using mid-2001 UK population estimates based on the 2001 Census. 2005–2009
mortality rates calculated using mid-2001 UK population estimates based on the 2001 Census. 2010–2016 mortality
rates calculated using mid-2011 UK population estimates based on the 2011 Census. Reproduced with permission from
the National CJD Research & Surveillance Unit, University of Edinburgh.2
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Genotype: codon 129
Methionine homozygosity at codon 129 (MM) is considered the most susceptible genotype for CJD,
with sCJD and vCJD occurring mostly in individuals with the MM genotype. Both methionine (MM)
and valine (VV) homozygotes at codon 129 of PRNP are at an increased risk of sCJD.70 In the north of
Europe, the MM genotype represents 38% of the general population, whereas 11% of the population
have the VV genotype and 51% are heterozygotes (methionine/valine; MV) at codon 129 of PRNP.71
An epidemiological study by Giaccone et al.72 of the PRNP genotype of 402 consecutive sCJD cases in
Italy revealed that 70.4% (n = 283) had the MM genotype, 15.4% (n = 62) were MV and 14.2% (n = 57)
were VV.72 Although the numbers of MV and VV sCJD cases appear comparable in this study, the fact
that over half of the population in Europe are MV indicates that the relative incidence of sCJD in
heterozygotes at codon 129 is low.
In 2006, Ironside et al.73 re-analysed three of the appendixes identified (from the 12,674 appendix and
tonsil samples analysed by Hilton et al.7) as positive for disease-associated PrP; two of the three were
found to be VV genotype, which provided the first indication that the valine homozygotes are also
susceptible to vCJD infection.73 The authors suggested that people infected with vCJD who are VV
may have a prolonged incubation period with subclinical infection that could cause secondary infection
via blood transfusion or surgery. Additionally, detection of subclinical prion accumulation in peripheral
tissue by Gill et al.74 from 16 positive appendix samples found that eight were MM, four were MV, and
four were VV at codon 129 of PRNP, indicating that genetic susceptibility for subclinical CJD was more
equally distributed in the population.
Heterozygosity at codon 129 of PRNP was generally believed to confer complete resistance to both
sporadic and acquired prion diseases.75 However, the most recent case of clinical vCJD in 2016 was
heterozygous37 and an additional possible vCJD case reported by Kaski et al.76 in 2008 was also
heterozygous, but this possible vCJD case was not confirmed by autopsy. Two case reports indicate that
the MV genotype is susceptible to iCJD, but the cases were subclinical. First, the case of a heterozygous
73-year-old male with haemophilia whose spleen at autopsy gave a strong positive result on repeated
testing for protease-resistant prion protein (PrPres) by western blot analysis, as reported by Peden et al.77
This patient had received over 9000 units of factor VIII concentrate prepared from plasma pools known
to include donations from a vCJD-infected donor. Second, a case in 2004 of subclinical vCJD from blood
transfusion, who was heterozygous at codon 129, and died from a cause unrelated to CJD78 highlights
the possibility of potential transmission to this genotype. A study using mice supports the notion that
transmission efficiency of vCJD is greatest in MM but indicates that all genotypes are susceptible,
with the MV and VV genotypes benefiting from apparent reduced transmission efficiency and longer
asymptomatic incubation periods.79
Disease duration and genotype
Prion protein–gene data from 378 of the Japanese patients diagnosed with sCJD, reported by Nagoshi
et al.,68 showed that 364 cases (96.3%) had the MM genotype but that disease duration was longest
for the 11 patients (2.9%) who were MV (mean, 32.2 months for MV vs. 16.6 months for MM and
13.2 months for VV).68 Begué et al.26 report data for the disease duration of sCJD from 59 definite
cases in Argentina. Genotype analysis indicated that the MV genotype was associated with the longest
disease duration (10.9 months), followed by the VV (5.6 months) and the MM genotypes (3.6 months).26
Data from Rudge et al.69 relating to CJD transmission via hGH in the UK also found that MM patients
had the shortest disease duration; MM patients had a mean disease duration of 7.8 months, the VV
patients 17 months and MV patients had a mean disease duration of 18.6 months (range 10–32 months).
In addition, the duration of disease from first symptom was significantly longer in the MV patients
(p = 0.02, two-tailed t-test). Although there were only four patients who were MM, three of these
had the most rapid disease progression (p = 0.04, Mann–Whitney U-test). Yamada et al.24 state that the
majority of the general Japanese population (93%) carry the MM genotype. Considering that a large
share of patients in the Argentinian sample also contained the MM genotype (n = 37, 66%), genotype
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data at codon 129 alone cannot account for the substantial difference in disease duration for sCJD
reported between Japan and other countries.
Data from Japan,68 Argentina,26 and the UK69 therefore indicate that the MV genotype is associated
with the longest disease duration compared with homozygotes. Pennington and Knight80 also reported
disease duration to be significantly longer in codon 129 heterozygotes for gCJD.
Variant Creutzfeldt–Jakob disease
The annual number of confirmed cases of clinical vCJD has declined since 2005. As of 2016, the
NCJDRSU recorded 178 cases of vCJD in the UK.1 The most recent vCJD case occurred in an individual
who was heterozygous at codon 129.37 A further 52 cases have been reported from other countries
around the world, which brings the global total of clinical vCJD cases to 231.81 Between 2005 and 2014,
68 vCJD cases were reported from 11 countries including the UK (n = 29), France (n = 19), Spain (n = 5),
Ireland (n = 3), the USA (n = 3), Holland (n = 3), Portugal (n = 2), Italy (n = 1), Canada (n = 1), Saudi Arabia
(n = 1) and Taiwan (n = 1).22 A total of 3 out of the 178 cases in the UK that occurred up to 2016 are
considered to have occurred through blood transfusion.2 A fourth case of vCJD transmission through
blood transfusion was identified in the spleen of an individual (heterozygous at codon 129) who died
of a non-CJD related cause. This is considered to be preclinical vCJD.78 Three further potential, but
unconfirmed, cases of CJD transmission through blood transfusion are described by Chohan et al.82 and
Davidson et al.83 A retrospective study by Molesworth et al.,84 which was performed to identify situations
where the transplantation of organs or tissues might have occurred in any of the 177 UK vCJD cases,
found no evidence of transplant-associated vCJD in the UK.84 The remaining 175 clinical vCJD cases
are presumed to be related to dietary exposure to BSE.85
Iatrogenic Creutzfeldt–Jakob disease
The most common causes of iCJD were hGH and dura mater grafts obtained from human cadavers.
A review of worldwide iCJD cases published by Brown et al.3 identified 469 cases from dura mater
grafts (n = 228), surgical instruments (n = 4), EEG needles (n = 2), corneal transplants (n = 2), hGH
(n = 226), hGN (n = 4) and packed red blood cells (n = 3).3
In the UK, 85 cases of iCJD were identified between 1970 and December 2016, and are described by
the NCJDRSU.1 In total, eight cases were from dura mater grafts, 76 from hGH and one from hGN.
All cases have since died, with a mean age at death for the hGH/hGN group of 35 years (range
20–51 years) and for the dura mater cases 46.5 years (range 27–78 years).
Subsequent to the three cases of blood transfusion transmitted vCJD described above, no new cases of
transfusion-associated infection have been identified since 2007, based on an epidemiological analysis
of CJD cases and blood transfusion recipients by Urwin et al.86 The Urwin et al.86 study referenced the
Davidson et al.83 paper but not the Chohan et al.82 paper. These two papers discuss three potential,
but unconfirmed, cases of CJD transmission via blood transfusion. Ward et al.87 studied the risks in
treatment for haemophilia and concluded that it is unlikely that any of the UK vCJD clinical cases to
date were infected through exposure to fractionated plasma products.87 The evidence regarding the
incidence of iCJD from surgery is discussed in the review on the risk of CJD transmission via surgery.
The estimated prevalence of subclinical variant Creutzfeldt–Jakob disease in the UK
In vCJD, prions appear to replicate extensively within lymphoid tissue; therefore, tonsil and appendix
tissues are some of the earliest sites that can be used to assess abnormal prion accumulation. Such
abnormal prion accumulation prior to the onset of clinical symptoms is regarded as subclinical CJD
for the purposes of risk assessment and is thought to represent a potentially background, but low,
level of infection in the population.88 Immunohistochemistry staining is regarded as highly indicative
of the abnormal prion protein pattern that has been observed in cases of vCJD, but not observed in
other types of CJD, and is used to estimate the approximate number of individuals who may go on to
develop vCJD or be asymptomatic carriers of the disease.89
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A key study conducted by Gill et al.,74 referred to as the ‘Appendix II’ study, examined subclinical prion
accumulation in excised peripheral tissues from general population cohorts born in 1941–60 and
1961–85.74 Detection of abnormal prion accumulation in appendix samples from these two cohorts
resulted in a central estimation of 1 in 2000 for populations exposed to the BSE epidemic. The Advisory
Committee on Dangerous Pathogens (ACDP) TSE subgroup produced a summary of findings16 following
completion of the most recent study of stored appendixes (‘Appendix III’) and calculated a rough central
prevalence estimate of asymptomatic carriers of vCJD in the UK population, previously presumed
unexposed to BSE, of approximately 1 in 4200 people or 240 per million people.15,16 This estimate is
based on results of immunohistochemical (IHC) staining of appendixes from two birth cohorts, which
are described in Table 3.
Variant Creutzfeldt–Jakob disease and bovine spongiform encephalopathy
The hypothesis of zoonotic transmission through dietary exposure from the BSE outbreak is largely
upheld as the most plausible route of vCJD infection in humans, and transmission has been replicated
in wild-type mice.90 Moreover, a recent study by Diack et al.91 examined two Spanish cases of vCJD: a
mother and son who resided in a BSE-endemic area, who are thought to have ingested bovine brain.91
The strain characteristics of both individuals are similar to the UK cases, implying BSE as the source of
infection and supporting the hypothesis of risk via ingestion of high-titre bovine material.
The Appendix III study75,76 highlights that abnormally stained appendixes associated with vCJD prion
accumulation have been confirmed in cohorts of people who were not considered to have had significant
exposure to BSE because they were either from appendixes removed before the BSE epidemic in the UK
(prior to 1980) or from appendixes from patients born after food safety measures to limit BSE were
implemented (after 1996). The presence of seven positive samples in these cohorts could suggest that
there is low background prevalence of abnormal prion protein staining in human lymphoid tissue that
may not represent subclinical vCJD or be related to the BSE outbreak, and may be unlikely to progress
to vCJD. Another possible interpretation is that the duration of the BSE epidemic and subsequent
ingestion by humans through the food chain was longer than the presumed duration of human exposure
to the BSE epidemic (between 1980 and1996). Moreover, planned statistical analysis, as described by
Gill et al.,74 found no difference between the prevalence observed in the cohort considered to be most at
risk of the BSE epidemic (people born 1961–85) and an older cohort (born 1941–60).
These two possible explanations are considered by the ACDP TSE subgroup as not necessarily being
mutually exclusive nor fully satisfactory.
Previous estimates of prevalence of abnormal prion in humans
Primary studies (published after 2005) that provide estimates for subclinical CJD in the general
population based on analysis of peripheral tissue are described in Table 4. Central estimates range
between 0 and 493 per million people in the population. Studies providing evidence of the prevalence
of vCJD prions in lymphoid tissues published prior to 2005 are described in a review published by
Olsen et al.94 This review includes the cross-sectional study by Hilton et al.7 that estimated the
prevalence in the sample population to be 120 per million from 11,228 appendixes.
TABLE 3 Results of the Appendix III study16
Appendix III cohort IHC stain results Central estimate
Appendixes removed between 1970 and 1979 and before the
BSE epidemic
Two positive samples from
14,692 appendixes
1 in 7000
Appendixes removed from patients born after 1 January 1996
and after measures to remove BSE were in place
Five positive samples from
14,824 appendixes
1 in 3000
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Obtaining definitive prevalence estimations
Subclinical vCJD can be detected through typical PrP staining in lymphoid tissue or through observation of
the presence of florid plaques in the brain at autopsy; however, systematic lymphoid or neuropathological
examination is not performed routinely in post-mortems. To collect a truly accurate picture of the prevalence
of CJD through abnormal prion protein in humans, the UK Health Protection Agency proposed the creation
of a post-mortem tissue archive.95 The study required tissue from a large number of post-mortems and the
participation of coroners in England andWales. However, the Coroners’ Society of England andWales
(CSEW) declined to participate in the study, citing various issues including its putative legality, cost and
feasibility.96 The CSEW concluded that to participate in the study would ‘adversely affect the independence
of the coronial service and would further erode public confidence’.97 McGowan and Viens95 describe that
as death investigation systems with substantial independence are not directly answerable to central
government, they cannot be instructed to participate in any disease surveillance programme, regardless
of how crucial it is to the protection of human health and safety.
Discussion of the incidence and prevalence of Creutzfeldt–Jakob disease
The incidence of CJD is relatively stable around the world (between 1 and 2 cases per million people)
but age-adjusted detection of sCJD is increasing in the UK as well as in other countries. Reasons
posited for this increase include improved case ascertainment and an ageing population. The estimated
prevalence of subclinical vCJD from lymphoid tissues of people in the UK who were exposed to the
BSE epidemic was 1 in 2000 people and the estimated prevalence of CJD-related prions in lymphoid
tissues in the UK population who are not thought to be exposed to the BSE epidemic was 1 in 4200
TABLE 4 Studies estimating the prevalence of CJD from peripheral tissue samples, published after 2005
Study
(first author and
year of publication) Design
Number of
samples
Predicted/estimated
prevalence Description of estimation
Gill et al. (2013)74 UK histological
analysis of
appendix samples
from the 1941–60
and 1961–85
birth cohorts
32,441 l 1 in 2000 or 493 per
million (95% CI
282 to 801
per million)
l 1941–60: 733 per
million (95% CI 269
to 1596 per million)
l 1961–85: 412 per
million (95% CI 198
to 758 per million)
l Found 16 to be positive
for subclinical abnormal
prion protein PrP
l 50% of the 16 positive
samples were MM, 25%
MV and 25% VV
de Marco (2010)92 Two estimations
based on UK
tonsil tissue
samples from the
1961–85 birth
cohort
10,075 l High: 109 per
million (95% CI 3 to
608 per million)
l Low: 0 per million
(95% CI 0 to 403
per million)
l One specimen showed
both positive and negative
results on further tests, so
the two estimates reflect
both positive and
negative scenarios
Clewley (2009)93 UK estimation
combining tonsil
tissue samples
63,007 (32,661
from the 1961–95
cohorts)
l 1961–85 cohort: 0
per million (95% CI
0 to 289 per million)
l 1961–1995 cohort:
0 per million
(95% CI 0 to 113
per million)
l 1986–95 cohort: 0
per million (95% CI
0 to 185 per million)
l 1996–2007 cohort:
0 per million
(95% CI 0 to 122
per million)
l No positive results from
63,007 tonsil specimens
from the birth cohort
in Britain, where most
cases of vCJD have
occurred
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people. This suggests a potentially constant underlying rate of abnormal prion accumulation in
lymphoreticular tissue in the UK population, which may or may not represent disease that will progress
to clinical CJD. Estimations of prevalence are currently limited to retrospective cohort studies of
anonymised tonsil or appendix samples.
The risk of Creutzfeldt–Jakob disease transmission via surgery
The literature searches retrieved no further published papers from the period 2005 to 2017 reporting
confirmed cases of stCJD, further to the four neurosurgical cases which occurred between 1952 and
1974.3 These four historical cases (three in the UK and one in France) are distinct from the known dura
mater and hGH iCJD cohorts, and occurred prior to the vCJD epidemic that began in the late 1980s. The
four historical surgical cases, therefore, represent a small proportion of the known iCJD cases (469 iCJD
cases according to Brown et al.3) and occurred when methods for cleaning surgical instruments were
not adequate assuming current decontamination standards. Consequently, the risk of CJD transmission
via surgery according to recent direct evidence appears to be low. However, the long asymptomatic
incubation periods noted in some cases of CJD, the difficulties of eradicating prions from neurosurgical
instruments (especially once adhered to dry instruments), the high levels of infectivity of CJD in the brain
and a presumed subclinical underlying prevalence (albeit low) in the general population mean that there is
a margin of uncertainty around detecting and quantifying the risk of CJD transmission via surgery.
Observational studies implicating surgery in Creutzfeldt–Jakob disease
Despite the absence of studies providing direct evidence of further cases of stCJD, a number of
papers were identified which allude to a potential relationship between CJD cases and prior surgery.
Papers that investigate but do not provide evidence of a direct link to surgery are listed in Table 5.
TABLE 5 Studies reporting links between CJD and surgery published between 2005 and 2017
Study (first author and
year(s) of publication) Design Source
Kobayashi (2015 and
2016)98–100
Two historical sCJD cases with neuropathological and
biochemical features of plaque-type dura mater-acquired-CJD.
The authors posit that these cases (a neurosurgeon and a
patient with a medical history of neurosurgery without dura
mater grafting) represent iCJD through cross-contamination
from neurosurgical instruments or through occupational
exposure as a neurosurgeon
Two published papers and a
conference abstract
Gnanajothy (2013)101 Case report of 64-year-old man diagnosed with CJD (type of
CJD not reported) 3 months after cataract surgery. The authors
discuss the possibility that the visual symptoms that prompted
the surgery might have represented onset of the disease rather
than it being the case that the procedure itself transmitted the
disease (i.e. the patient already had CJD)
Published paper
Tuck (2013)102 Case report of sCJD that was posited to be iCJD via surgery
because of the patient’s young age. At 33 years of age, the
patient experienced progressive deficits over 3 months. Review
of medical history revealed that a ventriculoperitoneal shunt
was placed at 11 years of age for hydrocephalus. Autopsy
results were consistent with sCJD
Conference abstract
Moreno (2013)103 A surveillance study in Meixoeiro Hospital (Spain) reported
12 cases of CJD (10 sCJD and 2 gCJD) from 1997 to 2010,
which represented a high average yearly rate of 4.6 per
million people (3.8 for sCJD and 0.8 for gCJD). According to
the Poisson distribution for the 12 cases (with an expected
annual incidence of 1.5 cases per million people), only 3.9
cases would have been expected over a 14-year period. A
total of 8 out of 12 CJD cases had undergone at least one
surgical or invasive medical procedure
Published paper
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TABLE 5 Studies reporting links between CJD and surgery published between 2005 and 2017 (continued )
Study (first author and
year(s) of publication) Design Source
Puopolo (2011)104 A case–control study found that ‘history of surgery’ was more
frequent in sCJD cases (n = 13, 2%; neurosurgery, n = 12;
cornea transplantation, n = 1) vs. no-CJD cases (n = 5, 1%;
neurosurgery n = 5) and none in genetic TSE patients. A crude
OR of 1.57 (95% CI 1.14 to 2.16) was reported. Results did
not reach statistical significance when adjusted for a 10-year
time lag
Published paper (included in
de Pedro-Cuesta et al.112)
de Pedro-Cuesta (2011)105
Mahillo-Fernandez
(2008)106
A case–control study of sCJD to look for risk factors from 167
sCJD cases in Denmark and Sweden. Surgery for ‘lower risk
procedures’ (i.e. surgery to veins, peritoneal cavity and lymph
nodes) compared with high-risk procedures (i.e. surgery to
brain, spinal cord, retina and optic nerve) carried out > 20 years
before disease onset was associated with an increased risk
of sCJD (OR 2.81, 95% CI 1.62 to 4.88).When tissues or
structures were reclassified by hypothetical transmission risk
at a latency of ≥ 1 year, surgery to the retina and optic nerve
were the most strongly associated risk factors (OR 5.53,
95% CI 1.08 to 28.0)
Two published papers
(included in de Pedro-Cuesta
et al.112)
Hamaguchi (2009)107,108 A case–control study in Japan with 753 sCJD patients and 210
controls. Surgery was not a risk factor for sCJD prior to disease
onset. However, 4.5% of sCJD patients underwent surgery after
onset of sCJD, including neurosurgery in 0.8% and ophthalmic
surgery in 1.9% of patients. Among the neurosurgery cases,
the symptoms of sCJD were misdiagnosed as those of other
neurological diseases, and the surgeries were performed near
disease onset. The authors concluded that, despite absence
of empirical evidence of transmission via surgery, the risk of
contracting CJD via surgery is still present because patients are
operated on after disease onset
Two published papers
(included in de Pedro-Cuesta
et al.112)
Ruegger (2009)109 A case–control study in Switzerland found that 69 sCJD
patients, compared with 224 controls, were more likely
(p < 0.05) to have travelled abroad, worked at an animal
laboratory, undergone invasive dental treatment, had
orthopaedic surgery, had ophthalmologic surgery after
1980, attended regular GP visits, taken medication regularly,
and consumed kidney. No differences between patients
and controls were found for residency, family history, and
exposure to environmental and other dietary factors. Other
types of surgery were not found to be a possible factor.
Previous under-reporting/misdiagnosis was proposed as the
most likely explanation for the increased annual mortality
Published paper (included
in de Pedro-Cuesta et al.112)
Ward (2006)110 Case–control study of 136 vCJD patients and 922 controls.
Investigation of risk factors in the UK identified dietary
exposure to contaminated beef products as the main route of
infection of vCJD with no convincing evidence of increased
risk through medical, surgical, or occupational exposure or
exposure to animals
Published paper (included
in de Pedro-Cuesta et al.112)
Ward (2008)111 A case–control study in the UK of 431 sCJD patients and 454
controls, found increased risk was not associated with surgical
categories chosen a priori but appeared most marked for ‘other
surgery’, especially the three subcategories: (1) skin stitches,
(2) nose/throat operations and (3) removal of growths/cysts/
moles. No convincing evidence was found of links between
cases undergoing neurosurgery or gynaecological surgery
Published paper (included
in de Pedro-Cuesta et al.112)
OR, odds ratio.
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Issues of reliability and validity in case–control studies
Because sCJD is idiopathic, its aetiological basis is presumed to be spontaneous but this is not known
with any certainty.89 Therefore, case–control studies are a frequently encountered design in estimating
possible and plausible risk factors for sCJD. de Pedro-Cuesta et al.112 caution about the potential biases
in these study designs in an assessment of 18 case–control studies of CJD. From a combined analysis
of studies, the authors found that history of surgery or blood transfusion was associated with a risk
of sCJD in some, but not all, recent studies using a 10-year or longer lag time, when controls were
longitudinally sampled. Furthermore, they found that none of surgical history, blood transfusion,
dental treatments or endoscopic examinations was linked to vCJD. However, the authors highlight
that the validity of the findings in these case–control studies may be undermined by (1) the selection
of control cases; (2) exposure assessment in lifetime periods of different durations; (3) disregarding
‘at-risk’ periods for exposure in the controls, or asymmetry between the case and control data; and
(4) confounding by concomitant blood transfusion at the time of surgery. They also postulate that
surgery at early clinical onset might be over-represented among cases.
As a retrospective study design, case–control studies are prone to bias. The source of cases and the
selection of control (matched or unmatched) cannot be performed blindly or impartially; therefore,
there is a high risk of selection bias on the researcher’s part. Owing to long incubation periods and the
reliance on family members’ reports of medical histories, there is also substantial likelihood of recall
bias. Case–control designs are also less useful when the study exposures are rare, as in the case of
surgery or blood transfusion. Therefore, the utility of these studies in attempting to fairly estimate risk
factors is limited. However, as CJD is rare, fatal and has a potentially long latency period, there are few
plausible alternative study designs to establish potential lifetime risk factors in humans. Therefore, the
use of community controls and ascertainment of surgical exposures through the use of medical records
in case–control designs is currently the most feasible approach for identifying the potential association
between surgery and CJD at a population level.
Risk of Creutzfeldt–Jakob disease through occupational exposure for
health-care professionals
In 2009, the Spanish CJD registry was notified of a case of sCJD in an experienced general
pathologist/neuropathologist, which prompted investigation into the possible risks to health-care
professionals in contact with CJD patients.113 As a result, Alcade-Cabero et al.113 reported the data
requested from the EuroCJD surveillance network, which documented 65 physicians or dentists
(including two pathologists) and 137 health-care workers from 8321 registered sCJD cases from
21 countries. Control data, which used ‘non-cases’ from five countries, recorded 15 physicians and
68 other health-care professionals among 2968 controls or non-cases, and suggested that there was no
relative excess of sCJD among health-care professionals. The study authors also performed a literature
review examining reports (n = 12) pertaining to 66 health-care professionals with sCJD, and analytical
studies on health-related occupations and sCJD (n = 5). From a range of occupations, only people
working at physicians’ offices were found to be at a statistically significant risk of sCJD [odds ratio
(OR 4.6, 95% CI 1.2 to 17.6)]. The authors concluded that a wide spectrum of medical specialties and
health-care professions are represented in sCJD cases and that there is no evidence of an increased
occupational risk for health-care professionals. The authors do caution that there may be a specific risk
in some professions associated with direct contact with high human-infectivity tissue. The NCJDRSU
continue to monitor occupational exposure to CJD in health-care professionals.
Risk of Creutzfeldt–Jakob disease in surgery and age
de Pedro-Cuesta et al.114 performed a retrospective analysis of 167 cases of sCJD between 1987 and
2003. From a study of 167 probable or definite CJD cases and 835 matched controls, the authors suggest
that a younger age at first surgery may increase the risks of acquiring sCJD: patients aged < 30 years
(OR 12.80, 95% CI 2.56 to 64.00), patients aged 30–39 years (OR 3.04, 95% CI 1.26 to 7.33) and patients
aged ≥ 40 years (OR 1.75, 95% CI 0.89 to 3.45), for anatomically classified surgical procedures. As highlighted
by the same authors in a different study,112 caution should be urged when interpreting conclusions from
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analyses on indirect evidence in retrospective samples. Additionally, the ≥ 40-year age group contains
those who are elderly and may die before clinical symptoms appear or may remain undiagnosed.
Risk of iCJD transmission through surgery can potentially occur when patients are unwittingly treated
in hospital at the time of symptom onset. Cruz et al.115 used a cross-sectional design to study surgical
procedures in sCJD patients and controls to estimate subclinical and clinical risks to future surgery.
The authors posit that patients with sCJD in the clinical stage undergo a considerably higher frequency
of surgical procedures than non-CJD patients, including neurosurgery. The authors argue that
identification of such potentially higher-risk events, where surgery is undertaken in infectious patients
around the onset of clinical symptoms, but prior to CJD diagnosis, might well constitute a priority in
clinical settings. A conference abstract by Kobayashi116 reinforces this concern by providing data from
the Japanese CJD Surveillance registry. From an analysis of 760 CJD patients, Kobayashi116 identify
that six patients had undergone neurosurgery after the onset but before the diagnosis of CJD during
the period from 1999 to 2008.116
Cases of suspected but unconfirmed Creutzfeldt–Jakob disease transmission
via neurosurgery
Patients may be identified as being ‘at increased risk’ of CJD if they have had surgery using instruments
that had been used on someone who went on to develop CJD or someone who was ‘at increased risk’ of
CJD.117 A study by Hall et al.118 reports that 154 patients in the UK are considered to be ‘at increased risk’
of various forms of CJD following neurosurgery. This paper reports that of these 154 patients, only 129
have been informed that they are at an increased risk of CJD, either because of deaths before notification
or because a local decision was taken not to inform the individual. Although no incidence of CJD has been
reported within these 154 patients, the authors highlight that ‘at-increased-risk’ patients often have a
relatively short life expectancy because of their medical conditions. Diagnosing asymptomatic infection
requires testing specific tissues that are most readily available at post-mortem. Few post-mortems have
been conducted when at-increased-risk individuals have died; therefore, some asymptomatic infections
may have been missed.
Two published papers119,120 from the USA report instances in which potential iCJD exposure via
neurosurgery was investigated in hospitals; however, no confirmed cases of transmission were
subsequently identified.
Risks in surgery other than neurosurgery
Prospective risks from surgery
A study by Baig and Phillips40 describes a case report of a male patient (aged 66 years) who had surgical
fixation of a hip fracture, most probably around the onset of CJD symptoms; therefore, given the lack of
symptoms, the standard sterilisation method was appropriately used. The authors highlight that this
standard decontamination method is typically not adequate for the eradication of the CJD prion protein,
thus presenting a theoretical risk of prion protein transmission through surgical equipment. The focus of
this paper is not on the implication that the patient contracted iCJD via surgical transmission but instead
highlights a circumstance where subsequent iatrogenic transmission may have occurred because of a
lack of high-risk decontamination procedures. However, surgery of low infective tissues in individuals
diagnosed with CJD is noted to be common and,110,111 therefore, surgery that did not involve high
(or medium) infectivity tissues would not be regarded as a risk of iatrogenic transmission.
A recent study by Orrú et al.121 found infectivity in the skin of sCJD patients, albeit at prion levels
1000–100,000 times lower than that in the brain and detectable only by an extremely sensitive assay.121,122
However, a study using humanised transgenic mouse models demonstrated that the skin prions were
infectious. The study authors argue that extra precautions should be taken during non-neurosurgeries
in sCJD patients, particularly when instruments will be re-used, because infectivity through skin was
previously unknown.
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A study by Notari et al.123 found from a neuropathological examination of a vCJD case in the USA that
as well as detection of PrPres in the brain, lymphoreticular system, pituitary and adrenal glands, and
gastrointestinal tract, PrPres was also detected in the dura mater, liver, pancreas, kidney, ovary, uterus
and skin.123 The authors concluded that the number of organs affected in vCJD is greater than
previously realised, and this further underscores the risk of iatrogenic transmission in vCJD.
Risks in eye surgery
Davanipour et al.124 postulate that ocular tonometry is a risk factor for contracting sCJD from a case–control
study conducted across 11 states in the USA. Contact tonometry is used by ophthalmologists to diagnose
glaucoma. The authors conclude that disposable covers or non-contact tonometry should be used in the
absence of adequate decontamination processes.124
Tullo et al.125 document that there were three recipients of either cornea or sclera from a woman who
died of biopsy-proven carcinoma of the bronchus in 1997, but was later neuropathologically identified
as having sCJD.125 At the time of publication, two recipients remained symptom-free of CJD, whereas
one patient had died, aged 92 years (7 years after surgery), showing some signs of dementia that were
not considered indicative of iCJD.
Jirsova et al.126 conducted an analysis of brain tissue samples from the frontal lobe of 1142 eye donors
obtained from three tissue banks in the Czech Republic. As no pathogenic prions were found, the authors
presume a very low risk of transmission of CJD through corneal graft transplantation. However, the
authors’ conclusion can be regarded as a logical fallacy, denying the antecedent, because in the absence of
sCJD cases in the analysis it is not possible to conclude on the risk of CJD transmission via surgery in
corneal graft transplantation. Additionally, Maddox et al.127 used data from corneal transplantation and
CJD deaths from 1990 to 2006 in a statistical analysis, to suggest that a case of coincidental sCJD will
occur among the population of corneal transplant recipients approximately every 1.5 years.127
Risks in dentistry
Bourvis et al.128 conducted a risk assessment of the transmission of sCJD in endodontic treatment in
the absence of adequate prion inactivation. The authors developed a mathematical model, which
incorporated experimental and observational data and expert consultation. They estimated that without
effective prion deactivation procedures, the risk of being infected during endodontic treatment ranged
between 3.4 and 13 per million procedures. The authors consider that strict respect of the official
recommendations on decontamination procedures is essential in dentistry, and even suggest that the
cost–benefit of single-use endodontic instruments should be re-evaluated. Everington et al.129 found no
evidence of an increased risk of vCJD associated with reported dental treatments in a case–control
study of UK vCJD patients.129 However, the authors do not rule out the possibility that some cases may
have resulted from secondary transmission via dental procedures. Azarpazhooh and Fillery130 highlight
that, although no definite cases of prion disease transmission have been reported, the theoretical risk
from dental instruments is low but real and, as a general rule, appropriate family and medical history
(including the risk for prion diseases) should be obtained from all patients before dental procedures.130
Discussion/summary of risk of Creutzfeldt–Jakob disease transmission via surgery
Although no studies have identified a new case of stCJD in the search period covered, many speculative
case–control reports of the relationship have been conducted. These analyses provide indirect
retrospective evidence implicating neurosurgery or surgery as a risk factor for CJD, but their design
is known to be at risk of bias and confounding. However, as CJD is rare, fatal and has a potentially
extended incubation period, there are few plausible alternative study designs to establish potential
lifetime risk factors for CJD in humans.
Indirect evidence points to other factors being relevant to CJD and surgery, including younger age at
first exposure, increased risk of surgery around the time of symptom onset, the risk to health-care
professionals, and the risk from procedures where high-risk decontamination measures are not in
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place. Although less relevant to the decision problem, clinical studies have recently demonstrated low
levels of CJD infectivity in skin. When considering vCJD, surgical procedures (other than high-risk
procedures) that could potentially be regarded as posing a risk of iatrogenic transmission include
appendectomy and tonsillectomy. However, no direct evidence exits to highlight a serious risk from
surgical procedures involving tissues that are not high risk.
Incubation periods of acquired transmissible spongiform encephalopathys
The purpose of this review was to identify published and unpublished evidence for the incubation
periods of acquired TSEs, especially CJD, in human populations. Evidence on incubation periods has
implications for determining the risk of transmission from surgical procedures. Eighteen full-text papers
were identified as relevant.
Studies of incubation periods
Studies relating to incubation periods of acquired TSEs are described in Table 6.
TABLE 6 Characteristics of included studies for incubation periods, ordered alphabetically
Study (first author and
year of publication) Design Population
Source of
infection Location
Number
of cases
Ae (2016)35 Epidemiological
surveillance
iCJD Dura mater
graft
Japan 149
Brown (2012)3 Epidemiological
surveillance
iCJD All International 469
Brown (2015)6 Review iCJD Neurosurgery International 6
Chohan (2010)82 Case study iCJD Blood products UK 1
Collinge (2008)131 Epidemiological
surveillance, cohort
Kuru Ingestion Papua New Guinea 11
Collinge (2008)132 Review Kuru Ingestion Papua New Guinea NA
Collinge (2006)133 Epidemiological
surveillance, cohort
Kuru Ingestion Papua New Guinea 11
Collinge (2006)134 Letter: reply regarding
Collinge et al.134
Kuru Ingestion Papua New Guinea NA
Davidson (2014)83 Retrospective cohort iCJD Blood products UK 9
Haïk (2014)135 Review CJD All International NA
Hamaguchi (2013)136 Epidemiological
surveillance
iCJD Dura mater
graft
Japan and
international
195
Heath (2006)137 Epidemiological
surveillance
iCJD Dura mater
graft
UK 8
Hirst (2005)138 Epidemiological
surveillance
iCJD hGH UK 1
Peden (2010)77 Case study iCJD Blood products UK 3
Meissner (2009)139 Retrospective cohort iCJD Dura mater
graft
Germany 10
Ritchie (2017)140 Epidemiological
surveillance, retrospective
cohort
iCJD hGH, dura
mater graft
UK 37
Rudge (2015)69 Epidemiological
surveillance, cohort
iCJD hGH UK 22
Wroe (2006)141 Case study iCJD Blood products UK 1
NA, not applicable.
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The diagnosis of definite or probable iCJD depends on identification of the likely source of contamination
to which patients have been exposed, as well as fulfilling the basic requirements for the definite or
probable diagnosis of CJD. Wherever possible, only the most recent and/or up-to-date data are
presented in Table 7, unless there is potential value in comparisons with data from earlier samples or
earlier publications which provide relevant details that are not reproduced in the more recent papers.
UK data on incubation
A summary of data on incubation periods for iCJD in the UK is presented in Table 8.
Dura mater grafts and genotypes
Frequency data and mean incubation periods by genotype are presented in Table 8 for the UK subset
of CJD cases that are known to be caused by dura mater. The worldwide number of iCJD cases due to
dura mater surgery exceeds 200, and it is known that the majority have occurred in Japan (n = 149).35
TABLE 7 Reported number of cases of iCJD (worldwide and UK) and incubation periods (mean and range)
Source of infection
Number of
cases (n)
Incubation periods for
overall data (years)
Studies/reports (first author and
year of publication)Overall UK Mean Range
Primary transmission
vCJD from ingestion/BSE 229 175a 12 – Haik (2014);135 NCJDRSU (2017)2
Kuru – 0 12b 4–> 40 Haik (2014);135 Collinge (2006);133
Ritchie (2017)140
Secondary transmission
Dura mater graft 228 8 12 1.3–30 Brown (2012);3 Haik (2014)135
Neurosurgical instruments 4c 3 1.4 1–2.3 Brown (2015);6 Brown (2012);3
Haik (2014)135
EEG needles 2 0 – 1.3–1.7 Brown (2015);6 Brown (2012);3
Haik (2014)135
Corneal transplant 2 0 – 1.5–27 Brown (2012);3 Haik (2014)135
Growth hormone 226 78 17 5–42d Ritchie (2017)140
21 20 8–31 Ritchie (2017)140 – online table 1
Gonadotrophin 4 0 13.5 12–16 Brown (2012)3
Packed red blood cells 3 3 – 6.5–8.3e Brown (2012);3 Haik (2014)135
2 2 Wroe (2006);141 Peden (2004);78
Ironside (2010);146 Chohan (2010)82
Total (secondary transmission) 471 81
a UK only: ACDP 2016; NCJDRSU,2 n= 178 (but this includes the three cases of blood transfusion). However, no
incubation data were provided.
b Collinge132 reported 11 new cases from 1996 to 2004 with a much longer mean incubation period of 48.7 years
(range 39–56 years) and with a much higher proportion of heterozygotes: 80% compared with < 50% in earlier
samples (Cervenova et al.,142 Klitzman et al.143).
c Possible additional cases of iCJD as a result of neurosurgery have also recently been identified (Brown and Farrell;6
Kobayashi et al.;144 Xiao et al.145), but no incubation data are available.
d Based on assumed midpoint date of multiyear periods of treatment, and the onset of symptoms (Ritchie et al.,140
online table 1).
e Incubation data are available only for the three clinical cases; two cases were non-clinical, i.e. there was transmission
by transfusion, but the patients died asymptomatic.
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Frequency data and mean incubation periods by genotype, extracted from Brown et al.,3 are also
presented in Table 9 for subsets of the worldwide (excluding Japan) and Japanese affected populations.
Hamaguchi et al.147 reported a mean incubation period of 12.1 years (range 1–30 years) for 142 patients in
Japan and 11.3 years (range 1–23 years) for a subset of 53 patients with published data from the other
countries, although this subset did not include a Dutch case of dura mater-related iCJD that had an
incubation period of 28 years, which is the longest reported incubation period outside Japan.148
Meissner et al.139 reported on a sample of 10 cases (nine from Germany and one from Croatia) of iCJD
related to dura mater, which were identified between 1993 and 2006. The median incubation period
was 18 years (range 9 to 23 years), with 90% of cases being homozygotes, the majority of which were
the MM genotype (80%). This study also reviewed published evidence from the literature on 27
international patients with iCJD because of dura mater grafts who had MRI data. Data on incubation
periods were available for 22 of these patients: the mean incubation period was 11.5 years
(range 1.6–23 years), with 95% being homozygotes, mainly of the MM genotype (81%).
Human growth hormone and genotypes
Table 10 presents frequency data and mean incubation periods by genotype for a subset of the known
CJD cases caused by hGH. It is reported that one particular preparation of hGH was most probably
responsible for cases of iCJD caused by hGH in the UK, to date.3,69
As reported in Table 7, 78 cases had been reported in the literature for the UK as of 2017,140 an
increase from the 65 cases reported previously.69 Ritchie et al.140 present data on subsets of 21 and
37 patients with available tissue samples; analysis was conducted on frozen tissue samples for the
former group. Both samples demonstrated the same pattern: patients with the MM genotype were
fewer and had consistently longer incubation periods, whereas the VV genotype had the shortest mean
incubation period. The heterozygous genotype MV was the most frequently identified genotype in both
subsets. There is potential for some crossover of data between the included studies, which cannot be
accounted for in this review.
TABLE 8 UK-only data for iCJD incubation periods (reported or calculated by the reviewer in years)
Source of infection Number of cases (n)
Mean incubation
period (years) Range (years)
Studies/reports
(first author and
year of publication)
Dura mater graft 1990–2012a 8b 7.8c 3.8–14.8c Heath (2006)137
3 11d 8–15 dRitchie (2017)140
Neurosurgical instruments 3 1.4 1.3–1.6 Brown (2015)6
EEG needles 0 NA NA –
Corneal transplant 0 NA NA –
Growth hormone 1990–2012a 78 NR NR Ritchie (2017)140
65 20 7–39 Brown (2012)3
21 19 11–31 dRitchie (2017)140
Gonadotrophin 0 NA NA –
Packed red blood cells 3 – 6.5–8.3 Brown (2012)3
Haik (2014)135
NA, not applicable; NR, not reported.
a Sample with frozen tissues from patients who died in 1990–2012.
b One of which was a porcine not human source of graft.
c Data reported as months, calculated by the reviewer as years.
d Supplementary online table 1.
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TABLE 9 Mean incubation periods by genotype for iCJD because of dura mater grafts
Location
Number of
cases (n)
Genotype
Homozygotes Heterozygotes
MM VV Total MV
Frequency (%)
Incubation
period (years) Frequency (%)
Incubation
period (years) Frequency (%)
Incubation
period (years) Frequency (%)
Incubation
period (years)
Not Japan3,136 54a 65 12 15 12 80a 12 20 16
bJapan3,136 54c 96 16 0 – 96 16 4 13
a Hamaguchi136 reports data for a subset of 29 patients with both MM and MV having a mean incubation period of 13 years, with 74.3% of a subset of 35 patients being homozygotes.
b 142 out of 228 known worldwide cases are from Japan.3,136 Note: according to an abstract by Ae et al.35 149 cases now reported in Japan, with a mean incubation period of
13 years and a maximum period of 30 years.
c Hamaguchi136 reports the same figures for 58 patients.
TABLE 10 Mean incubation periods reported from included studies by genotype for iCJD caused by human growth hormone
Location
Cases with
genotype
data/total
known cases
Genotype
MM MV VV Homozygotes Heterozygotes
Study (first
author and year
of publication)
Frequency,
n (%)
Incubation
period (years)
Frequency,
n (%)
Incubation
period (years)
Frequency,
n (%)
Incubation
period (years) Frequency
Incubation
period (years)
Incubation
period (years)
UK 21/78
(1990–2012)a
2 (10) 30 12 (57) 18.5 7 (33) 15.7 43% 19 19 years bRitchie (2017)140
UK 37 10% 68% 22% 32% Ritchie (2017)140
UK 56/65 8 (14) 30.8 33 (59) 23.4 15 (27) 14.3 41% 23 Rudge (2015)69
UK 22
(2000–2014)
4 (18) 31.8 17 (77) 28.6 1 (5) 20.6 23% 29 Rudge (2015)69
UK 28 1 (4) 21 13 (50) 23 14 (46) 18 54% 20 23 Brown (2012)3
France 111/119 54% 12 15% 9 69% 11 17 Brown (2012),3
Haik (2014)135
USA 11/29 55% 21 18% 18 73% 20 23 Brown (2012)3
a Sample with frozen tissues from patients who died in 1990–2012. Hirst138 reports a case of hGH with an incubation period of 24 years.
b Online tables 1 and 3.
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These findings were broadly similar to those reported for another subset analysis of iCJD patients using
imaging, molecular and autopsy data.69 Rudge et al.69 present data on a subset of 22 patients from 56
patients with genotypic data available. They studied a cohort of 22 patients diagnosed between 2000
and 2014, and combined relevant data from these patients with data for 34 published cases up to 2000.
In the cohort of 22 patients, Rudge et al.69 presented a range of possible incubation times calculated from
(1) the last injection of any type of growth hormone to onset of symptoms; (2) the midpoint of that series
of injections to onset of symptoms; and (3) the first injection to onset of symptoms. The mean and ranges
were (1) mean 25.9 years (range 18.3–33.6 years); (2) mean 29.3 years (range 20.6–37.6 years); and
(3) mean 32.8 years (range 23.2–43.3 years).69 Incubation times between the cohort of 22 patients and
a large subset of the UK group as whole were also compared.69 The mean incubation times were longer
in the latter cohort, but there was a noteworthy change in the proportion of MM and VV homozygote
genotypes between the two periods; there was only one case of the VV genotype in the period 2000–14
compared with 14 occurring before 1998, whereas seven of the eight MM homozygotes occurred after
2004.69 These findings are quite distinct from those for dura mater grafts in terms of the distribution of
genotypes and their incubation periods: incubation periods for iCJD caused by dura mater grafts appear
shorter and are dominated by the MM genotype (see Table 9). The group with iCJD affected by hGH are
equally distinct in terms of genotype, from individuals with sCJD.140
Discussion/summary of incubation data
The incubation periods for CJD reported in the published literature range from 1 to 42 years, with the
shortest durations occurring in stCJD and the longest durations occurring in kuru or iCJD via hGH.
Different incubation times might occur because of the resistance of different genotypes. Evidence from
kuru studies132,133 indicates that incubation times are shorter and mortality risk is significantly greater
in those with the homozygous genotype (MM or VV) compared with the heterozygous genotype (MV),
which has longer incubation times; older survivors are, therefore, more likely to be MV.131,134 However,
the hGH data suggest that this might not always be the case, given the longer incubation times for
MM homozygote patients and shorter times for VV homozygotes.
Where the proportions of heterozygotes and homozygotes are similar across countries or groups but
the incubation times are different, it has been proposed that differences in these incubation times
might be because of infection with different strains or subtypes of the CJD agent.135,140 For example,
most cases of hGH iCJD in France were of the MM genotype, whereas in the UK the VV and MV
genotypes predominated. Infections that appear to affect certain genotypes in a particular location may
reflect an absence of genotypic resistance to a particular strain and, thus, have shorter incubation
times. Hence, it is believed that the MM genotype in the UK hGH iCJD cohort had the longest
incubation times because the infectious strain was of the VV or MV genotype. Other possible factors
include higher infectious doses and/or differences in the actual data, for example where the precise
date of likely contamination is known, incubation times appear to be shorter.3
Diagnoses of sCJD could potentially be made that are actually iatrogenic in origin. Correct identification
can be difficult if cases of iCJD initially present as sCJD. Ritchie et al.140 and Kobayashi et al.144 report that
some of the MM1 genotype present as sCJD, but others might be able to be distinguished as iCJD
based on the presence of kuru plaques: this has been demonstrated for hGH in the UK.140 Consequently,
there might be more evidence forthcoming on incubation of iCJD as more cases are identified that
previously were considered to be sCJD, but revised to iCJD following neuropathological examination.
The infectivity of Creutzfeldt–Jakob disease
The purpose of this review was to identify relevant published and unpublished evidence on the
infectiousness of CJD in terms of CJD type, subtype or prion strain, genotype of the recipient,
infectivity of infectious tissue, and the infectious mass required to transmit CJD.
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Few relevant papers addressing the research question in humans were identified; however, 38 papers
from a range of scientific approaches were found to highlight themes that potentially relate to CJD
infectivity. Therefore, papers were organised thematically for CJD infectivity and are presented as a
narrative secondary discourse.
Studies discussing the infectivity of Creutzfeldt–Jakob disease
Infectious mass required to transmit Creutzfeldt–Jakob disease
The risk of any individual becoming infected by CJD is considered to be related to the dose of
infectious material received. A quantitative estimation of infectivity in CJD is traditionally ascertained
using end-point dilution titration and is expressed as median infective dose in terms of ID50.
No new evidence regarding the quantity of infective material required to transmit CJD in humans was
identified in the period covered by the searches. The estimations used in the original mathematical
model to estimate the risk of vCJD transmission via surgery12,13 and implemented in IPG19614 are
reported in Table 11.
Higher infectious titres than those estimated in Table 11 have been detected in animal studies using
novel methods for end-point titration. For example, Makarava et al.149 used protein misfolding cyclic
amplification (PMCA) with beads to propagate abnormal prion protein scrapie (PrPSc) (infectious
isoform/protease K-resistant prion protein) in Syrian hamsters. Using this method, they were able to
detect infectious titres ranging from 108.6 to 1012.8. A study by Halliez et al.150 also found that it was
possible to detect higher levels of vCJD infectious titre in a human spleen using a novel bioassay than
with a gold-standard immunoblot bioassay. As methods for end-point titration improve, it is therefore
likely that some variation in the estimated titres used in IPG196 and noted in Table 11 will be
observed in the future.
Codon 129 genotype and susceptibility
All individuals, irrespective of genotype at codon 129 (MM, MV or VV), are now known to be susceptible
to sCJD and secondary transmission of vCJD through routes such as blood transfusion; however, the
phenotype (or observable physical properties) for MV and VV cases has been noted to be less predictable
because of reduced transmission efficiency and increased incubation periods.79,89 The vCJD prion or
agent appears to replicate in lymphoid tissues during the asymptomatic phase of the incubation period.151
A study152 of abnormal prion protein accumulation in peripheral tissues from MV individuals has been
undertaken to understand the infectivity and the risk of horizontal transmission. Bishop et al.152 inoculated
TABLE 11 Estimated infectious titre of human tissue by surgical procedure in NICE IPG19614
Risk of CJD transmission Surgical procedure Infectivity
High Brain and pituitary gland 108 ID50s/g
Posterior eye, retina and optic nerve
Intradural spine operations
Neuroendoscopy
Medium Spinal cord 106 ID50s/g
Tonsils 105.5 ID50s/g
Spleen 105.5 ID50s/g
Lymphoid tissue 104.5 ID50s/g
Anterior eye 103.5 ID50s/g
Peripheral nerves
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mice with brain and spleen samples from a subclinical vCJD recipient and the clinical vCJD donor. They
found transmission of vCJD from the spleen to the mice but not from the brain of the subclinical vCJD
recipient, whereas there was transmission from both the spleen and the brain tissues from the clinical
vCJD donor. The authors concluded that spleen tissue from the MV genotype can propagate the vCJD
agent and that the infectious agent can be present in the spleen without central nervous system (CNS)
involvement and that ‘silent’ spread within the human population is, therefore, a possibility from
heterozygous carriers. This finding was also echoed by Halliez et al.150 in their evaluation of novel methods
for end-point titration of vCJD in the human spleen. The authors posit the notion that lymphoid tissue
exhibits a higher capacity than the brain to replicate prions even after low-dose infection and highlight
potential silent carriers of vCJD in lymphoid tissue as a key issue.150
Subtype or phenotype of Creutzfeldt–Jakob disease
In sCJD, an interaction between the host genotype at codon 129 and the causative agent identified
as either PrPSc type 1 or PrPSc type 2 produces different clinical and histopathological phenotypic
expressions, which may be influenced by other factors such as route of infection or locations of the initial
PrPSc conversion.153 In sCJD, six major subtypes carrying diverse clinical and pathological features have
been identified: (1) MM1/MV1, (2) VV2, (3) MV2 with kuru plaques (MV 2K), (4) MM2-cortical (MM2C),
(5) MM2-thalamic (MM2T) or sporadic fatal insomnia and (6) VV1.154 In mice studies, all subtypes
have been found to be transmissible to at least one genotype.155 Four major prion strains have been
proposed to underlie sCJD, iCJD, kuru and some gCJD cases, which are termed M1, V2, M2 and V1.89
Variant CJD, however, can be distinguished from other categories of CJD owing to the unique PrPres
biochemical glycotype referred to as type 2B or type 4, which are also found in cases of natural BSE and
other BSE-related conditions.90
Definitive information on the phenotype can be identified only following neuropathological
examination, which provides the opportunity to establish whether or not CJD may have been acquired
as opposed to being sporadic or genetic causes. Kobayashi et al.98 propose the distinctive combination
of the MM genotype at codon 129, kuru plaques and intermediate-type PrPSc as a reliable criterion for
the identification of iatrogenically acquired CJD cases among presumed sCJD cases. Additionally, some
studies highlight that, although exclusive type 1 (sCJDMM1) or type 2 (sCJDMM2) cases do exist, a
frequent co-occurrence has been noted of both PrPSc type 1 and type 2 in sCJD in different areas, or
the same area, of the brain from a single sCJD patient.156 This finding complicates the diagnosis and
the current classification of sCJD,153 with Parchi et al.154 highlighting the importance of assessing the
cerebral cortex from each of the four lobes (striatum, hippocampus, thalamus and cerebellum) to avoid
misclassification of disease. For example, Jansen et al.157 report from an analysis of CJD cases in the
Netherlands that a ‘pure’ phenotype was demonstrated in 60.1% of patients, whereas a mixed
phenotype was detected in 39.9% of all sCJD cases. Similarly, an abstract by Mackay et al.158 reports
that 26 out of 108 sCJD patients (24%) had both type 1 and type 2 proteins on Western blot analysis.
Mackay et al.158 argue that the lack of distinct clinical or pathological findings in the six discrete
subtypes suggests that these groups do not represent unique strains of prions but rather groupings
over a spectrum of disease. These findings underline the importance of neuropathological assessment
of CJD cases to document the phenotypic variability and help to disclose the aetiology of CJD strains
and efficiency of transmission, where possible.
Route of transmission
The route of transmission may also be relevant to the infectivity of iCJD. A study of five dura mater
iCJD cases conducted by Iwasaki et al.159 indicated that the initial symptoms at perceived sCJD onset
appeared to be closely related to the graft site in the brain, indicating a direct transmission of CJD from
the graft site to the adjacent brain. Sakai et al.160 also support the finding of a relationship between the
initial clinical manifestation and the site of graft in patients with dura mater graft-associated CJD.160
Beringue et al.161 demonstrated in a study of transgenic mice that prion strain divergence can occur
on transmission of human primary vCJD, and that peripheral exposure in mice resulted in inefficient
neuroinvasion with asymptomatic, life-long infection of the lymphoid compartment.161
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Beringue et al.162 raise the possibility that human-to-human transmission of vCJD might produce
alternative neuropathological phenotypes and that lymphoid tissue examination of CJD cases classified as
sporadic might reveal an infection by vCJD-type prions. Cali et al.163 demonstrated that novel phenotypes
may arise as a result of the adaptation of heterologous prion strains of sCJD through contaminated
growth hormone.163 A conference abstract by Peden et al.164 also described that human-to-human
transmission of prion disease may affect the seeding properties of the PrPSc associated with the disease.
Their analysis compared the seeding properties of iCJD tissue samples (including both hGH and dura
mater) with sCJD tissue samples using a real-time quaking-induced conversion (RT-QuIC) assay, which
showed lower seeding properties for secondary iCJD cases than for sCJD cases. The authors note that
their findings refute the hypothesis that secondary transmission of a human prion disease results in
acquired virulence (or harmfulness). This is supported by a study by Galeno et al.,67 which found that a
novel strain from an atypical CJD in a heterogeneous 69-year old woman who had been treated with
phospholipids extracted from bovine brains was not transmissible to transgenic mice but transmitted
exclusively to bank voles. The authors note that bank voles are susceptible to a variety of human and
animal prions with an efficacy that is often higher than that observed in transgenic mice.67
Detection of Creutzfeldt–Jakob disease
Whether or not and when asymptomatic carriers of CJD become infectious is important in understanding
the potential risks of contamination during surgery. Bougard et al.165 described an assay that detected
prions 1.3 and 2.6 years before the clinical onset of disease in plasma samples from two blood donors
who later developed vCJD. The authors report that the ability to identify presymptomatic (n = 2) and
symptomatic (n = 18) vCJD-positives in a blinded cohort of 256 plasma samples comprising sCJD,
Alzheimer’s disease, Parkinson’s, other neurological diseases and healthy controls indicates the possibility
of detecting incubating or silent carriage of vCJD prions.
Identification of abnormal prion accumulation in peripheral lymphoreticular tissue is commonly
considered to be a marker of subclinical vCJD that may subsequently develop into clinical vCJD.
However, the reliability of this marker for representing subclinical or indeed, clinical, vCJD has been
questioned. Mead et al.166 highlight a case of clinical vCJD whose presentation, imaging findings,
cerebrospinal fluid investigation results and clinical progression were typical of other vCJD cases.
However, subsequent examination of multiple tissues from a biopsy and at autopsy showed minimal
deposition of disease-associated prion protein in tonsil tissue.166 This patient also received a negative
score from a blood test specifically for vCJD, the direct-detection assay. The authors note that this
case demonstrates that even patients with end-stage vCJD may have minimal prion colonisation in
lymphoreticular tissue.
Absence versus presence of abnormal prion accumulation may occur because of the sensitivity of the CJD
assay employed. Examination of 14-3-3 proteins in both the cerebrospinal fluid and a RT-QuIC assay are
commonly employed tests that are considered to be sensitive and specific for sCJD detection, although
less so for vCJD.167 For example, the identified heterozygous clinical vCJD patient, aged 36 years in 2016,37
tested negative for the 14-3-3 protein, RT-QuIC assay and vCJD-focused direct-detection assay, but
immunoblotting of brain homogenate at autopsy confirmed the presence of vCJD prions. Moreover,
immunostaining performed in this patient for abnormal prion protein-labelled amyloid plaques highlighted
a relative lack of peripheral tissue involvement, with only minute amounts detected in the spleen and no
detection in the appendix or mesenteric lymph nodes. However, Douet et al.168 used a highly sensitive
PMCA assay to assess abnormal prion accumulation in the identified heterozygous subclinical vCJD
patient, aged 82 years in 2017. Previous investigations had not detected abnormal prion protein or
infectivity in the brain, indicating a lack of CNS involvement at the time of death.78,152 However, using this
assay they found vCJD prions in all lymphoid organs and a wide variety of other tissues, including the
salivary gland, lung and liver. The authors caution that the identification of wide vCJD involvement in the
peripheral tissues of a preclinical patient further indicates the potential for iatrogenic transmission of this
fatal neurological condition by surgical procedures.
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Transmission to and from peripheral tissues
The infectious load is known to be higher in certain tissues, such as CNS tissues,14 and, therefore, the risk
of infectivity from peripheral tissue has been questioned. Studies report conflicting findings regarding the
infectivity of peripheral tissues. For example, Bishop et al.152,169 reported that spleen tissue from the MV
genotype preclinical vCJD blood recipient was transmissible in a study using transgenic and wild-type
mice. The authors highlight that significant levels of infectious agent are present in the spleen before
CNS involvement.152,169 However,Wadsworth et al.170 found from an animal study of transgenic mice that,
although vCJD prion infection was readily reported following inoculation with frozen vCJD brain or
appendix, and formalin-fixed, paraffin-embedded (FFPE) brain, no infectivity was detected from FFPE
vCJD spleen or FFPE appendix samples.170 The authors caution that the absence of detectable infectivity
in fixed, known positive vCJD lymphoreticular tissue does not definitively prove that vCJD transmission
cannot occur through appendix specimens, as the assays used were not able to detect the low levels of
infectivity previously found in the positive control lymphoreticular tissue following formalin fixation by
Hilton et al.7 However, in contrast, Halliez et al.150 more recently found that lymphoid tissue exhibits
higher capacity than the brain to replicate prions using novel detection methods.
Infectivity of genetic Creutzfeldt–Jakob disease
The potential for horizontal transmission of gCJD, as discussed previously, was raised by the unusually
high prevalence of gCJD in Slovakia.47 Ritchie et al.171 report from an animal study of squirrel monkeys
that no clinical or pathological signs of CJD were observed following blood transfusion of either sCJD or
vCJD of the intracerebral-inoculated monkeys after euthanasia at 7 years. However, there was evidence
that GSS, a form of gCJD, transmitted autopsy-proven disease to two intracerebral-inoculated monkeys
after incubation periods of 34 and 39 months. Ritchie et al.17 conclude that these results, and other
studies from rodents and non-human primates, suggest that blood donations of GSS (and perhaps other
familial forms of TSE) carry more risk than those from vCJD.171 The infectiousness of CJD via blood is
not directly relevant to the current decision problem of CJD risk via surgery. However, consideration of
the potential differences of infectiousness of the CJD types may be relevant when considering the risks
of horizontal transmission in the future and in particular localities.
MV genotype as protective: PrPSc allotype
Allotype refers to an inherited set of determinants or a sequence of amino acids and other proteins that
demonstrate heterogeneity, which is specific for an individual but more common in an ethnic group.
The relative contribution of each PrP allotype to the infectious disease associated with the abnormal
isoform of prion protein (PrPSc) is unknown. Moore et al.172 found from an analysis of four heterozygous
cases of sCJD that the PrPSc allotype ratio is highly variable, with PrPSc (-M129 and -V129) differing
markedly between different regions within the same sCJD brain.172 However, an analysis of six
heterozygous cases of iCJD found that the composition of PrPSc iCJD was more homogenous and
tended to contain a higher proportion of PrPSc-V129 than heterozygous cases of sCJD. The presence of
two different PrP allotypes in the same brain can often lead, in a dose-dependent manner, to inefficient
PrPSc formation and increased disease incubation. However, the study authors report that in both types
of CJD (sCJD and iCJD), the PrPSc allotype ratio had no correlation with CJD type, age at clinical onset
or disease duration. This evidence suggests that, therefore, factors other than PrPSc allotype abundance
must influence the clinical progression and phenotype of heterozygous cases of CJD.
Discussion/summary of infectivity of Creutzfeldt–Jakob disease
When opportunities for CJD transmission occur, a range of factors are likely to influence how the
disease will manifest itself in terms of clinical phenotype, neuropathological pattern, incubation period
and disease duration. These factors include an interaction between the genotype at PRNP codon 129,
infecting prion strain, route of transmission and location of PRNP conversion. Moreover, the method
of detection and the analysis of CJD is crucial in obtaining detailed and accurate neuropathological
confirmation of CJD type in order to posit the most plausible explanations for acquisition of iCJD.
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Although few data regarding infectious dose or infectious titre in humans have been published to
supersede the information used to populate the model built by ScHARR in 2005,12 some animal studies
using advanced detection methods indicate that infectious doses > 108 ID50 are possible.
The evidence on the efficacy of prion decontamination procedures for
surgical instruments
The purpose of this review was to identify published and unpublished evidence for the efficacy of
decontamination procedures in terms of reducing the infectivity of prions adhering to steel wires or
other steel materials. The review focuses principally on log-reductions in the infectious titre, that is the
reduction in the load of infectivity on steel (wires) before and after the decontamination processes.
Log-reductions are a common measure of decontamination and the review could inform this parameter
in the health economic model. This systematic review includes studies that investigate autoclaving, the
principal process currently employed in the NHS, as well as decontamination procedures that might be
used in addition to autoclaving.
According to a 2014 report by the House of Commons Science and Technology Committee,173 a
potentially effective decontaminant (Rely+On®; DuPont, Midland, MI, USA) to be used prior to autoclaving
experienced barriers to its uptake in the NHS owing to (1) the perceived low risk of iCJD through surgical
transmission and (2) resistance to the inclusion of an additional step in the decontamination process.173
It should therefore be noted that, first, based on the number of known cases, the risk of iCJD through
surgical transmission has not increased markedly since 2013–14, which suggests evidence on new
decontaminants might not be taken up in practice. Second, any decontaminants identified by this systematic
review as potentially being effective, but also representing an additional step, might experience the same
barriers to uptake.
Decontamination studies
Studies reporting log-reductions of prion infectivity after autoclaving with/without
other processes
Five studies174–178 reported log-reductions of prion infectivity after autoclaving with and without other
decontamination processes (Table 12). In terms of prion strain, three studies used 10% brain homogenate
of 263K hamster scrapie,174–176 two used vCJD,176,177 and the following prion strains were investigated in
only a single study: 127S,177 M1000178 and BSE 6PB1.176 All studies used steel wires contaminated with the
prion (one study also used steel sheets176) and all studies investigated autoclaving at 121 or 134 °C for
specified amounts of time, as a decontamination procedure.
The efficiency of autoclaving was assessed alone and in combination with a range of other
decontaminants. These included sodium hydroxide (NaOH), sodium hypochlorite (NaOCl), sodium
dodecyl sulfate (SDS), hydrogen peroxide (H2O2) and various other enzymatic and alkaline detergents.
These decontaminants were also investigated alone or in combination with other decontaminants.
Selected results from these investigations are reported in Table 13.
The log-reductions produced by autoclaving at 134 °C for 18 minutes for the 263K prion strain ranged
from 4.11174 to > 5–6,176 with transmission rates of 57% and 50%, respectively. The log-reduction was
only 2.2 (100% transmission) for the M1000 strain. Autoclaving at 134 °C for 18 minutes combined with
NaOH or an alkaline detergent produced log-reductions of > 5 to 6, as well as lower transmission rates
(28% for NaOH and 0% for the alkaline detergent) for the 263K prion strain.176 Autoclaving at 134 °C for
5 minutes combined with alkaline cleaners or 0.2% SDS or 0.3% NaOH at different concentrations and/or
different durations, also produced log-reductions of > 5.5 for the 263K prion strain.175
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The only process reported to have produced a log-reduction of > 5 and a transmission rate of 0% is
autoclaving at 121 °C for 20 minutes plus 0.3% rapid multienzyme cleaner trial formulation (RMEC) B
at 60 °C for 30 minutes.178
TABLE 12 Characteristics of studies reporting log-reductions in prion contamination on steel surfaces after autoclaving
with and without other processes
Study (first
author and year
of publication) Prion strain(s)
Source
material
(% w/v) Steel
Decontamination methods
Assay usedAutoclaving Other
Belondrade
(2016)177
127S scrapie
and vCJD
BH (10) Wires l 121 °C:
20 minutes
l 134 °C:
20 minutes
l 0.1 N NaOH: 15 minutes
l 1 N NaOH: 60 minutes
l 0.2% NaOCl: 15 minutes
l 2% NaOCl: 15 minutes
l 0.2% SDS /0.3% NaOH:
10 minutes
PMCA
Lawson (2007)178 M1000 BH (10) Wires l 121 °C:
20 minutes
l 134 °C:
18 minutes
l RMEC A
(enzymatic detergent)
l RMEC B
(enzymatic detergent)
l 1.0M NaOH: 60 minutes
Tga20 mice
WB
Lehmann (2009)174 263K scrapie BH (10) Wires l 134 °C:
18 minutes
l H2O2: 30 minutes
l AF: 10 minutes
l Np-Np-H2O2/Cu:
10 minutes – 5 minutes –
15 minutes)
l Dp-Dp-H2O2/Cu:
10 minutes – 5 minutes –
15 minutes
l Np-Dp-H2O2/Cu:
10 minutes – 5 minutes –
15 minutes
l Nmp-Nmp-PAA/Cu:
10 minutes – 5 minutes –
15 minutes, at 40 °C
Syrian
golden
hamsters
Lemmer (2008)175 263K scrapie BH (10) Wires l 134 °C:
5 minutes
l 1.0M NaOH: 60 minutes
at 23 °C
l 2.5% NaOCl: 60 minutes
at 23 °C
l Alkaline cleaner 0.5% and
1%: 5/10 minutes at 55 °C
l 0.2% SDS/0.3% NaOH:
5/10 minutes at 23 °C
l Disinfectant with 0.2%
PAA/0.075–0.225%
NaOH: 120 minutes
at 23 °C
Syrian
golden
hamsters
Rogez-Kreuz
(2009)176
263K scrapie,
vCJDa and
BSE 6PB1a
BH (10 or
20)
Wires,
sheetsa
l 134 °C:
18 minutes
l 1 N NaOH: 60 minutes
l H2O2: 10 or 20 minutes
l 2% enzymatic detergent:
10 minutes at 37 °C
l 1% alkaline detergent A:
10 minutes at 70 °C
l 1% alkaline detergent B:
10 minutes at 55 °C
Syrian
golden
hamsters,
WBa
AF, alkaline detergent, surfactants, chelatant; BH, brain homogenate; Dp, detergent and disinfectant for manual process;
NaOCl, sodium hypochlorite; NaOH, sodium hydroxide; Nmp, detergent for washer (machine) process (used at 40 °C);
Np, detergent for manual process; PAA, peracetic acid; RMEC, rapid multienzyme cleaner trial formulation; SDS, sodium
dodecyl sulfate; WB, Western blot; w/v, weight/volume.
a In vitro only.
DOI: 10.3310/hta24110 Health Technology Assessment 2020 Vol. 24 No. 11
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
35
TABLE 13 Results of studies reporting log-reductions in prion contamination on steel surfaces after autoclaving with and
without other processes
Study (first
author and year
of publication)
Prion
strain
Decontamination methods
Log
reduction
Transmission
rate, n/N (%)
Incubation
period days,
n (SD)Autoclaving Other
Belondrade
(2016)177
127S 121 °C: 20 minutes ≥ 5 10/12 (83) NR
134 °C: 20 minutes FE 0/12 (0) NR
vCJD 121 °C: 20 minutes 5 1/8 (12.5) NR
134 °C: 20 minutes FE 0/8 (0) NR
Lawson (2007)178 M1000 121 °C: 20 minutes 1.6 100% 106 (2)
134 °C: 3 minutes 1.5 100% 104 (3)
134 °C: 18 minutes 2.2 100% 120 (5)
134 °C: 3 minutes 0.3% RMEC B: 60 °C
for 30 minutes
≥ 4.5 10% 166 (NR)
121 °C: 20 minutes 0.3% RMEC B: 60 °C
for 30 minutes
> 5 0% –
Lehmann (2009)174 263K 134 °C: 18 minutes 4.11 57% 140
aLemmer (2008)175 263K 134 °C: 5 minutes 0.5% alkaline
cleaner: 5 minutes
at 55 °C
≥ 5.5 NR NR
134 °C: 5 minutes 0.5% alkaline
cleaner: 10 minutes
at 55 °C
≥ 5.5 NR NR
134 °C: 5 minutes 1% alkaline cleaner:
5 minutes at 55 °C
≥ 5.5 NR NR
134 °C: 5 minutes 1% alkaline cleaner:
10 minutes at 55 °C
≥ 5.5 NR NR
134 °C: 5 minutes 0.2% SDS/0.3%
NaOH: 5 minutes at
23 °C
≥ 5.5 NR NR
134 °C: 5 minutes 0.2% SDS/0.3%
NaOH: 10 minutes
at 23 °C
≥ 5.5 NR NR
134 °C: 5 minutes Disinfectant with
0.2% PAA/
0.075–0.225%
NaOH: 120 minutes
at 23 °C
> 2 to < 3 NR NR
Rogez-Kreuz
(2009)176
263K 134 °C: 18 minutes ≥ 5 to 6 50% 428 ± 103
134 °C: 18 minutes 1 N NaOH:
60 minutes
≥ 5 to 6 28% 554 ± 197
134 °C: 18 minutes 2% enzymatic
detergent:
10 minutes at 37 °C
4 100% 131 ± 17
134 °C: 18 minutes 1% alkaline
detergent A:
10 minutes at 70 °C
≥ 5 to 6 0% 525 ± 149
263K in
vitro
134 °C: 18 minutes ≥ 5.4 NR NR
FE, fully efficient as no positive wires found; NR, not reported; PAA, peracetic acid; RMEC, rapid multienzyme cleaner
trial formulation.
a Bioassay 2 only (bioassay 1= 2004 data).
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The aim of some studies is development of a prion detection assay, rather than the development of
the decontaminant.177
Studies reporting log-reductions of prion infectivity after processes other
than autoclaving
Eleven studies reported log-reductions of prion infectivity after various decontamination processes,
principally enzymatic detergents that did not use autoclaving (Table 14). In terms of prion strain, seven
studies used 10% or 20% brain homogenate of 263 K hamster scrapie,174–176,179–182 three used vCJD,177,179,180
two used ME7183,184 and the following prion strains were investigated in only a single study: Rocky
Mountain Laboratory (RML),185 BSE 6PB1 and TGB1,181 M1000178 and 127S.177 Nine studies used steel
wires contaminated with the prion, one study used steel tokens183 and one used steel sheets.176
TABLE 14 Studies reporting log-reductions in prion contamination on steel surfaces after decontamination processes
other than autoclaving
Study (first
author and year
of publication) Prion strain
Source material
(% w/v) Steel
Decontamination methods
other than autoclaving Assay used
Beekes (2010)179 263K scrapie,
vCJD (MM1),
sCJD
BH (10) Wires l 0.2% SDS/0.3% NaOH in
20% or 30% n-propanol
Hamsters, WB
Bellon (2014)180 263K, vCJD
(mouse adapted)
BH (20) Wires l 0.1–0.45 mol/l NaOH:
4–45 °C for
5–240 minutes
Hamsters, WB
Belondrade
(2016)177
127S scrapie,
vCJD
BH (10) Wires l 0.1 N NaOH: 15 minutes
l 1 N NaOH: 60 minutes
l 0.2% NaOCl: 15 minutes
l 2% NaOCl: 15 minutes
l 0.2% SDS/0.3% NaOH:
10 minutes
Surf-PMCA
Edgeworth
(2011)185
RML BH (10) Wires l Rely+On
l Prionzyme® (Genecor,
Rochester, NY, USA)
l 0.8% and 1.6% Hamo®
100 PID
l 2M NaOH
l 20% NaOCl
Tga20 mice,
Tg20 mice
SSBA
Fichet (2007)181 263K scrapie,
6PB1 BSE, TGB1
BSE
BH (10) Wires l 6% liquid H2O2:
20 °C for 60 minutes
l 2 mg/l gaseous H2O2:
30 °C (3 pulses)
l 2 mg/l gaseous H2O2:
30 °C (6 pulses)
Animal, WB
aHervé (2010)182 263K scrapie NR Wires l Cold atmospheric plasma Animal
Hervé (2010)183 ME7 BH (NR) Tokens l Four unspecified enzyme
cleaning products,
commonly used in UK
SSDs: 43 or 50 °C for
5 minutes
EDIC/EF and
WB
Howlin (2010)184 ME7 BH (10) Wires l Presoak, plus unspecified
enzyme pretreatment
(containing proteases),
plus alkaline detergent
(includes potassium
hydroxide) (Hamo® 100)
EDIC/EF and
WB
continued
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The efficiency of a range of decontaminants was assessed. Selected results from these investigations
are reported in Table 15. It was reported by Edgeworth et al.185 that the following processes inactivated
RML prions below the detection limit of the in vitro standard steel-binding assay (SSBA), stated to be
equivalent to a reduction of 8 logs: Rely-On PI (DuPont), Prionzyme plus 2 M NaOH, and 2M NaOH.
It was noted, however, that the decontaminating effect of Prionzyme (Genencor) was indistinguishable
from that of the diluent in which the decontaminant was prepared (2 M NaOH solution, following the
TABLE 14 Studies reporting log-reductions in prion contamination on steel surfaces after decontamination processes
other than autoclaving (continued )
Study (first
author and year
of publication) Prion strain
Source material
(% w/v) Steel
Decontamination methods
other than autoclaving Assay used
Lawson (2007)178 M1000 BH (10) Wires l RMEC A
(enzymatic detergent)
l RMEC B
(enzymatic detergent)
l 1M NaOH: 60 minutes
Tga20 mice,
WB
Lehmann (2009)174 263K scrapie BH (10) Wires l H2O2: 30 minutes
l AF: 10 minutes
l Np-Np-H2O2/Cu:
10 minutes – 5 minutes –
15 minutes
l Dp-Dp-H2O2/Cu:
10 minutes – 5 minutes –
15 minutes
l Np-Dp-H2O2/Cu:
10 minutes – 5 minutes –
15 minutes
l Nmp-Nmp-PAA/Cu:
(10 minutes – 5 minutes –
15 minutes, 40 °C)
Hamsters
Lemmer (2008)175 263K scrapie BH (10) Wires l 1M NaOH: 60 minutes
at 23 °C
l 2.5% NaOCl: 60 minutes
at 23 °C
l 0.5% and 1% alkaline
cleaner: 5/10 minutes at
55 °C
l 0.2% SDS/0.3% NaOH:
5/10 minutes at 23 °C
l Disinfectant with 0.2%
PAA /0.075–0.225%
NaOH: 120 minutes at
23 °C
Hamsters
Rogez-Kreuz
(2009)176
263K scrapie,
vCJD,b BSE 6PB1b
BH (10 or 20) Wires,
sheetsb
l 1 N NaOH: 60 minutes
l H2O2: 10 minutes,
20 minutes
l 2% enzymatic detergent:
10 minutes at 37 °C
l 1% alkaline detergents
A: 10 minutes at 70 °C
l 1% alkaline detergents B:
10 minutes at 55 °C
Hamsters, WB
AF, alkaline detergent, surfactants, chelatant; BH, brain homogenate; Dp, detergent and disinfectant for manual process;
EDIC/EF, episcopic differential interference contrast/epifluorescence microscopy; Nmp, detergent for washer (machine)
process (used at 40 °C); Np, detergent for manual process; NR, not reported; PAA, peracetic acid; PMCA, protein
misfolding cyclic amplication; SSBA, standard steel-binding assay; SSDs, sterile service departments; surf, stainless-steel
wire surfaces as carriers of prions; WB,Western blot; w/v, weight/volume.
a Abstract only.
b In vitro only.
CLINICAL EVIDENCE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
38
TABLE 15 Results of studies reporting log-reductions in prion contamination on steel surfaces by processes other than
autoclaving
Study (first
author and year
of publication)
Prion
strain
Decontamination
methods
Log-
reduction
Transmission
rate
Incubation
period days,
n (SD)
Other
(e.g. TICUw)
Beekes (2010)179 263K 0.2% SDS/0.3% NaOH in
20% n-propanol
≥ 5.5 0/10 503
0.2% SDS/0.3% NaOH in
30% n-propanol
≥ 5.5 0/9 503
vCJD 0.2% SDS/0.3% NaOH in
20% n-propanol
3.3 NR NR
sCJD 0.2% SDS/0.3% NaOH in
20% n-propanol
3.3 NR NR
Bellon (2014)180 vCJD 0.1–0.45 mol/l NaOH:
25–45 °C for 5–240
minutes
≥ 3.8 0/8 NR
263K 0.45 mol/l NaOH: 4 °C
for 60 minutes
4.9 2/8 441
0.2 mol/l NaOH: 15 °C
for 15 minutes
5 1/5 237
0.2 mol/l NaOH: 15 °C
for 60 minutes
≥ 5 0/8 NR
0.45 mol/l NaOH: 15 °C
for 30 minutes
≥ 5.2 0/8 NR
0.45 mol/l NaOH: 15 °C
for 60 minutes
≥ 5.2 0/8 NR
0.15 mol/l NaOH: 25 °C
for 60 minutes
4.1 5/9 215
0.45 mol/l NaOH: 25 °C
for 60 minutes
4.7 3/10 382
0.45 mol/l NaOH: 25 °C
for 240 minutes
≥ 5.4 0/8 NR
0.45 mol/l NaOH: 40 °C
for 5 minutes
≥ 5.3 0/8 NR
0.45 mol/l NaOH: 40 °C
for 15 minutes
5.1 1/6 364
0.1 mol/l NaOH: 45 °C
for 5 minutes
≥ 5.4 0/8 NR
0.1 mol/l NaOH: 45 °C
for 15 minutes
≥ 5.4 0/8 NR
Belondrade
(2016)177
127S 0.1 N NaOH: 15 minutes ≥ 3 12/12 NR
vCJD 0.1 N NaOH: 15 minutes 3 6/8 NR
Edgeworth
(2011)185
RML Rely-On PIa 5.5 0/19 > 250
Rely-On PIb 8 NR NR < 0.003 TICUw
Prionzyme plus 2M
NaOHb
8 NR NR < 0.003 TICUw
2M NaOHb 8 NR NR < 0.003 TICUw
0.8% Hamo 100b NR NR NR 0.3c
1.6% Hamo 100b NR NR NR 0.07c
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TABLE 15 Results of studies reporting log-reductions in prion contamination on steel surfaces by processes other than
autoclaving (continued )
Study (first
author and year
of publication)
Prion
strain
Decontamination
methods
Log-
reduction
Transmission
rate
Incubation
period days,
n (SD)
Other
(e.g. TICUw)
Fichet (2007)181 263K 6% liquid H2O2,: 20 °C
for 60 minutes
1 11/11 (100%) 114 (13)
2 mg/l gaseous H2O2:
30 °C (3 pulses)
> 5.5 0/8 > 540
2mg/l gaseous H2O2:
30 °C (6 pulses)
> 5.5 0/8 > 540
6PB1 BSE 2mg/l gaseous H2O2:
30 °C (3 pulses)
> 5.5 0/9 > 540
TGB1 BSE 2mg/l gaseous H2O2:
30 °C (3 pulses)
> 5.3 0/9 > 540
dHervé (2010)182 263K Cold atmospheric plasma > 6 NR NR
Hervé (2010)183 ME7 Cleaner 4 (most
efficient): 50 °C for
5 minutes
3 NR NR 99.21% of initial
prion amyloid
load removed
Howlin (2010)184 ME7 Unspecified enzyme
pretreatment (containing
proteases) without
presoak
Approximately 2 log greater reduction in prion amyloid than
presoak alone even if allowed to dry and 3 log-reduction if
process was started immediately after contamination (wet)
Unspecified enzyme
pretreatment (containing
proteases) with presoak
1 log-reduction in prion amyloid if process was started
immediately after contamination (wet) instead of being
allowed to dry
Unspecified enzyme
pre-treatment
(containing proteases)
plus alkaline detergent
w/d
Prion-associated amyloid concentration levels were reduced
below the experimental cut-off value of 0.001 ng/mm,2 wet
or dry
Lawson (2007)178 M1000 1M NaOH: 60 minutes 2.7 100% 130 (19)
1% RMEC A: 50 °C for
30 minutes
≥ 4.5 80% 204 (18)
0.3% RMEC B: 60 °C for
30 minutes
≥ 3.5 60% 147 (13)
Lehmann
(2009)174
263K H2O2: 30 minutes ≥ 5.25 0% ≥ 370
AF: 10 minutes ≥ 5.25 0% ≥ 370
Np-Np-H2O2/Cu:
10 minutes – 5 minutes –
15 minutes
4.55 43% 133
Dp-Dp-H2O2/Cu:
10 minutes – 5 minutes –
15 minutes
≥ 5.25 20% 159
Np-Dp-H2O2/Cu:
10 minutes – 5 minutes –
15 minutes
≥ 5.25 0% ≥ 370
Nmp-Nmp-PAA/Cu:
10 minutes – 5 minutes –
15 minutes, at 40 °C
3.43 67% 102
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TABLE 15 Results of studies reporting log-reductions in prion contamination on steel surfaces by processes other than
autoclaving (continued )
Study (first
author and year
of publication)
Prion
strain
Decontamination
methods
Log-
reduction
Transmission
rate
Incubation
period days,
n (SD)
Other
(e.g. TICUw)
Lemmer (2008)175 263K 1.0M NaOH: 60 minutes
at 23 °C
≥ 5.5 NR NR
2.5% NaOCl: 60 minutes
at 23 °C
≥ 5.5 NR NR
0.5% alkaline cleaner:
5 minutes at 55 °C
≥ 4 to < 5 NR NR
0.5% alkaline cleaner:
10 minutes at 55 °C
> 5 to ≤ 5.5 NR NR
1% alkaline: 5 minutes
at 55 °C
> 5 to ≤ 5.5 NR NR
1% alkaline cleaner:
10 minutes at 55 °C
≥ 5.5 NR NR
0.2% SDS/0.3% NaOH:
5 minutes at 23 °C
≥ 5.5 NR NR
0.2% SDS/0.3% NaOH:
10 minutes at 23 °C
≥ 5.5 NR NR
Disinfectant with 0.2%
PAA/0.075–0.225%
NaOH: 120 minutes
at 23 °C
> 5 to ≤ 5.5 NR NR
Rogez-Kreuz
(2009)176
263K H2O2: 10 minutes ≥ 5 to 6 50% 443 ± 140
H2O2: 20 minutes ≥ 5 to 6 50% 428 ± 142
2% enzymatic detergent:
10 minutes at 37 °C
1.1 100% 95 ± 0
1% alkaline detergent A:
10 minutes at 55 °C
≥ 5 to 6 11% 446 ± 153
1% alkaline detergent B:
10 minutes at 55 °C
≥ 5 to 6 0% 524 ± 42
Sterrad NX1 (Advanced
Sterilization Products
Services Inc, Irvine, CA,
USA) advanced cycle
≥ 5 to 6 0% 570 ± 18
Sterrad NX2 continuous
advanced cycles
≥ 5 to 6 0% 574 ± 0
1% alkaline detergent A
(10 minutes at 55 °C)
plus Sterrad NX1
advanced cycle
≥ 5 to 6 0% 559 ± 22
1% alkaline detergent B
(10 minutes at 55 °C)
plus Sterrad NX1
advanced cycle
≥ 5 to 6 0% 562 ± 16
263K in
vitro
Sterrad NX1 advanced
cycle
≥ 5.4 NR NR
NR, not reported; PAA, peracetic acid; TICUw, tissue culture infectious units on wires; w/d, wet or dry.
a By bioassay in Tga20 mice alone.
b By SSBA.
c By far the least effective: more ineffective than autoclaving or Rely-On for Prionzyme, or 2M NaOH. Note that
Prionzyme’s effectiveness is no different from the solution of 2M NaOH (in which it is prepared), plus neither is
suitable for decontamination of certain surgical instruments and 2M NaOH is highly hazardous.185
d In vivo.
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manufacturer’s instructions), that is treatment with 2 M NaOH alone also resulted in no detectable
infectivity remaining on the steel surface. The only process reported to have produced a log-reduction
of ≥ 5 and a transmission rate of 0% for the RML prion strain was Rely+On PI.
The only process or combination of processes reported to have produced a log-reduction of ≥ 5 and a
transmission rate of 0% for the 263K prion strain were 0.2% SDS/0.3% NaOH in 20% or 30% n-propanol;179
0.2 mol/l NaOH at 15 °C for 60 minutes; 0.45 mol/l NaOH at 15 °C for 15 or 30 minutes; 0.45 mol/l
NaOH at 25 °C for 240 minutes; 0.45 mol/l NaOH at 40 °C for 5 minutes; 0.1 mol/l NaOH at 45 °C for
5 or 15 minutes;180 2 mg/l gaseous H2O2 at 30 °C for 3 or 6 pulses;181 H2O2 for 30 minutes; AF (alkaline
detergent, surfactants, chelatant) for 10 minutes; and combinations of enzymatic detergents and
disinfectants Np-Dp-H2O2/Cu (for 10 minutes – 5 minutes – 15 minutes),174 the alkaline detergent B at
1% for 10 minutes at 55 °C, the Sterrad NX1 advanced cycle and Sterrad NX2 continuous advanced cycles
(H2O2 and gas plasma), and the alkaline detergents A or B at 1% for 10 minutes at 55 °C, in combination
with the Sterrad NX1 advanced cycle,176 and cold atmospheric plasma.182 According to Rogez-Kreuz
et al.,176 no insoluble prion (PrPres) signal was detected for BSE 6PB1 or vCJD ‘after exposure to steam
in either of the two Sterrad systems’. The only process reported to have produced a log-reduction of
≥ 5 and a transmission rate of 0% for the BSE prion strains 6PB1 and TGB1 were 2mg/l gaseous H2O2
at 30 °C for three pulses.181 None of the treatments for the ME7, vCJD, 127S or M1000 prion strains
reported a log-reduction of ≥ 5 and a transmission rate of 0%.177,178,182,184
Supplementary evidence: studies reporting outcomes other than log-reductions
after autoclaving with/without other processes
Six studies185–190 reported outcomes other than log-reductions (Table 16). In terms of prion strain,
two studies used 10% or 20% brain homogenate of RML186 and two studies investigated sc237 and
sCJD,187,188 with the following prion strains investigated in only a single study: 263K scrapie,189 and 301 V
BSE and cattle BSE.188 Five studies used steel wires contaminated with the prions and one study189 used
steel spheres. All studies investigated autoclaving at 121, 134 or 137 °C for specified amounts of time as a
decontamination procedure; one study investigated autoclaving at 65 and 121 °C.188
TABLE 16 Studies reporting infectivity (but not log-reductions) from prion contamination on steel surfaces after
autoclaving with and without other processes or decontamination processes without autoclaving
Study (first
author and year
of publication)
Prion
strain
Source
material
(% w/v) Steel
Decontamination methods
Assay usedAutoclaving Other
Baxter (2005)189 263K BH (20) Spheres l 137 °C:
18 minutes
l Trigene (MediChem
International
(Manufacturing) Ltd,
Queenborough,
UK) disinfectant
l Radio-frequency
gas plasma
Hamsters
Edgeworth
(2011)185
RML BH (10) Wires l 134 °C:
18 minutes
l Rely+On
l Prionzyme
l 8% and 1.6% Hamo
100 PID
l 2M NaOH
l 20% NaOCl
SSBA
Giles (2007)188 Sc237
sCJD
BH (10) Wires l 65 °C: 30 minutes,
120 minutes and
18 hours
l 121 °C: 15, 30
and 120 minutes
l 2% SDS plus
1% AcOH
Tg7 and
Tg23372 mice
Giles (2008)190 301V
BSE
Cattle
BSE
BH (10) Wires l 65 °C: 8 minutes
l 121 °C:
120 minutes
l 134 °C:
120 minutes
l 4% SDS plus
1% AcOH
Tg2091 mice
Tg4092 mice
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The efficiency of autoclaving was assessed alone and in combination with a range of other
decontaminants. These included SDS, acetic acid (AcOH), NaOH, radiofrequency (RF) gas plasma,
Trigene disinfectant and various other enzymatic detergents. Selected results from these investigations
are reported in Table 17.
TABLE 16 Studies reporting infectivity (but not log-reductions) from prion contamination on steel surfaces after
autoclaving with and without other processes or decontamination processes without autoclaving (continued )
Study (first
author and year
of publication)
Prion
strain
Source
material
(% w/v) Steel
Decontamination methods
Assay usedAutoclaving Other
Jackson (2005)186 RML BH (10
and 20)
Wires l 121 °C:
20 minutes
l 134 °C:
20 minutes
l Enzymes:
SDS-PK-Pronase
l 2M NaOH
l LpH, LpHse
l Endozyme Plus
(Ruhof, Mineloa,
NY, USA)
Tg20 mice,
CD-1 mice, WB
RML BH (10) Wires l 134 °C:
20 minutes
Enzymes Tg20 mice,
CD-1 mice, WB
Peretz (2006)187 Sc237
sCJD
BH (10) Wires l 121 °C: 15, 30
and 120 minutes
l 134 °C: 15, 30
and 120 minutes
l 2% SDS plus
1% AcOH
l 4% SDS plus
1% AcOH
Tg7 and
Tg23372 mice
Micro BCA
Protein assay
(Pierce,
Rockford,
IL, USA)
AcOH, acetic acid; BH, brain homogenate; PK, proteinase K; WB, western blot; w/v, weight/volume.
TABLE 17 Results of studies reporting infectivity (but not log-reductions) from prion contamination on steel surfaces
after autoclaving with and without other processes or decontamination processes without autoclaving
Study (first author and
year of publication) Prion strain
Decontamination methods
Transmission
rate
Incubation
period days,
n (SD)Autoclaving Other
Baxter (2005)189 263K 137 °C: 18 minutes Trigene disinfectant 5/5 202 ± 28
Trigene disinfectant 0/5 466a
RF gas plasma 0/5 466a
Edgeworth (2011)185 RML 134 °C: 18 minutes NR 5% NR
bGiles (2007)188 Sc237 in Tg7
mice
65 °C: 30 minutes 2% SDS + 1% AcOH 100% 82± 0.7
65 °C: 120 minutes 2% SDS + 1% AcOH 68% 269 ± 3.2
65 °C: 18 hours 2% SDS + 1% AcOH 0% > 400
121 °C: 15 minutes NR 100% 160 ± 7.3
121 °C: 30 minutes NR 20% > 400
121 °C: 120 minutes NR 0% > 400
121 °C: 15 minutes 2% SDS + 1% AcOH 0% > 400
121 °C: 30 minutes 2% SDS + 1% AcOH 0% > 400
121 °C: 120 minutes 2% SDS + 1% AcOH 0% > 400
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TABLE 17 Results of studies reporting infectivity (but not log-reductions) from prion contamination on steel surfaces
after autoclaving with and without other processes or decontamination processes without autoclaving (continued )
Study (first author and
year of publication) Prion strain
Decontamination methods
Transmission
rate
Incubation
period days,
n (SD)Autoclaving Other
sCJD in
Tg23372 mice
65 °C: 30 minutes 2% SDS + 1% AcOH 86% 354 ± 1.6
65 °C: 120 minutes 2% SDS + 1% AcOH 44% > 500
65 °C: 18 hours 2% SDS + 1% AcOH 25% > 500
121 °C: 15 minutes NR 22% > 500
121 °C: 30 minutes NR 0% > 500
121 °C: 120 minutes NR 73% 414 ± 15
121 °C: 15 minutes 2% SDS + 1% AcOH 0% > 500
121 °C: 30 minutes 2% SDS + 1% AcOH 0% > 500
121 °C: 120 minutes 2% SDS + 1% AcOH 0% > 500
Giles (2008)190 301V 134 °C: 15 minutes NR 96% 161
134 °C: 30 minutes NR 57% 438
134 °C: 120 minutes NR 14% > 600
NR 1% AcOH: 65 °C
for 18 hours
100% 117
NR 4% SDS: 65 °C for
18 hours
100% 127
NR 4% SDS + 1%
AcOH: 65 °C for
30 minutes
73% 267
NR 4% SDS + 1%
AcOH: 65 °C for
120 minutes
33% > 600
NR 4% SDS + 1%
AcOH: 65 °C for
18 hours
58% 410
134 °C: 15 minutes 4% SDS + 1% AcOH 5% > 600
134 °C: 30 minutes 4% SDS + 1% AcOH 0% > 600
134 °C: 120 minutes 4% SDS + 1% AcOH 0% > 600
BSE 134 °C: 15 minutes NR 84% 384
134 °C: 30 minutes NR 100% 375
134 °C: 120 minutes NR 89% 420
NR 1% AcOH: 65 °C
for 18 hours
91% 354
NR 4% SDS: 65 °C for
18 hours
100% 368
NR 4% SDS + 1%
AcOH: 65 °C for
30 minutes
42% > 500
NR 4% SDS + 1%
AcOH: 65 °C for
120 minutes
26% > 500
NR 4% SDS + 1%
AcOH: 65 °C for
18 hours
4% > 500
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TABLE 17 Results of studies reporting infectivity (but not log-reductions) from prion contamination on steel surfaces
after autoclaving with and without other processes or decontamination processes without autoclaving (continued )
Study (first author and
year of publication) Prion strain
Decontamination methods
Transmission
rate
Incubation
period days,
n (SD)Autoclaving Other
134 °C: 15 minutes 4% SDS + 1% AcOH 0% > 500
134 °C: 30 minutes 4% SDS + 1% AcOH 0% > 500
134 °C: 120 minutes 4% SDS + 1% AcOH 0% > 500
Jackson (2005)186 RML
(20% w/v)
Tg20 mice
121 °C: 20 minutes NR 0/6a NR
134 °C: 20 minutes NR 0/4b NR
NR LpH 5/5 91 (SEM 2.6)
NR LpHse 3/5c 70 (0)
NR Endozyme Plus 5/5 81 (1)
NR Enzymes SDS-
PK-Pronase: 40 °C
for 60 minutes
0/3 NR
121 °C: 20 minutes Enzymes SDS-
PK-Pronase: 40 °C
for 60 minutes
0/5d NR
134 °C: 20 minutes Enzymes: SDS-
PK-Pronase: 40 °C
for 60 minutes
0/4 NR
RML
(20% w/v)
CD-1 mice
134 °C: 20 minutes NR 0/9 NR
134 °C: 20 minutes 2M NaOH 0/10 NR
134 °C: 20 minutes Enzymes SDS-
PK-Pronase: 40 °C
for 60 minutes
0/8 NR
NR Enzymes SDS-
PK-Pronase: 40 °C
for 60 minutes
0/10 NR
RML
(10% w/v)
Tg20 mice
134 °C: 20 minutes NR 13/13c 108
(12.4 SEM)
NR Enzymes SDS-
PK-Pronase: 40 °C
for 60 minutes
1/18 (101) NR
Peretz (2006)187 Sc237 in Tg7
mice
121 °C: 15 minutes NR n = 10, 100% 160 ± 7.3
121 °C: 30 minutes NR 20% > 400
121 °C: 120 minutes NR 0% > 400
121 °C: 15 minutes 2% SDS + 1% AcOH 0% > 400
121 °C: 30 minutes 2% SDS + 1% AcOH 0% > 400
121 °C: 120 minutes 2% SDS + 1% AcOH 0% > 400
134 °C: 15 minutes NR 87% 96 ± 0.6
134 °C: 30 minutes NR 55% 262 ± 10
134 °C: 120 minutes NR 9% > 400
134 °C: 15 minutes 4% SDS + 1% AcOH 0% > 400
134 °C: 30 minutes 4% SDS + 1% AcOH 4% > 400
134 °C: 120 minutes 4% SDS + 1% AcOH 0% > 400
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Only one study reported the outcome ‘tissue culture infectious units on wires’ (TICUw).185 This study
recorded that autoclaving at 134 °C for 18 minutes reduced the TICUw measure of the RML prion
strain to 0.03, which is reported to be equivalent to a reduction of 5.5 logs (see Table 15).
The remaining studies all reported transmission rates. The transmission rates produced by autoclaving
at 134 °C for 15 minutes and 30 minutes for the 301 V BSE prion strain were 96% and 57%,
respectively, and for cattle BSE they were 84% and 100%, respectively.190 The transmission rates
produced by autoclaving at 134 °C for 20 minutes for the RML prion strain ranged from 25% (1/4) to
100% (13/13) in Tg20 mice and 0% (0/9) in CD-1 wild mice.186 The unusually high transmission rate in
the larger sample of Tg20 mice was explained by the autoclaving process being affected by partial
sealing of the glass tubes containing the steel wires, which impaired the penetration of the steam.186
The transmission rates produced by autoclaving at 121 °C for 15 minutes and 30 minutes for the
Sc237 prion strain were 100% and 20%, respectively, and for sCJD, 22% and 0%, respectively.187,188
Finally, the transmission rates produced by autoclaving at 134 °C for 15 minutes and 30 minutes for
the Sc237 prion strain were 87% and 55%, respectively, and for sCJD 73% and 63%, respectively.187
The following combinations of autoclaving and other processes are reported to have produced a
transmission rate of 0% or ≤ 5%: autoclaving at 134 °C for 15, 30 or 120 minutes plus 4% SDS and
1% AcOH for the 301 V, cattle BSE,190 Sc237 and sCJD prions strains;187 autoclaving at 121 °C for
15, 30 or 120 minutes plus 2% SDS and 1% AcOH for the 301 V and cattle BSE prion strains;190 and
autoclaving at 65 °C for 18 hours plus 2% SDS and 1% AcOH for the Sc237 and sCJD prions strains.188
Autoclaving at 134 °C for 20 minutes plus SDS-proteinase K (PK)-Pronase at 40 °C for 60 minutes also
produced a 0% transmission rate for RML prion strains.186
Without autoclaving Trigene disinfectant and RF gas plasma, and SDS-PK-Pronase at 40 °C for 60
minutes, also produced transmission rates of 0% in the 263K and the RML prion strains, respectively.186,189
TABLE 17 Results of studies reporting infectivity (but not log-reductions) from prion contamination on steel surfaces
after autoclaving with and without other processes or decontamination processes without autoclaving (continued )
Study (first author and
year of publication) Prion strain
Decontamination methods
Transmission
rate
Incubation
period days,
n (SD)Autoclaving Other
sCJD
Tg23372
121 °C: 15 minutes NR n = 10, 22% > 500
121 °C: 30 minutes NR 0% > 500
121 °C: 120 minutes NR 73% 414 ± 15
121 °C: 15 minutes 2% SDS + 1% AcOH 0% > 500
121 °C: 30 minutes 2% SDS + 1% AcOH 0% > 500
121 °C: 120 minutes 2% SDS + 1% AcOH 0% > 500
134 °C: 15 minutes NR 73% 218 ± 4.1
134 °C: 30 minutes NR 63% 242 ± 2.8
134 °C: 120 minutes NR 46% > 500
134 °C: 15 minutes 4% SDS + 1% AcOH 0% > 500
134 °C: 30 minutes 4% SDS + 1% AcOH 0% > 500
134 °C: 120 minutes 4% SDS + 1% AcOH 0% > 500
NR, not reported; SEM, standard error of mean; w/v, weight/volume.
a All animals in these groups were clinically sound when euthanized at 466 days.
b The data for decontamination at 121°C are the same data as reported in Peretz 2006.187
c Wires being placed in partially sealed glass tubes appears to have impaired the autoclaving process.
d Total numbers infected (but only apparent post-mortem): a= 2/6, b= 1/4; c= 4/5, d= 1/5.
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Supplementary evidence: studies reporting evidence for levels of protein residue on
surgical instruments after cleaning
Nine studies183,191–198 reported this outcome after autoclaving with and without other decontamination
processes (Table 18): seven studies192–198 for surgical instruments and two studies for endoscopes.183,191 All
studies were conducted in the UK. Seven studies183,193–198 reported on protein residue on instruments
acquired between one and nine NHS trusts; the number of trusts involved was not reported in two
studies.191,192 All studies reported that cleaning essentially involved conventional procedures for the
equipment concerned. With the exception of two studies,192,193 the assay appears to have involved detection
of protein in situ on the instruments. Where reported, the number of instruments ranged from 2 to 1000.
There was no consistency in the measures used to quantify and report the residual protein
contamination of surgical instruments after conventional cleaning and sterilisation in a sterile service
department (SSD). Murdoch et al.193 reported a mean amount of protein per instrument of 71.67 µg
(range 8–91 µg); Baxter et al.192 reported a median range of 163–756 µg per instrument; Lipscomb
et al.194,195 reported residual contamination using an unvalidated ‘contamination index’ and reported
that 56% of instruments (out of a total of 23) from a single NHS trust showed severe contamination
(contamination index score of > 3–4) in at least one of the sample regions, whereas 66% of
instruments (n = 260) from nine NHS primary care trusts showed equivalent severe contamination
(contamination index score of > 3–4). According to this contamination index, a classification of 3
represents 0.42–4.2 µg of protein/mm2 and a classification of 4 is > 4.4 µg of protein/mm2. The most
recent study,196 reported residue ‘per instrument side’ for evaluated instruments from craniotomy sets
(n = 187): 87% of instruments were found to have < 5 µg per instrument side and 96% were found to
have < 10 µg per instrument side. Two papers did not explicitly quantify the residual protein but only
noted its presence.197,198 The studies assessing endoscopes reported either < 10 ng of protein/mm2
after processing183 or the ‘equivalent to 1–4 µg of proteins per channel, except in one channel which
harboured . . . equivalent to almost 33 µg of residual proteins for the whole channel’.191
Residual mass/protein studies
Studies reporting the impact on protein absorption and/or the relative efficacy of
cleaning when keeping instruments wet or dry before processing
Four studies (five papers) reported a comparison between ‘wet’ and ‘dry’ instruments in terms of
precleaning protein absorption or post soaking or cleaning protein residue (Table 19). All studies were
conducted in the UK, used steel tokens or wires and the same contaminant: 1 µl drops of ME7-infected
brain homogenate. Detection was made of in situ contamination using the same techniques: SYPRO®
(Life Technologies Corporation, Carlsbad, CA, USA) ruby protein stain and episcopic differential
interference contrast/epifluorescence microscopy. Across the studies, drying times before assessment
ranged from 15 minutes200 to 24 hours.200,201
The process to keep steel tokens or wires ‘wet’ was different in each study: Secker et al.98 used a ‘wet
bag’ (Humibag), that is a sealed bag containing 35 ml of distilled water for set time periods; Secker et al.201
used an air-tight container lined with moist tissue for 17 hours; Howlin et al.184 treated steel wires
immediately, rather than allowing them to dry; and Lipscomb et al.199 treated steel tokens with one of four
presoak treatments for 5 minutes, followed by 17 hours’ drying time. The dry conditions for comparison
were: air dry or a ‘dry bag’ for comparable times to the ‘wet bag’;200 air dry for 24 hours;201 air dry for
16 hours;184 and air dry for 17 hours.199 Different temperatures were evaluated but this text will focus
only on the findings for room temperature (or the closest available data) across studies. Three of the four
studies used the enzymatic cleaner Klenzyme (Steris, Mentor, OH, USA).
Both Secker et al. studies200,201 reported on protein residue after 24 hours at room temperature
before cleaning: 324.7 ± 15.0 ng of protein/mm2 for the air dry conditions compared with 6.0 ± 3.5 ng
of protein/mm2 for the wet conditions (98.2% reduction compared with air dry; p ≤ 0.001)201 and
1000 ± 205.0 ng of protein/mm2 for the air dry conditions compared with 31.9 ± 5.3 ng of protein/mm2
DOI: 10.3310/hta24110 Health Technology Assessment 2020 Vol. 24 No. 11
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
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TABLE 18 Study characteristics and results
Study (first author
and year of
publication) Country Source
Surgical
instruments
(number) Cleaning cycle Assay/in situ
Residual protein contamination of
surgical instruments after conventional
cleaning and sterilisation in a sterile
service department
Mean protein per
instrument (µg)
Median protein per
instrument (µg)
Baxter (2006)192 UK SSDs from a
random sample
of NHS trusts
Five trays
(n = 120)
Routine hospital cleaning
and sterilisation
Ninhydrin/acid
stripping of surfaces and
hydrolysing of proteins
NR 163–756 µg (range)a
bLipscomb (2006)194 UK SSD from one
NHS trust
Ranged in
shape and size
(n = 23)
Traditional machine
washer-disinfector
cleaning procedures
SYPRO ruby protein stain
and EDIC/EF microscopy
Unclearc
Results indicated that over half (56%) of
the instruments inspected showed severe
(classes 3–4) contamination in at least one
of the sample regions, 35% were moderately
contaminated (class 3), and only 9%
displayed low-level deposition (class 0–2).
The overall mean contamination index
value for all the instruments was 2.8
bLipscomb (2006)195 UK SSDs from nine
anonymous NHS
primary care
trusts
Nine sets
(n = 260)
Traditional machine
washer-disinfector
cleaning procedures
SYPRO ruby protein stain
and EDIC/EF microscopy
In situ
Levels of soiling (scores averaged for each
instrument): severe (66%: contamination
index score, > 3 to 4); moderate (17%:
contamination index score, > 2 to 3);
low level (7%: contamination index score,
0 to 2). Across the nine trays, the mean
contamination index per instrument set
ranged from 2.4 to 3.6; overall mean
contamination index value for all the
instruments was 3.2. Contamination index:
class 3 is 0.42–4.2 µg of protein/mm2 and
class 4 is > 4.4 µg of protein/mm2
Statistical analysis indicated that there
was significant difference in the levels of
contamination between the different types
of instrument, with needle holders and
tissue forceps (as hinged instruments)
showing contamination levels significantly
higher than some other instruments
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Study (first author
and year of
publication) Country Source
Surgical
instruments
(number) Cleaning cycle Assay/in situ
Residual protein contamination of
surgical instruments after conventional
cleaning and sterilisation in a sterile
service department
Mean protein per
instrument (µg)
Median protein per
instrument (µg)
Murdoch (2006)193 UK Five Department
of Health and
Social Care
hospitals
A range of
instruments
(n = 43)
Autoclaved ‘
quantification methods’,
i.e. levels of protein
removed from instruments
and identified in the
‘buffer’ or ‘wash’
71.67 µgd
8–91 µg (range)e
NR
Baxter (2006)197 UK One NHS trust A basic
neurosurgical
tray in regular
use (n = 6)
‘Conventional hospital SSD
procedures (washing and
autoclaving) n = 3; ‘conventional
hospital SSD procedures’ plus
RF gas plasma, n = 3
EDX
Unclearc
Protein contamination on instruments
was identified after the conventional SSD
procedure, but was ‘not directly quantified
. . . the analyses simply show the elemental
composition of these residues’
Baxter (2009)198 UK One NHS trust Forceps (n= 2) ‘Conventional hospital SSD
procedures’ (washing and
autoclaving)
EDX
in situ
Measure of residual protein is by units
of fluorescence after conventional SSD
processes, but before and after RF gas
plasma treatment
Smith (2018)196 UK One NHS trust.
Some instruments
‘artificially soiled’
with Edinburgh
soil
The five most-
commonly used
neurosurgery
sets (n= 1000)
‘Automated washer disinfector’
in SSD (untreated), plus
instruments treated with
two types of wetting agents
[PreKlenz (Steris, Mentor, OH,
USA) and sterile water]
SDS extraction and OPA,
ProReveal (Synoptics,
Cambridge, UK). Unclearc
10 craniotomy sets
only: instruments,
n = 305 (OPA assay,
and includes 40
artificially soiled
instruments):
< 30 µg, except for
one untreated
instrument: sharp
elevator: 44.02 µgf
NR
continued
D
O
I:
1
0
.3
3
1
0
/h
ta2
4
1
1
0
H
e
a
lth
T
e
ch
n
o
lo
g
y
A
sse
ssm
e
n
t
2
0
2
0
V
o
l.2
4
N
o
.1
1
©
Q
u
een
’s
P
rin
ter
an
d
C
o
n
tro
ller
o
f
H
M
SO
2
0
2
0
.T
h
is
w
o
rk
w
as
pro
d
u
ced
b
y
Stevenso
n
et
a
l.u
n
d
er
th
e
term
s
o
f
a
co
m
m
issio
n
in
g
co
n
tract
issu
ed
b
y
th
e
Secretary
o
f
State
fo
r
H
ealth
an
d
So
cial
C
are.T
h
is
issu
e
m
ay
b
e
freely
repro
d
u
ced
fo
r
th
e
pu
rpo
ses
o
f
private
research
an
d
stu
d
y
an
d
extracts
(o
r
in
d
eed
,th
e
fu
ll
repo
rt)
m
ay
b
e
in
clu
d
ed
in
pro
fessio
n
al
jo
u
rn
als
pro
vid
ed
th
at
su
itab
le
ackn
o
w
led
gem
en
t
is
m
ad
e
an
d
th
e
repro
d
u
ctio
n
is
n
o
t
asso
ciated
w
ith
an
y
fo
rm
o
f
ad
vertisin
g.
A
pplicatio
n
s
fo
r
co
m
m
ercial
repro
d
u
ctio
n
sh
o
u
ld
b
e
ad
d
ressed
to
:
N
IH
R
Jo
u
rn
als
Lib
rary,
N
atio
n
al
In
stitu
te
fo
r
H
ealth
R
esearch
,
E
valu
atio
n
,
Trials
an
d
Stu
d
ies
C
o
o
rd
in
atin
g
C
en
tre,
A
lph
a
H
o
u
se,
U
n
iversity
o
f
So
u
th
am
pto
n
Scien
ce
P
ark,So
u
th
am
pto
n
SO
1
6
7
N
S,U
K
.
4
9
Protein extraction and
TABLE 18 Study characteristics and results (continued )
Study (first author
and year of
publication) Country Source
Surgical
instruments
(number) Cleaning cycle Assay/in situ
Residual protein contamination of
surgical instruments after conventional
cleaning and sterilisation in a sterile
service department
Mean protein per
instrument (µg)
Median protein per
instrument (µg)
Different sets:
instruments n= 187
(ProReveal assay):
87% (163/187):
< 5 µg of protein
per instrument side;
96% (179/187):
< 10 µg per
instrument side
Hervé (2013)183 UK Manufacturer,
contaminated
with ‘Edinburgh
soil’
Endoscopes
(n =NR)
An ‘enzymatic cleaner used in a
number of endoscopy units’
SYPRO ruby protein stain
and EDIC/EF microscopy
Unclear
Contamination was < 10 ng/mm2 after
standard cleaning (see figure 3 in Hervé
and Keevil,183 for details)
Hervé (2016)191 UK Unknown
number of
‘hospital-based
endoscopy units’
(n= 6)
Endoscopes
(n = 6)
An ‘enzymatic cleaner: Enzol’
(Enzol, Johnson & Johnson,
New Brunswick, NJ, USA)
SYPRO ruby protein stain
and EDIC/EF microscopy
Unclear
Level of microcontamination absorbed into
the luminal surface of the endoscope:
0.1–0.9 µg of protein/m. With the
exception of one endoscope channel
(with protein residues equivalent to almost
33 µg), most protein residues remained
under the equivalent of 1–4 µg per channel
EDIC/EF, episcopic differential interference contrast/epifluorescence microscopy; EDX, energy-dispersive X-ray spectroscopy; NR, not reported; OPA, orthophthaladehyde; SSD, sterile
service department.
a A significant difference was observed in mean levels of protein contamination between trays (p < 0.0001).
b Contamination index.
c Unclear: not reported in Methods, but detection methods indicate evaluation of proteins in situ.
d Calculated from table II: 3082 [total protein µg per instrument/43 (total number of instruments)].194
e A significant difference was observed in mean levels of protein contamination between hospitals (p < 0.0001).
f Smith et al. (2018),196 Supplemental table XV.
Note
Contamination index: class 3 is 0.42–4.2 µg of protein/mm2 and class 4 is > 4.4 µg of protein/mm2.
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TABLE 19 Study characteristics and results
Study (first author
and year of
publication) Country Contaminant Steel medium Pretreatment Assay/in situ Dry Wet
Differences in residual protein (ng/mm2)
contamination of wires or tokens
Dry Wet
Lipscomb (2007)199 UK 1-µl drops of
ME7-infected
BH
Surgical 316L
grade SS tokens
(10 × 25mm)
Klenzyme®;
Endozyme AW;
Enzol; Liquid 52
(Hamo Liquid 52,
Steris, Mentor,
OH, USA)
SYPRO ruby
and EDIC/EF
microscopy; in
situ
DT = 17 hours.
No presoak/
pretreatment
DT= 17 hours
5 minutes for
each: Klenzyme,
8 ml/l; Endozyme
AW, 4 ml/l;
Enzol, 8 ml/l;
liquid 52, 8 ml/l
Final residual
protein
contamination at
22 °C:a
l Control = 100%
Percentage of final
residual protein
contamination
compared with
control at 22 °C:a
l Klenzyme= 19%
l Endozyme
AW = 36%;
l Enzol = 4%;
l Liquid 52= 17%
Howlin (2010)184 UK 1-µl drops of
ME7-infected
BH
Surgical 316L
grade SS wires
(5 × 0.16 mm)
Klenzyme;
Pre-Klenz
(presoak gel)
Western blot;
in situb
DT = 16 hours
followed by
pretreatments
DT= 0 hours
(immediate
treatment)
Total protein removal (ng/mm2):
immediate treatment with Pre-Klenz,
produced a 2 log-reduction compared
with ‘dry’ controls
aSecker (2011, 2010)201,202 UK 1-µl drops of
ME7-infected
BH
Surgical 316L
grade SS tokens
(25 × 75mm)
Klenzyme;
Endozyme
SYPRO ruby
protein stain
and thioflavin T
(Sigma Aldrich,
St Louis, MO,
USA), EDIC/EF
microscopy; in
situb
DT = 24 hours;
air RT or F
(4–8 °C)
DT= 24 hours;
moist: air-tight
container lined
with moist
tissue; RT or F
(4–8 °C)
l RT = 324.7 ±
15.0 ng/mm2
l F = 243.8 ±
17.9 ng/mm2
l Klenzyme
applied after
2 hours:
RT = 18.0 ±
9.3 ng/mm2
(90.1% reduction
compared with
untreated
air-dry control)
l Endozyme
applied after
2 hours:
RT = 194.3 ±
7.9 ng/mm2
l RT = 6.0±
3.5 ng/mm2
(98.2% reduction
compared with
dry; p ≤ 0.001)
l F = 56.8 ±
12.9 ng/mm2
(76.7% reduction
compared with
dry; p ≤ 0.001)
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TABLE 19 Study characteristics and results (continued )
Study (first author
and year of
publication) Country Contaminant Steel medium Pretreatment Assay/in situ Dry Wet
Differences in residual protein (ng/mm2)
contamination of wires or tokens
Dry Wet
Secker (2015)200 UK 1-µl drops of
ME7-infected
BH (equivalent
to 1 µg total
protein)
Surgical 316L
grade SS tokens
(10 × 30mm)
Prolystica 2 ×
alkaline detergent,
working pH 10.1
or Progenica
(Serchem Ltd,
Telford, UK)
detergent,
working pH 10.9
SYPRO ruby
protein stain
and thioflavin T;
EDIC/EF
microscopy;
in situb
Air for (DT):
l 15 minutes
l 30 minutes
l 1 hour
l 2 hours
l 24 hours
l (RT and F)
Wet bag: sealed
bag with 35 ml
of distilled water
for (DT):
l 15 minutes
l 30 minutes
l 1 hour
l 2 hours
l 24 hours
l (RT and F)
24 hours’ humidity:
l RT, 55–70%
l F, 46–69%
Protein absorption
precleaning (RT):
l 15 minutes,
15.3 ±
4.8 ng/mm2
l 24 hours,
1000 ±
205.0 ng/mm2
Prolystica (RT):
l 1 hour, 54.8 ±
13.7 ng/mm2
l 2 hours, 918.6 ±
54.0 ng/mm2
l 24 hours,
1026.1 ±
92.5 ng/mm2
Prolystica (F):
l 1 hour, NR
l 2 hours, NR
l 24 hours,
605.1 ±
89.5 ng/mm2
24 hours’ humidity:
l RT, 90%
l F, 90%
Protein absorption
precleaning (RT):
l 15 minutes,
18.5 ±
4.2 ng/mm2
l 24 hours, 31.9±
5.3 ng/mm2
Prolystica (RT):
l 1 hour, NR
l 2 hours, NRc
l 24 hours, NRc
Prolystica (F):
l 1 hour, NR
l 2 hours, NRc
l 24 hours, NRc
Progenica (RT):
l 1 hours, NR
l 2 hours, NR
l 24 hours, NRc
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Study (first author
and year of
publication) Country Contaminant Steel medium Pretreatment Assay/in situ Dry Wet
Differences in residual protein (ng/mm2)
contamination of wires or tokens
Dry Wet
Progenica (RT):
l 1 hour, NR
l 2 hours, 112.0 ±
41.4 ng/mm2
l 24 hours,
743.2 ±
155.5 ng/mm2
Progenica (F):
l 1 hour, NR
l 2 hours,
1095.6 ±
359.1 ng/mm2
l 24 hours,
1247.9 ±
132.1 ng/mm2
Progenica (F):
l 1 hours, NR
l 2 hours, NR
l 24 hours, NRc
Dry bag: tied,
clear polythene
bag for (DT):
l 15 minutes
l 30 minutes
l 1 hour
l 2 hours
l 24 hours
l (RT and F)
24 hours humidity:
l RT, 55–80%
l F, 47–90%
Protein absorption
pre-cleaning (RT):
l 15 minutes,
30.6 ±
27.7 ng/mm2
l 24 hours,
785.6 ±
310.8 ng/mm2
(Repeat from above)
24 hours humidity:
l RT, 90%
l F, 90%
Protein absorption
pre-cleaning (RT):
l 15 minutes,
18.5 ±
4.2 ng/mm2
l 24 hours, 31.9 ±
5.3 ng/mm2
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TABLE 19 Study characteristics and results (continued )
Study (first author
and year of
publication) Country Contaminant Steel medium Pretreatment Assay/in situ Dry Wet
Differences in residual protein (ng/mm2)
contamination of wires or tokens
Dry Wet
Prolystica (RT):
l 1 hour, 84.7 ±
30.9 ng/mm2
l 2 hours, NRc
l 24 hours, NRc
Prolystica (F):
l 1 hour, NR
l 2 hours, NRc
l 24 hours,
181.5 ±
39.4 ng/mm2c
Progenica (RT):
l 1 hour, NR
l 2 hours, NR
l 24 hours,
154.5 ±
7.0 ng/mm2c
Progenica (F):
l 1 hour, NR
l 2 hours, NR
l 24 hours, NRc
Prolystica (RT):
l 1 hour, NR
l 2 hours, NRc
l 24 hours, NRc
Prolystica (F):
l 1 hour, NR
l 2 hours, NRc
l 24 hours, NRc
Progenica (RT):
l 1 hour, NR
l 2 hours, NR
l 24 hours, NRc
Progenica (F):
l 1 hour, NR
l 2 hours, NR
l 24 hours, NRc
BH, brain homegenate; DT, drying time; EDIC/EF, episcopic differential interference contrast/epifluorescence microscopy; F, refrigerated. NR, not reported; RT, room temperature;
SS, stainless steel.
a Data for 30 °C too but ‘efficacy changes little between the ambient temperatures’.201
b Unclear: not reported in methods, but comments in discussion sections of papers indicate measurement was of in situ proteins, e.g. Howlin et al.:184 ‘A concentration of 0.03 ng/mm2
prion-associated amyloid was detected in situ on the wires’; Secker et al.:200 ‘ThT/SR dual stain alongside sensitive EDIC/EF microscopy was the chosen detection method due to its
sensitivity down to the picogram range and its ability to detect in situ amyloid contamination as well as total protein’.
c Level of difference is p ≤ 0.05 compared with the room temperature. Air sample for same time point (data for dry bag and wet bag indicate statistically significantly reduced levels
of residual protein).
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for wet conditions.200 After the application of presoaks or cleaners, Lipscomb et al.199 reported a reduction
in protein between 64% and 96% on the presoaked or treated tokens compared with the dry, untreated
controls and Howlin et al.184 reported a reduction of approximately 2 logs in protein residue for tokens
treated immediately (not allowed to dry) with the PreKlenz presoak compared with wires that were
allowed to dry for 16 hours. Secker et al.200 and Lipscomb et al.199 also reported that the longer the drying
times, the more difficult it was to remove the contamination.
Discussion/summary of studies on residual mass and decontamination
The published evidence suggests that standard cleaning practices within SSDs do not achieve levels of
≤ 5 µg residual protein per instrument for all instruments, as required by current guidance.203. However,
these published data are based on different assays and detection methods and the most recent data196
suggest that as much as 87% of assessed instruments might have protein residue of < 5 µg per instrument
side, and 96% might have residue of < 10 µg per instrument side. Recent papers200,201 also report very large
differences in protein absorption on instruments kept in dry or wet conditions, with the latter producing as
much as a 98.2% reduction in protein absorption compared with dry conditions (p ≤ 0.001).201 Standard
cleaning in SSDs might, therefore, be expected to produce residual protein levels of ≤ 5 µg per instrument
side for neurosurgical instruments kept in moist or wet conditions before processing. There is also some
evidence for reduced contamination of endoscope channels if kept wet, although the evidence is
more equivocal.183
The findings for autoclaving at 134 °C for 15–20 minutes in the more recent sample of studies are
generally similar to those previously reported for publications up to 2004: log-reductions of between 4
and 5, with highly variable transmission rates (ranging from 0% to 100%) that are generally > 50%. It is
generally accepted that autoclaving alone only partially inactivates TSE prions.119,204–207 The majority of
studies published in 2004 and earlier focused on the 263K scrapie prion strain, whereas the more recent
data have investigated efficiency of autoclaving on a wider range of prions, for example RML and various
CJD and BSE strains. Some strains, such as the M1000 strain, appear to be more resistant to autoclaving.
Certain combinations of autoclaving and enzymatic or alkaline detergents have also been reported to
achieve log-reductions of infectivity in excess of 5 and transmission rates of 0% in animal assays: for
the 263K, RML, 301 V, cattle BSE, Sc237 and sCJD prions strains, alkaline detergents,176 0.2% SDS/
0.3% NaOH,175 RMEC B,178 4% SDS plus 1% AcOH,187,190 H2O2 and gas plasma (Sterrad NX1 and 2
cycles).176 It has been reported that, based on the evidence, the following should be sufficient to achieve
adequate levels of inactivation and decontamination of prions bound to steel wires: a combination of
an alkaline or enzymatic detergent followed by autoclaving, with each process known to produce a
log-reduction of ≥ 5.205
Within the specified requirements of dose, time and temperature of exposure, a number of decontaminants,
without autoclaving, were also reported to achieve log-reductions of ≥ 5 and/or 0% transmission across
a range of prion strains. These include Rely-On PI (DuPont) and Prionzyme (Genecor);185 NaOH;180,185
Trigene disinfectant and RF gas plasma;189 SDS-PK-Pronase;186 H2O2 and gas plasma;174,176; and combinations
of enzymatic detergents and disinfectants.174 However, it has also been stated that NaOH and NaOCl,
although effective, ‘are not compatible with various pieces of medical equipment, and . . . present a serious
handling hazard for healthcare employees’,174 although NaOH is reported to be less corrosive than
NaOCl.119,205 A combination of immersion in NaOH or NaOCl followed by autoclaving is recommended by
the World Health Organization.4,119
It has been acknowledged that these studies do not permit a direct comparison of their respective
findings and that the findings are, in some cases, contradictory or discrepant because they have been
conducted under different conditions (such as differing prion strains, drying times, whether in vitro or in
vivo, different animal assay, infectious titre of the material used, time and temperature of the exposure
to the decontaminant, dose of the decontaminant, observation period, substrate used, infectivity
detection method used.119,176,186,204,205,208 Such differences also make direct comparison between findings
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difficult for human prions and other TSE prions.177 It is also noted that all are laboratory studies that do
not necessarily reflect procedures used in clinical settings; the papers retrieved for this systematic
review included studies of surgical instruments and SSDs,189,193,209 but they report contamination only
with proteins (not prions) after standard decontamination processes. Although steel wires are generally
accepted to be the most useful simulator to test prion adherence to steel surgical instruments, it is also
recognised that they do not clean in the same manner as larger, more complicated surfaces.206,209
The evidence that instruments used for high-risk procedures remain in their
original sets after decontamination
The purpose of this review was to identify relevant published and unpublished evidence to determine
the extent to which instruments used in neurosurgery remain in a specific set after decontamination
procedures as per NICE guidance (IPG196).14 Labelling or tracking systems may be in place to maintain
the integrity of such sets and to reduce or prevent the migration of instruments between sets. Evidence
for the migration of instruments between sets might have implications for the risk of transmission of
disease between patients undergoing neurosurgery. A report by the ACDP TSE subgroup estimated that
the likelihood of at least one instrument migrating in or out of a neurosurgical set is 50%.117 This
document contains a project report and guidance for the Department of Health and Social Care to
employers on the precautions to control the risk of exposure of employees and others to TSE agents
from work activities. The estimate does not appear to be supported by any evidence. However, if such a
high level of migration of instruments during high-risk posterior segment surgery occurred, this could
potentially promote a self-sustaining epidemic of CJD or vCJD.
Studies relating to evidence that instruments used for high-risk procedures remain in their
original sets after decontamination
The number and type of included studies are shown in Table 20.
TABLE 20 Characteristics of included studies
Study
(first author
and year of
publication) Country
Time
period Design Strategy Details
Belay (2013)119 USA 1998–2012 Audit and evaluation
of neurosurgery
performed on CJD
patients
None An audit of the ability of
specified centres to
identify particular
instruments and sets
The study provides
limited quantitative
evidence on sets and
set-splitting
NICE (2016)210 England NR Qualitative and
observational:
interviews and a
single site visit for
neurosurgery
The implementation
of guidance on
maintaining set
integrity
Qualitative evidence on
the barriers to achieving
or maintaining set
integrity
The study provides
limited qualitative
evidence on sets and
set-splitting
NR, not reported.
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Only two studies were identified that provided any evidence on whether or not instruments for
procedures on high-risk tissues remain in their original sets.119,210 In 2013, an article was published by
Belay et al.119 reporting an audit to identify instruments and sets of instruments that might have been
used on patients known to have CJD. The sample was limited to CJD index cases from US hospitals
and reported to the US Centers for Disease Control and Prevention. The aim of the audit was to
identify patients who subsequently underwent neurosurgery with the same instruments or sets used
on the CJD index case. There was no reported strategy in place to maintain or to evaluate set integrity.
The audit reported that a single hospital could have between 1 and 12 sets of instruments for
neurosurgery, that 12 of the 19 affected hospitals had multiple sets and that in 11 of these 12
hospitals those sets used on a CJD patient could not be identified (Table 21).
The second study was an unpublished report produced for NICE in 2016.210 The aim of the study
was to explore the barriers and facilitators affecting the implementation of NICE IPG19614 on the surgical
transmission of CJD. The document reported findings concerning the identification of at-risk patients and
the acquisition of instruments but also covered the principal perceived barriers to the implementation of
the guidance on set integrity, which required keeping all instruments for neurosurgery within their
designated sets or ‘kits’. The sample was limited to four NHS trusts in the UK. The report did not provide
a detailed methodology for the study. Study participants (‘clinicians and other users’) reported multiple
barriers to maintaining set integrity, that is guaranteeing that instruments did not migrate between sets.
These are detailed in Table 21 and included: the absence of an adequate and reliable instrument-tracking
system; errors in scanning instruments that did have barcodes; the periodic inaccessibility of tracking
systems; and their failure to be completely integrated with patient records. The study also reported,
however, that set integrity had been improved in the sampled settings by stopping the use of SIs and the
increased use of single-use instruments. It is important to note that the report provided no quantitative
evidence on whether or not instruments for high-risk surgery remained in their sets, but given that
participants reported many problems with identifying and tracking certain instruments, the migration of at
least some instruments between neurosurgery sets is probable.
TABLE 21 Findings of included studies
Study (first author
and year of
publication) Findings
Belay (2013)119 l By the time of a CJD diagnosis, the identification of contaminated instruments had become
almost impossible in some hospitals, in part because 12 out of 19 (63%) hospitals were
known to have multiple neurosurgical sets
l The number of neurosurgical sets per hospital ranged from 1 to 12 (data permitting)
l It was not possible to identify the CJD-contaminated sets in 11 (58%) of the 19 hospitals;
therefore, it was also not possible to determine the exact number of patients exposed to the
instruments used on the index patient in these hospitals
NICE (2016)210 Barriers that affect the implementation of the guidance on keeping instruments for high-risk
surgery within specific sets:
l High cost of sets and lack of clarity over responsibility for paying for full sets
l Lack of clarity on categories of patients who are to be exposed to particular sets
l Lack of conviction regarding level of transmission risk to patients
l Less paediatric work in a hospital, less likely to have specific sets for the younger cohort
l Absence of an adequate and reliable instrument-tracking system
¢ Some barcoding/laser etching has been undertaken in some sites, but this can be at a high
cost and some instruments are too small to barcode
¢ There are errors in scanning
¢ Tracking system is not always accessible and is not fully integrated with patient records
Facilitators that enable the implementation of the guidance:
l Use of single-use or disposal of reusables where possible (more frequently than previously)
l Reasonable cost of some disposables
l Users report that use of SIs, which might migrate between sets, has been stopped
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Discussion/summary of evidence on set-keeping for high-risk procedures
Very little research has been undertaken to evaluate whether or not instruments for high-risk
neurosurgeries remain in their designated sets. The two studies identified for this systematic review
reported only limited evidence on this question. One study was conducted in the USA and reported
that instruments could not be identified in the vast majority of cases where they had been used on
a patient who was later diagnosed with CJD, and where there were multiple sets in a hospital.119
The second study210 was performed in the highly relevant setting of the NHS, but is unpublished
and its methodology was poorly reported. It did not report quantitative evidence on whether or not
instruments for high-risk surgery remained in their sets; rather, the evidence consisted of clinicians’
and users’ reported experiences of implementing NICE IPG196 guidance14 on keeping instruments
for high-risk surgeries in their designated sets. These participants reported a range of barriers to set
integrity, but also reported more frequent use of single-use instruments and anaesthetic equipment,
and that SIs were no longer used. These developments reduce the absolute levels of migration of
contaminated instruments between sets. Evidence to substantiate the estimated likelihood of 50% for
at least one instrument migrating in or out of a neurosurgical set, posited in the Department of Health
and Social Care guidance report117 is therefore limited, but indicates that there is a high probability
that at least some if not all instruments in neurosurgery sets do migrate between sets.
The evidence for complication rates of single-use compared with reusable
instruments for high-risk procedures
The aim of this review was to identify any published or unpublished evidence for the safety of
single-use instruments compared with reusable instruments for high-risk procedures. Safety was to
be determined by the relative frequency of complications. This review excluded instruments, including
anaesthetic equipment, that would not normally come into contact with high-risk tissues205,211 or
that are now single use.210 Evidence on safety outcomes might have implications for the viability of
single-use or disposable instruments as an alternative to reusable instruments for high-risk procedures.
Studies relating to evidence for complication rates of single-use compared with reusable
instruments for high-risk procedures
No relevant papers were identified pertaining to this review question.
Discussion/summary of complication rates for single-use versus reusable instruments
An unpublished report produced for NICE in 2016210 explored the barriers to and facilitators of affecting
the implementation of NICE IPG19614 on the surgical transmission of CJD. The report summarised the
findings of an observational site visit and interviews with ‘clinicians and other users’ in a sample of
four NHS trusts in the UK. The participants reported more frequent use of single-use instruments
and anaesthetic equipment than before, and that single-use instruments were increasingly relatively
inexpensive. However, no published or unpublished studies were identified by this systematic review
that compared complication rates for single-use instruments with the complication rates for reusable
instruments employed in the designated high-risk neurosurgeries. The relative efficacy and safety of
these groups of instruments or devices are therefore unknown.
The evidence for the likelihood of future surgery for a patient undergoing
high-risk procedures
The purpose of this review was to identify relevant published and unpublished evidence to determine
the risk of future surgery for a patient undergoing high-risk neurosurgical procedures. A risk
assessment study performed for the Department of Health and Social Care212 reported that one factor
that can have a significant impact on infection dynamics is the chance of individuals having two or
more operations (especially surgery to the CNS or posterior eye). The aim of this review was to assess
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the potential number of high-risk tissue exposures to potentially contaminated instruments,
which might then have implications for the risk of transmission of disease to patients undergoing
high-risk procedures.
Studies relating to evidence for the likelihood of future surgery for a patient undergoing
high-risk procedures
Only one study was identified that provided any evidence on the risk or rate of neurosurgery after a first
neurosurgical procedure213 (Table 22). The aim of the study was to assess the feasibility of post-mortem
surveillance of patients who had undergone neurosurgical procedures at least 5 years previously, in
order to explore the prevalence of subclinical vCJD. To do this, the article analysed the relationship
between mortality rates and reoperation rates by procedure. The annual incidence of mortality in this
cohort ≥ 5 years after the first instance of neurosurgery was as low as 3% for certain procedures that
would not be considered as high risk (such as primary/revision excision of a lumbar disc), whereas a
greater likelihood of mortality was associated with other procedures (e.g. brain excisions and the
drainage of extra- and sub-dural haematomas).
The article reported the extraction and analysis of patient records’ data relating to the 10 most frequent
neurosurgical operations performed in Scotland in the period 1993–2001, focusing on four procedures
considered to present a medium or high risk of CJD prion transmission: drainage of extra- and sub-dural
haematoma; cerebral aneurysm operations; primary or revisional decompression operations; and the
creation of ventricular shunts.213 Two additional potentially relevant procedures from this paper have also
been included here: unspecified excision of brain and excision of brain lesion(s); this is because of their low
5-year survival rates (41.5% and 29.9%, respectively). In terms of the current review, the aim was to
document the potential for surgical transmission through contaminated instruments by establishing the
rate of future high-risk procedures following an index procedure. It is not clear whether, in the Bird et al.213
report, the future procedures are always the same as the index procedure (i.e. if the index procedure was
concerned with ventricular shunts, then the reported rates of future procedures also related only to
ventricular shunts) or whether they might be a neurosurgical procedure different from the index
procedure. The evidence was presented as event rates for procedures deemed to be of high or medium
potential risk of vCJD transmission (Table 23).
The data indicate that the proportion of individuals in this sample having a second or third procedure
(or more) within 5–10 years after an initial neurosurgical procedure differed depending on the index
procedure (see Table 23). This ranged from 10.7% for individuals having one or more additional
procedures for the drainage of extra- and sub-dural haematoma to 49.5% for individuals having one
or more additional procedures related to a ventricular shunt. In the case of ventricular shunts, the
majority (57.2%) of those who had subsequent procedures were also likely to have more than one
additional procedure.
TABLE 22 Characteristics of included studies
Study
(first author
and year of
publication) Country
Time
period Design
Type of
surgery Details
Bird (2009)213 UK (Scotland) 1993–2001 Audit and
evaluation
Neurosurgery Neurosurgery (and proportions of
patients experiencing more than one
procedure) and mortality
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Discussion/summary of risk of future surgery in high-risk procedures
The Bird et al.213 paper is a UK (Scottish-based) study analysing relatively recent patient records’ data
on the actual proportions of patients undergoing one or more medium- or high-risk neurosurgical
procedure. This evidence indicates that, depending on the procedure, between 50% and 90% of
patients are unlikely to have a second high-risk procedure within 5–10 years of the initial procedure
and that the number of patients undergoing additional procedures, with their increased risks of
surgical transmission, depends heavily on the procedures involved. The potential for the Bird et al.213
paper to inform the model is limited, as the paper did not focus solely on high-risk procedures and
does not compare the risk of additional procedures with control data for those who had not undergone
an index high-risk procedure.
TABLE 23 Findings of Bird et al.213 on subsequent event rates for selected neurosurgical procedures for any patient
within the time period 1993–2001
Procedure
Only one subsequent
procedure after the
index procedure,
% (n/N)
More than one
subsequent procedure,
% (n/N)
Proportion of individuals
with a subsequent
procedure who underwent
more than one, % (n/N)
Drainage of extra- and sub-dural
haematomaa
8.3 (221/2654) 2.4 (63/2654) 22.2 (63/284)
Cerebral aneurysm operations 14.8 (264/1782) 7.1 (127/1782) 32.5 (127/391)
Creation of ventricular shunts 21.2 (191/900) 28.3 (255/900) 57.2 (255/446)
Excision of brain: unspecifieda 12.1 (110/911) 6.9 (63/911) 36.4 (63/173)
Excision of brain lesion (e.g. frontala) 13.0 (139/1072) 5.6 (60/1072) 30.2 (60/199)
a Not specified as high risk.
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Chapter 3 Cost-effectiveness
Background
Previous modelling work assessing the risks of surgical transmission of CJD was undertaken by
ScHARR, culminating in a report in 2006.11 Henceforth, this will be known as the ScHARR report.
This report was part of the evidence base appraised by the CJD Advisory Sub-Committee (CJDAS), which
produced IPG196.214 This guidance highlighted three high-risk surgical areas: neurosurgery, posterior eye
and neuroendoscopy. It was recommended that migration of instruments between sets should be abolished
and that single-use instruments were not recommended on the basis of cost-effectiveness with the
exception of accessories for neuroendoscopy. A separate recommendation was made that separate sets of
instruments should be established for patients born after 1 January 1997 (who are unlikely to have been
exposed to the BSE epidemic).
An update of the previous work was undertaken by ScHARR. However, with the agreement of NICE,
the current work focuses solely on surgical procedures deemed to be high risk. This update incorporates the
latest evidence on key model parameters and assess a range of appropriate strategies and interventions.
Reasons for updating IPG196 include the continued evolution of high-quality and less expensive single-use
instruments; the lack of adoption of new decontamination methods potentially effective against human
prions; the findings of abnormal prion accumulation in the appendixes of patients born after 1996; and
anecdotal reports that the recommendations of IPG196 have proved to be difficult to implement, or
unachievable, for a number of units. The primary deliverable was a report for a NICE committee that had
been convened for the purposes of providing an update to IPG196.
The analyses undertaken assess the potential transmissions of all forms of CJD, which include sCJD,
fCJD and iCJD. Throughout the report, any CJD cases that have been caused by surgical transmission
will be abbreviated to stCJD.
Elicitation
Many model parameters are subject to considerable uncertainty and were populated following two
elicitation sessions undertaken in 2005, one with epidemiological experts and one with decontamination
experts. These elicitations were reported in Stevenson et al.11 and the results are repeated in this report.
At a meeting of the NICE interventional procedures committee and ScHARR in October 2017, it was
decided that the elicitation related to epidemiological parameters should be reconducted to address
possible concerns relating to the lack of potential to be misdiagnosed with a different neurodegenerative
disease, and with the incubation periods previously elicited. This elicitation session was undertaken on
18 January 2018; the results of the elicitation exercise are in Appendix 4.
Elicitation methods
The 2018 elicitation session was conducted using the Sheffield Elicitation Framework (SHELF).
Four experts participated in a face-to-face facilitated workshop. The experts first completed a training
exercise (using a quantity known to the facilitator, but unknown to the experts) to familiarise themselves
with the elicitation methodology. For each parameter, the experts first recorded their probability
judgements individually without conferring. Experts were asked to separately consider lower and upper
plausible limits; different scenarios that might lead to high values or low values of the parameter.
Probabilities were not attached to these plausible limits; the purpose of eliciting the limits is to
mitigate the effects of anchoring and overconfidence, which may occur if a ‘best guess’ is first provided,
followed by some assessment of uncertainty around such a guess.
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The experts were then asked to provide median values by dividing their plausible ranges into two
intervals judged to be equally likely. They were then asked to divide each interval into two further
equally likely intervals, hence providing their lower and upper quartiles.
Each expert then declared his/her judgements to the facilitator, who then presented a graphical
comparison of all the experts’ individual judgements. Disagreements between the experts’ judgements
were highlighted and the experts were invited to justify their own opinions and question each other.
Following the discussion, the experts were asked to imagine a rational impartial observer (RIO): an
independent observer who has heard and understood the discussion, and on that basis formed his/her
own probability judgements. It was for the experts to decide how much weight a RIO would give to the
different opinions/arguments that had been stated; if the experts disagreed, with no convincing experts
to favour one side over the other, RIO’s uncertainty would be expected to reflect the disagreement.
The experts agreed on a median and quartiles for RIO’s distribution. The facilitator then fitted a
probability distribution to these judgements, by choosing a parametric family of distributions and
selecting parameter values using a least-squares fit to the cumulative distribution function. The
selected distribution was presented to the experts, with feedback in the form of 5th and 95th
percentiles (which had not been directly elicited). The experts were asked to comment on whether or
not the fitted distribution was an acceptable representation of RIO’s uncertainty and whether or not
the level of uncertainty would be justified based on the proceeding discussion. The distribution would
be modified as necessary, before being adopted within the ensuing calibration and probabilistic
sensitivity analysis (PSA).
Experts were recruited from within the NICE advisory committee. We believed that the workshop
format was important to allow for sufficient training of and discussion between the experts. However,
owing to the time scale of the project, it was possible to convene only one workshop with four experts.
Cost-effectiveness literature review
The literature searches of bibliographic databases were performed on 14 August 2017 and yielded
1108 citations. Forty-eight citations were obtained for full text retrieval. Evidence from none of the
papers was directly used within the model, but some provide context or alternative values and have
been detailed in the context of alternative values for the de novo model.
The conceptual model
Previously, authors of this report had undertaken work for the CJDAS to assess the cost-effectiveness
of single-use instruments to reduce the risk of vCJD through surgical procedures.11 The paper by
Stevenson et al.12 provided further information, where they had utilised a Bayesian approach to take into
account data observed since the generation of the results for NICE and submission of the manuscript.
As this model was used by the research team in the initial appraisal in 2005, there was a preference to
use, or adapt, this model unless it was shown to be not fit for purpose.
Within the literature review by Bennett et al.13 a publication was identified, which was not conceptually
different from Stevenson et al.12 but used a system dynamics approach. Bennet et al.13 had three broad
aims: (1) to clarify the possible scale of vCJD infection via surgical instruments, (2) to identify the most
important factors contributing to this risk and (3) to help prioritise scientific research. Conclusions
from the Bennet et al.13 paper were that ‘the risk of surgical transmission of vCJD could not be
dismissed’ and that improvements to decontamination ‘should be respectively cost-effective unless
vCJD turned out to be a very rare disease’. As the paper by Bennett et al.13 was published earlier
than that of Stevenson et al.12 (2005 compared with 2009), this was not preferred to the previous
modelling structure.
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A further paper by Garske et al.215 was identified that reported that key determinants of future cases
of CJD were the number of times an instrument is re-used, the infectivity of contaminated instruments
and the effectiveness of decontamination. These results came from a differential equation model that
did not consider instrument migration nor the mass transferred to a patient. The former was noted to
be a key parameter in Stevenson et al.,12 which also explored uncertainty in the mass transferred and
was published later than the Garske et al.215 paper (which was published in 2006) and thus this model
was not deemed preferable to that of Stevenson et al.12
Based on the authors’ critique of Bennett et al.13 and Garske et al.,215 there appeared no strong reason
to diverge from a model foundation as described by Stevenson et al.12 This model was amended in
consultation with the NICE committee, most noticeably to include the possibility that patients may be
an stCJD case but could be diagnosed with an alternative neurodegenerative disease.
A schematic of the conceptual model relating to infection transmission in Stevenson et al.12 is shown in
Figure 4; this model works on an individual patient level for those with CJD infection. The modelling unit
was a geographical area representing a population 1/27 of the size of England, which was assumed to
have a neurosurgical centre and a posterior eye centre. Population of the model is detailed in Key model
parameters. Figure 4 depicts the flows of patients, instrument sets and SIs that have the potential to
transmit CJD surgically. Patients have been categorised into three discrete groups: (1) patients who are
not infected with CJD; (2) patients who are infected with CJD who are not infectious; and (3) patients
who are infected with CJD and are infectious, but asymptomatic. Patients who have clinical CJD would
not be operated on with reusable instruments and are assumed to be outside the modelling process.
Across time, patients can move (1) from the non-infected state to the infectious but asymptomatic state
following an operation with a contaminated instrument, and (2) to the infected and infectious state
when the incubation period of the disease for that patient has been reached; additionally, patients can
be removed from the model when the CJD infection becomes symptomatic. In all states, patients can
die in accordance with background mortality rates applicable to the age of the hypothetical patient.
The decontamination cycle removes mass from the instruments and reduces the infectious titre
where applicable.
Patient
population
Patients return to the
appropriate group
Infected and
infectious
Infected but
not yet
infectious
Not infected
Patients are
sampled with a
probability that
depends on
surgery type,
age and prior
surgery status
Sets are used
in order
Instrument set
storage
Set 1
Set 2
Set n
Operation
(neurosurgery,
posterior eye
surgery)
Instrument sets and SI
are decontaminated
In each operation between
0 and 6 SI are used
Decontamination
cycle
SI storage
SI 1
SI 2
SI n
If a patient is infectious
at the time of the
operation, then the
instruments gather
infectious mass.
If the instruments
contain infectious mass
prior to the operation,
then the patient may
become infected
FIGURE 4 The conceptual model relating to the infection process. Reproduced from Stevenson et al.,12 with permission
from Journal of the Operational Research Society.
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During the operation, decontamination process and instrument-storing process, instruments may
migrate between sets. Furthermore, SIs cannot always be distinguished from similar items in the main
instrument set and migration between SIs and instruments from the main set can occur. The rate of
instrument migration is important in circumstances where there are multiple contaminated instruments
in one set. Therefore, maintaining set fidelity can limit the spread of infection compared with a
situation where the contaminated instruments are spread across a number of sets, which can result in
a greater number of subsequent transmissions. In order to model this, dynamic SIs were modelled at
an individual level, whereas sets were modelled with the possibility of instrument migration.
A key change in the methodology is that where previously patients born after 1996 were excluded
from the original ScHARR model, these were explicitly included in the updated modelling work. The
rationale for the change was that it may be the case that such patients can be infectious, whereas
previously this was not thought possible, and that this explicitly allows an evaluation of the health
and cost implications of removing the guidance that patients born after 1996 should use different
instrument sets to the remainder of the population.
Figure 5 provides the conceptual model for determining the outcomes for patients who have become
infected. There has been a fundamental change in this process since the initial work undertaken by
ScHARR, as the possibility that patients who become symptomatic following infection with CJD are
misdiagnosed as having a different neurodegenerative disease is included. Further details are provided
in following sections.
The model was run from 1 January 2004, the year at which a proportion of key distributions within the
model were elicited, to 2018 in the calibration period. This duration included a 1-year warm-up period
from 1 January 2004 to 1 January 2005, which allowed for the possibility that instruments were
contaminated with CJD prions at the start of 2005. The expected number of modelled CJD cases
(estimated based on the number of transmissions that resulted in clinical infection and the elicited
probability of correct diagnosis) between 2005 and 2018 were then compared with those potentially
observed in the UK to establish plausible bounds for use within the PSA and then subsequently to
determine likelihood ratios for each PSA configuration. This process is described in further detail in a
later section (see Appendix 7).
Patients die
without CJD
symptoms 
Patients diagnosed
with another
neurodegenerative
disease
Patient classified
as having stCJD
Patient classified
as having
sCJD
Incubation
period
simulated
Patient infected
Life expectancy
has been estimated
Yes No No
No Yes
Yes
Is incubation
period greater
than life
expectancy?
Once clinical
symptoms appear
is CJD correctly
diagnosed?
Is CJD classified 
as surgically
transmitted?
FIGURE 5 The conceptual model relating to patient outcome post infection.
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Having established parameter configurations that were plausibly consistent with the number of stCJD
cases potentially observed, the model was run for a further 5 years to look at the potential loss of
health because of stCJD associated with each strategy evaluated. The 5-year period was agreed with
the NICE advisory committee to be an appropriate time period that would be sufficiently long to allow
potential cases of stCJD to become apparent, but short enough that the computational time required
to generate the results was not excessive and that it did not limit the committee to a decision which
could not be changed in the longer term if required. The 5-year period matched the value used by
Stevenson et al.12 The measure of benefit was reported in terms of life-years gained and quality-
adjusted life-years (QALYs). A lifetime perspective was undertaken for the patients simulated to have
high-risk surgery within the 5-year period.
The model was constructed in Simul8 (© 2017 Professional Edition Simul8 Corporation, Glasgow, UK).
A NHS and Personal Social Services perspective was taken and both costs and benefits were discounted
at 3.5% per annum as recommended by NICE.216
Key model parameters
Parameters relating to the probability and the mass of prions being transferred to
surgical instruments
The underlying probability of Creutzfeldt–Jakob disease prions within central
nervous tissue in the asymptomatic population
The experts in the elicitation session indicated that the previously elicited distributions relating to the
prevalence of CJD prions in all tissue for patients aged 16–39 years in 2005 could still be used for
the prevalence of CJD prions in central nervous tissue in 16- to 39-year-olds in the current analysis;
although, they acknowledged that the range would produce an overestimate as the probability in all
tissue would be greater than that confined to just the CNS. The experts disagreed with the previous
experts in whether or not the prevalence would be greatest in the 16–39 years age group compared
with the 0–15, 40–69 and ≥ 70 years age groups. The current experts believed that the elicited
distribution should be used for all age groups. The distribution used to populate the model is shown in
Figure 6 and represents a beta (1.240, 2225.393) for the prevalence. The distribution provides a 95%
credible interval (CrI) ranging from 26 to 1875 people per million.
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FIGURE 6 The prevalence of CJD prions within central nervous tissue.
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The NICE committee asked for two scenarios to be evaluated, which used different assumptions for
the patients born after 1996, henceforth denoted the P96 group. In one scenario, it was assumed
that the P96 group were not infectious, as they were assumed unlikely to have been exposed to the
BSE epidemic; in an alternative scenario it was assumed that the P96 group had the same probability
of being infectious as the general population.
The residual mass per surgical instrument
The ScHARR report11 assumed that the mass on an individual instrument was 2.88 mg of wet-tissue
equivalent for instruments used for tonsillectomies, and 1.26 mg of wet-tissue equivalent for instruments
used in general surgery. This mass was assumed to be independent of size and complexity. The source for
this was ‘provided by Professor Baxter and colleagues from the University of Edinburgh’,11 with these data
reported in a different form within Baxter et al.192 It was assumed that the tonsillectomy value was
generalisable to the residual mass on a brain and posterior eye surgery.When multiplied by the number of
instruments assumed to be in each set, this equated to 51.84 mg of wet-tissue equivalent on brain surgery
instrument sets and 25.92 mg of wet-tissue equivalent on posterior eye instrument sets. Each SI would
have a wet-mass equivalent of 2.88 mg. These values were assumed fixed.
During discussions on the parameterisation of residual mass, a committee member highlighted a
recently published article,196 which suggested that the residual protein mass is likely to be < 5 µg
protein mass per instrument side. This is considerably less than that used in the previous ScHARR
report,11 which was 576 µg of protein mass (2.88 mg of wet-tissue equivalent).
A preliminary inspection of articles discussing residual mass was undertaken, which indicated that
protein mass ranged between 163 and 756 µg (120 instruments) in Baxter et al.192 and between
8 and 91 µg (mean 71.67 µg; 43 instruments) in Murdoch et al.193 Lipscomb et al.195 presented further
evidence, which was based on a set from each of nine NHS trusts (260 instruments in total), and
reported that 66% of all instruments showed severe contamination in at least one sample area,
equating to > 4.4 µg of protein/mm2.
Examining the data in Baxter et al.192 and Murdoch et al.,193 the mean residual protein mass per
instrument in 2004 was set to 200 µg (95% CI 150 to 250 µg) in consultation with NICE committee
members.
However, the data reported in Smith et al.,196 and further data marked as academic-in-confidence
obtained from a NICE committee member (anonymous, May 2018), indicate that there has been a
reduction in mass over time for the hospitals where data has been recorded. In discussion with
committee members, it was assumed that this change, which is assumed to be related to guidance on
keeping instruments moist prior to decontamination, would have occurred in 2012 in line with the
purchase of new instruments for those units that had adhered to IPG196. Following discussion with
committee members, the mean residual mass for those units that were compliant with guidance to
keep instruments moist was assumed to be 10 µg. In the 90% of units that did not adhere to IPG196,
it was assumed that two-thirds of these (i.e. 60% of total units) would not keep instruments sufficiently
moist and that 200 µg of residual mass would remain on each instrument, with the remaining third
(i.e. 30% of total units) adequately keeping instruments moist. It was assumed that the reduction in
protein residue on instruments will translate into a reduction in the possibility of transmission of stCJD.
This conceptual model was operationalised by assuming that the mass harvested from a patient from
2012 onwards was 5% (10/200) of the mass assumed to be harvested prior to 2012. Any infectious
mass already on an instrument was assumed to remain on the instrument following measures to keep
instruments moist.
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The proportion of residual mass on brain and posterior instruments that is transferred
to a patient
This value was estimated in the original elicitation exercise, which was undertaken to inform the
previous work by ScHARR.11 A depiction of the distribution for the proportion of residual mass
transferred to the patient is provided in Figure 7. This has a mean of 31.5% and a 95% CrI 0.4% to
87.1%, showing considerable uncertainty.
The proportion of residual mass on brain and posterior instruments that is removed
in a subsequent decontamination cycle
This value was estimated in the original elicitation exercise, which was undertaken to inform the
previous work by ScHARR.11 A depiction of the distribution for the proportion of mass transferred to
the patient is provided in Figure 8. This has a mean of 0.9% and a 95% CrI of 0.0% to 4.0%.
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FIGURE 7 The proportion of residual mass transferred to a patient.
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FIGURE 8 The proportion of residual mass removed in a subsequent decontamination cycle.
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The proportion of mass on instruments that is replaced with new tissue per brain or
posterior eye operation
In accordance with the previous ScHARR model,11 it was assumed that the residual mass on an
instrument was in steady state. Therefore, the sum of the mass transferred to the patient and the mass
removed in the next decontamination cycle equals the newly acquired mass from the operation. The
mean value of the proportion of the mass removed from instruments during an operation is 32.4%,
with an estimated 95% CrI of 1.1% to 88.4%. Any SIs that were used were assumed to gather the
same mass as instruments in the main set.
Residual mass, proportion transferred to a patient, proportion removed during the
operation and the mass harvested during neuroendoscopy
The spreadsheet calculations that were performed to obtain the proportion of mass transferred to the
patient and the proportion removed in the next decontamination cycle for rigid neuroendoscopes and
flexible neuroendoscopes used in the previous modelling work11 could not be retrieved, but the values
used in the PSA were available. These values have been re-used in the modelling, although it appears
that there was a discrepancy between the mass transferred from a patient to a rigid neuroendoscope
lumen used in the model and the mass that was reported in table 11 of the ScHARR report,11 with
the former being 10 times smaller. For the updated work, we have erred on the side of caution and
assumed that the greater mass is harvested per operation.
For information, key statistics on the proportion of mass harvested from a patient, the proportion of
mass transferred to a patient and the proportion of mass removed in the next decontamination cycle
are provided in Table 24.
Parameters relating to the decontamination of surgical instruments
The assumed infectious titre of tissues containing Creutzfeldt–Jakob disease prions
In the previous modelling undertaken,11 brain and posterior eye tissue were assumed to have
108 ID50 per gram, with this value assumed to be fixed and applied from the moment the patient
became infectious to the moment when clinical symptoms of CJD were observed, in which instance
reusable instruments would not be used on the patient.
The NICE committee requested, based on the collective experience of its members, that the previous
assumptions were amended to allow more heterogeneity in patients who have CJD prions in high-risk
tissue. First, the mean infectious titre was varied between 107 and 109 ID50 per gram, assuming a
uniform distribution. Second, it was assumed that 20% of patients would have an infectious titre 1
log higher than the mean and that 20% of patients would have an infectious titre 1 log lower than
the mean, with the remaining 60% of patients having the mean value. This approach incorporates
uncertainty around the mean estimate as well as patient heterogeneity, with individual patient values
ranging from 106 to 1010 ID50 per gram.
TABLE 24 Information relating to the mass transferred to a patient, mass washed off in subsequent decontamination
cycles and mass harvested from a patient
Type of
neuroendoscope
Proportion of mass
transferred to a patient,
mean (95% range in the
PSA)
Proportion of mass that has already
been decontaminated that is removed
in the next decontamination cycle,
mean (95% range in the PSA)
Mass harvested from
a patient (µg), mean
(95% range in the PSA)
Flexible 19.5% (3.10% to 49.73%) 70.6% (42.10% to 91.22%) 2.37 (0.74 to 4.21)
Rigid 0.61% (0.00% to 2.99%) 1.22% (0.00% to 5.24%) 0.48 (0.00 to 2.24)
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The effectiveness of current decontamination processes in reducing infectivity
The distributions produced from the elicitation exercise to inform the ScHARR report11 were
considered appropriate by the NICE committee. These were split into three categories: (1) the
effectiveness of infectivity reduction in the first decontamination cycle, (2) the effectiveness of
infectivity reduction in subsequent decontamination cycles and (3) the mass removed in second and
subsequent decontamination cycles. The model assumes that there have been no improvements in the
reduction in infectivity since 2004.
The effectiveness of infectivity reduction in the first decontamination cycle
The distribution assumed for the infectivity reduction associated with the first cycle of autoclaving is
displayed in Figure 9. This has a mean log-reduction of 2.50 and a 95% CrI log-reduction of 1.42 to 3.58.
The distribution assumed for the infectivity reduction associated with the first cycle of detergents is
displayed in Figure 10. This has a mean log-reduction of 0.64 and a 95% CrI log-reduction 0.04 to 2.03.
Note that detergents used in cleaning neuroendoscopes were assumed to not reduce infectivity.
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FIGURE 9 The reduction in infectivity in the first autoclaving cycle.
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FIGURE 10 The reduction in infectivity in the first detergent cycle.
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The effectiveness of infectivity reduction in subsequent decontamination cycles
It was assumed in the ScHARR report11 that the second and third autoclaving cycles would reduce
prion infectivity, although this would be to a lesser extent than the initial autoclaving cycle. These
further autoclaving cycles would occur following a subsequent operation. The log-reduction on the
second and third autoclaving cycle was expressed as a proportion of the reduction estimated in the
first cycle. The distribution assumed for the multiplier is shown in Figure 11. This distribution has a
mean of 0.157 with a 95% CrI of 0.043 to 0.330.
It was assumed in the ScHARR report11 that the second detergent cycle would reduce prion infectivity,
although this would be to a lesser extent than the initial autoclaving cycle. The log-reduction on the
second and third autoclaving cycle was expressed as a proportion of the reduction estimated in the
first cycle. The distribution assumed for the multiplier is shown in Figure 12. This distribution has a
mean of 0.474 with a 95% CrI of 0.047 to 0.931.
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FIGURE 11 The proportion of autoclave cycle 1 log-reduction achieved by cycles 2 and 3.
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FIGURE 12 The proportion of detergent cycle 1 log-reduction achieved by cycle 2.
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The proportion of mass that has been through a decontamination cycle that is
removed in subsequent decontamination cycles
This has been detailed in The proportion of residual mass on brain and posterior instruments that is
removed in a subsequent decontamination cycle for brain and posterior eye instruments and in Residual
mass, proportion transferred to a patient, proportion removed during the operation and the mass harvested
during neuroendoscopy for neuroendoscopes.
The probability of disposing of a reusable instrument
In the ScHARR report,11 it was assumed that following use an instrument had a 1/250 probability of
being disposed of (range 1/200–1/300) with all infectious load on the instrument destroyed. In
discussions with the committee, it was believed that the serviceable life of a reusable instrument was
longer than that previously assumed and the probability of an instrument being disposed of was
reduced to 1/2500 with a range of 1/2000–1/3000.
For each instrument that was disposed of in a brain surgery set, it was assumed that between 0% and
12% (sampled from a uniform distribution) of infectious load was removed from the set. For each
instrument disposed of in a posterior eye surgery set, it was assumed that between 0% and 25%
(sampled from a uniform distribution) of infectious load was removed from the set. The midpoints of
these distributions (6.0% and 12.5%, respectively) were chosen such that it was close to the proportion
of the set that one instrument comprised. This is (see Parameters relating to instrument migration, costs
and safety) a 1/14 probability (7%) for an instrument in a neurosurgery set and a 1/9 probability (11%)
for an instrument in a posterior eye surgery set. Uncertainty was incorporated by allowing a range
between 0% and approximately twice the midpoint value.
Parameters relating to instrument migration, costs and safety
The instruments assumed on model set-up
In the modelling undertaken for the ScHARR report,11 it was assumed that there were 12 brain surgery
sets with 18 instruments assumed to come into contact with potentially infectious mass; 12 posterior
eye surgery sets with nine instruments assumed to come into contact with potentially infectious mass;
and one rigid neuroendoscope and one flexible neuroendoscope, both of which had a single accessory.
Following discussion with the committee, it was assumed that the number of instruments coming into
contact with high-risk tissue in brain operations was lower than previously thought, with the number
reduced to 14 instruments (previously 18).
For brain and posterior eye sets, the instrument sets were used in rotation. For neuroendoscopy
operations, it was assumed that 75% were undertaken with rigid neuroendoscopes (which can be
autoclaved) and 25% were undertaken using flexible neuroendoscopes (which cannot be autoclaved).
Brain and posterior eye sets were also complemented by six types of SI, each of which had six instruments
that were used in rotation. During each operation, each SI had a 20% chance of being required.
For neuroendoscopy, IPG196214 recommended that all neuroendoscopy accessories became single
use. For simplicity, however, it was assumed that this was not followed, based on the committee’s
estimation of units that had adhered to IPG196 and with an assumption that one SI was used in all
operations. If a large number of deaths was observed related to neuroendoscopy, this assumption
would be amended.
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Recommendations on instrument migration and use of supplementary
instruments in IPG196
Maintaining the integrity of surgical instrument sets was shown to be a key parameter affecting the
incremental cost-effectiveness ratios (ICERs) associated with the introduction of single-use surgical
instruments.12 The ScHARR report11 made the following assumptions in relation to set integrity:
1. That the probability of an instrument being swapped with a similar instrument in a separate set was
50%, while the set was undergoing the decontamination process. This value was selected following
discussion with clinicians and review of evidence. When instruments migrate between sets it was
assumed that between 0% and 20% (sampled from a uniform distribution) of the infectious material
in ‘set A’ would move to ‘set B’, with between 0% and 20% (sampled from a uniform distribution)
of the infectious material in set B being moved to set A. These values were chosen as there were
approximately 10 instruments in a surgical set, which would be expected to contain 10% of all mass
(infectious or not) and that there would be expected uncertainty around the proportion of mass
contained on individual instruments.
2. That when a SI was used, there was a 50% chance that this instrument would join the set with a
similar instrument from the set becoming the ‘new’ SI. When this occurs, all infectious load on
the SI is added to the set, and between 0% and 10% of the infectious load (sampled from a
uniform distribution) in the set is assumed to reside on the new SI. The distribution used to model
infectious mass transference as a result of SI migration is associated with smaller mass levels than
non-SI instruments.
The model has the facility to alter the levels of set migration following the publication of IPG196,214
which recommended that migration of instruments between sets should be abolished and that SIs
that come into contact with high-risk tissues should either be single-use or remain with the set
to which they have been introduced. However, owing to logistical and/or financial problems in
implementing IPG196,214 these recommendations were not fully adhered to by all hospitals. The model
has been set up so that it is assumed that after 2012 no SIs are used for those units that are assumed
to adhere to IPG196.
The costs associated with single-use instruments
A NICE committee member stated that the costs of single-use sets are likely to lie in the region of
£350–500 and that the cost of a single-use rigid neuroendoscope is £710; no cost was identified for a
single-use flexible neuroendoscope (anonymous, May 2018).
The costs associated with reusable instruments
In the ScHARR report,11 it was assumed that a brain surgery set costs £3500 and that a posterior eye
set costs £1000. Based on the number of instruments that come into contact with high-risk tissue, the
cost of an individual reusable instrument is likely to be in the region of £100–200.
The ScHARR report11 assumed that a reusable rigid neuroendoscope costs £397 and a reusable flexible
neuroendoscope costs £9300. More recent prices estimate that a reusable rigid endoscope set including
instruments would cost approximately £8850, with a flexible endoscope costing approximately £21,000.
Although there will have been inflation during the period, the increase in prices for rigid neuroendoscopes
in particular, look high. Clinical advice suggests that in 2005 these were very cheap, disposable rigid
neuroendoscopes, but that these have since been withdrawn. This puts downwards pressure on the
costs of the reusable rigid neuroendoscopes and, furthermore, it is likely that the volume of sales of
neuroendoscopes has decreased resulting in an increase in the price.Whatever the reasons underlying
the increase, the NICE committee were comfortable that the prices used in this report was appropriate.
COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
The costs associated with decontaminating reusable instruments
Data provided by a committee member indicated that the cost of decontaminating a reusable
instrument was, on average, £0.60 in Scotland (personal communication, May 2018). Assuming that
this result is generalisable to England, this would correspond to a decontamination cost of £8.40 for a
high-risk tissue brain set and £5.40 for a high-risk tissue posterior eye set.
The costs associated with disposing single-use sets
For simplicity, we have assumed that the costs of disposing of single-use sets are included within the
purchase price. Given the relatively wide range in the costs assumed for a single-use high-risk tissue
set (£350–500), the authors of this report deemed that this simplifying assumption would not cause
significant inaccuracy.
The costs associated with keeping instruments moist
Data reported in Smith et al.196 state that the cost of NHS bags would be £440 per 7355 neurosurgical
trays reprocessed, equating to £0.06 per bag. Calculations based on the additional savings that could
be made ‘using tap water and tray liner’ suggests that the costs of these elements are also £0.06 per
tray. Thus, it has been assumed that the cost of keeping instruments moist was £0.12 per set
conditional on using NHS bags, tap water and a tray liner.
The assumed safety of single-use instruments
In the base case it is assumed that the complication rates and outcomes are identical for reusable
instruments and single-use instruments. The NICE committee believed this assumption was reasonable.
The costs associated with systems to allow instruments to be tracked
NICE committee members provided data from an unpublished Society for British Neurosurgeons
survey and from costs recorded at their own units, which indicated that £750,000 across a 5-year
period, including necessary equipment, would be a reasonable estimate (anonymous, May 2018).
Sensitivity analyses were intended using £500,000 and £1,000,000.
Parameters relating to the probability of infection, the incubation time and consequences
if clinical symptoms appear
The conceptual model of estimating the probability of infection when prions are
transferred to the patient
In the earlier ScHARR model,11 the probability of infection was estimated using the mass transferred to
the patient (in grams) and the infectious titre of the mass (in terms of ID50 per gram, where an ID50 is
the dose required to infect 50% of the susceptible population). It was assumed that the relationship
between the number of ID50 and the probability of infection was:
Probability of infection =MIN(Number of ID50transferred × 50%, 100%), (1)
such that 2 ID50 or more would result in a certain infection. In the earlier ScHARR model, the use of a
geometric sequence was used, such that 2 ID50 would result in only 75% of patients being infected
(1–0.52). However, the committee did not want to use this assumption because the dose to infection
was not robustly known and high levels of ID50 transferred could be associated with definite, rather
than a high probability of infection, and the committee wished to err on the side of caution. The linear
assumption was upheld by the NICE appraisal committee.
The mass assumed to be transferred per operation is detailed in The proportion of residual mass on brain
and posterior instruments that is transferred to a patient and the assumed infectious titre per gram is
detailed in Parameters relating to the decontamination of surgical instruments.
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In a key change from the ScHARR report,11 it was assumed that all patients, regardless of age or
genotype, were susceptible to CJD infection.
The incubation period following surgically transmitted Creutzfeldt–Jakob
disease infection
The incubation period associated with stCJD was elicited from clinical experts in January 2018 (see
Appendix 4). The results are contained in Appendix 1, but are briefly detailed here. The elicited results
differed from those previously elicited in that (1) distributions were no longer elicited for each
genotype, as it was assumed that a single distribution could cover all genotypes given the incubation
period would be affected by the genotype of the recipient, the infecting prion and the infectious dose
provided; (2) uncertainty in the mean estimates was formally captured; and (3) it was assumed that all
genotypes were susceptible to CJD.
Four incubation intervals were specified; in the base case, each interval was assumed to be equally
likely. These were (1) 0.25 to 2 years, (2) 2 to 10 years, (3) 10 to 20 years and (4) 20 to 50 years.
Within each time interval a uniform distribution was used on the assumption that each value was
equally likely to occur. To allow for uncertainty around the mean incubation period, it was proposed
that the first probability of being in the first three intervals would range between 10% and 40%,
whereas the probability of being in the fourth interval (20 to 50 years) would lie between 15%
and 35%.
As indicated in Figure 5, should the incubation time be less than the patient’s life expectancy (sourced
from the Office for National Statistics217), the patient would display clinical symptoms. Otherwise, the
patient would die without CJD symptoms. Each year a proportion of patients incubating CJD die as a
result of non-CJD-related reasons, in line with data reported by the Office for National Statistics.217
The probability of non-CJD-related death was dynamic between 2005 and 2014, using the appropriate
life table, but was assumed to use life tables from 2014 to 2023.
The infectious period following surgically transmitted Creutzfeldt–Jakob
disease infection
The proportion of the incubation period associated with stCJD for which a patient was considered
infectious and able to pass CJD prions to instruments was taken from the elicitation session used
to inform the earlier ScHARR report.11 This distribution is shown in Figure 13. The mean of this
distribution is 20.0%, indicating that the patient is infectious for only the last 20% of the incubation
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FIGURE 13 The proportion of the incubation period during which the patient is infectious.
COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
74
period. The 95% CrI for this parameter ranged from 15.3% to 25.2%. It has been assumed that the
infectious titre of CJD prions is at the maximum value for the entire infectious period.
Estimations of the relative likelihood of returning to high-risk surgery
Patients who are infectious can return to surgery and may do so at a quicker rate than people who have
not experienced prior surgery. The earlier ScHARR report11 assumed that (1) people who had previous
brain surgery were 43 times more likely to have a further brain operation than people without a history of
a brain operation; (2) people who had previous posterior eye surgery were 60 times more likely to have a
further posterior eye operation than people without a history of a posterior eye operation; and (3) people
who had previous neuroendoscopy were 761 times more likely to have a further neuroendoscopy than
people without a history of a neuroendoscopy. These values were based on Hospital Episode Statistics
(HES) data that were extracted by a third party (Northgate Information Solutions; Zellis, Hemel Hempstead,
UK) and were assumed to be applicable for use in the updated modelling. Having performed sensitivity
analyses in the construction of the model, by increasing the relative rates by 10, the model did not appear
sensitive to this variable and the values were left at the values used previously.
The assumed costs and quality-adjusted life-years associated with
Creutzfeldt–Jakob disease
Once clinical symptoms have developed, it is assumed that patients accrue no further QALYs as a
result of the severity of the condition. The earlier ScHARR report11 used a value of £40,000 for the
costs associated with treating a case of CJD. This has been updated using the inflationary indices,218,219
which estimate an inflation value of 302.3/240.9 (1.25) between 2005–6 and 2016–17 using the
Hospital and Community Health Services index. Data reported in Barnett and McLean220 indicate that
costs of additional care and/or equipment were approximately £10,500 per person from invoices
received from 33 patients, although the authors of the paper state that ‘local agencies contributions
have not been quantified’. This is lower than that assumed in the original ScHARR model, which has
been maintained as the base-case value and is favourable to strategies to reduce future stCJD cases.
For simplicity, we have assumed that the cost, from a NHS and Personal Social Services perspective,
in 2017–18 for a CJD case was £50,000.
The probability that a person with Creutzfeldt–Jakob disease symptoms are not
diagnosed with Creutzfeldt–Jakob disease
It is possible that patients with CJD may be diagnosed with another neurodegenerative disease. This
possibility was not considered in the initial ScHARR report,11 but was requested following a meeting of
the NICE committee. The distribution of patients who were presumed to be diagnosed with another
neurodegenerative disease was elicited from experts in January 2018 (see Appendix 1 for full details)
for two age bands, with the experts willing to allow the misdiagnosis in the aged 60–80 years category
to be the average of the two other age bands: those aged < 60 years and those aged > 80 years.
The distribution for those patients aged < 60 years is shown in Figure 14.
The mean value is 13.0% with a 95% CrI 0.4% to 26.8%. The distribution for those patients aged > 80 years
is shown in Figure 15. The mean value is 55.0% with a 95% CrI of 18.6% to 88.4%.The simulated distribution
for patients aged between 60 and 80 years of age inclusive is shown in Figure 16. This distribution has a
mean of 34.0% with an estimated 95% CrI of 13.5% to 54.3%.
It should be noted that based on the advice of clinical experts on the committee, there has been no
change in CJD case ascertainment levels since 2005. This is partially supported by data from the
NCJDRSU in the UK (25th Annual Report (see Figure 32), which showed similar age-specific mortality
rates between 2005–9 and 2010–16 in those aged 60–64 years and those aged 75–79 years.
However, the age-specific mortality rates were higher in the 70–74 years of age group in 2010–16
than in 2005–9, which could be indicative of better ascertainment in recent years. The assumption of
equal ascertainment would favour single-use instruments.
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In patients who are correctly diagnosed with CJD, the model does not explicitly distinguish between sCJD
and stCJD and thus the probability node at the far right of Figure 5 is not contained in the model. However,
it is appreciated that patients with stCJD may be categorised as sCJD, and these are used when calibrating
the model output to the numbers of observed cases. This is described in more detail in The potentially
unobserved number of surgically transmitted Creutzfeldt–Jakob disease cases between 2005 and 2018.
Parameters relating to the numbers of operations that are considered to be high-risk and
the characteristics of patients undergoing these operations
The operations considered to be at risk
In consultation with NICE, only high-risk operations are modelled, which have been subdivided into those
related to the brain, those related to posterior eye operations and those involving neuroendoscopy.
The operations, using HES data to four characters, that are considered to be high-risk were identified by
an expert on the NICE committee and are contained in Appendix 5. For brain operations, an expert on the
NICE committee grouped the operations into those with normal life expectancy, those where the patient
would be expected to survive 18 months, and those with a 50% probability of death at 18 months and a
50% probability of a normal life expectancy.
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FIGURE 15 The proportion of patients over 80 years with clinical CJD symptoms who are diagnosed with another
neurodegenerative disease.
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FIGURE 14 The proportion of patients < 60 years with clinical CJD symptoms who are diagnosed with another
neurodegenerative disease.
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Only the main procedure codes have been used rather than all the procedure codes, as there is a
possibility that more than one high-risk HES code is undertaken within the same operation, using the
same instrument set. In the modelling, the HES data have been inflated by 15% as in the ScHARR
report11 to take into consideration that not all of the additional operations (between the main
procedure and all procedures) are conducted simultaneously with another high-risk code, and also to
incorporate operations undertaken by the private sector in non-NHS hospitals.
The estimated number of operations reported within the HES data since 1 January 2005 is provided
in Table 25. For future years, the average number of operations in the last 3 years was assumed to
continue. Operations were assumed to happen at a constant rate throughout the year. It should be
noted that the values in Table 25 are those reported in the HES data as main procedures and have
been increased by 15% within the model in line with the earlier modelling undertaken by ScHARR.
Hospital Episode Statistics data provide age breakdowns for each code, with more granularity from
the year 2012 than prior to this date. Analysis of these data indicated that the age profile of patients
remained relatively stable across time for each of the three brain operation groupings, for neuroendoscopy
and for posterior eye operations. Therefore, for simplification, the age profile within 2016–17 was assumed
to apply throughout the model. Depictions of each assumed age profile are provided in Appendix 6.
Calibration targets
The observed number of surgically transmitted Creutzfeldt–Jakob disease cases between
2005 and 2018 and the potentially unobserved number of surgically transmitted
Creutzfeldt–Jakob disease cases
The observed number of surgically transmitted Creutzfeldt–Jakob disease cases
between 2005 and 2018
There are no cases of CJD that have been categorised as stCJD during this period.
D
e
n
si
ty
3.0
2.0
1.0
0.0
0 20 40 60
Percentage of patients misdiagnosed
FIGURE 16 The simulated proportion of patients aged between 60 and 80 years inclusive with clinical CJD symptoms
who are diagnosed with another neurodegenerative disease.
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The potentially unobserved number of surgically transmitted Creutzfeldt–Jakob
disease cases between 2005 and 2018
There are two possible ways in which patients with stCJD can be misdiagnosed. The first is that
another neurodegenerative disease is diagnosed; this has been discussed in The costs associated with
decontaminating reusable instruments. The second way that stCJD can be misdiagnosed is that a different
form of CJD (in particular sCJD) is the presumed diagnosis, as a previous operation may not be
recalled. The potential number of patients misdiagnosed as a different form of CJD was investigated.
Data were supplied to a NICE committee member by the NCJDRSU, which detailed whether or not
patients who had a diagnosis of CJD since 2005 had a history of neurosurgery or posterior eye
surgery, as well as a brief description of the operation. These data were reviewed by a NICE committee
member who categorised each patient as having an operation that was of high risk (and, therefore,
potentially a stCJD case) or not. The committee member erred on the side of caution, stating whether
or not the operation could have the potential to transmit CJD prions to the patient. However, it is
possible that some of the cases reviewed occurred in other parts of the UK than England, to which this
guidance is limited, which would result in an overestimated calibration target.
For posterior eye surgery, there were potentially 24 individuals who had undergone surgical operations
that could have transmitted CJD, although only 10 of these had operations in 2005 or later. The year
of the operation is important, as we want to calibrate the model only to cases where the patient had
been infected during the modelling period. For brain surgery, there were potentially 13 individuals who
had undergone operations that could have transmitted CJD. There were no dates provided for the
TABLE 25 The number of operations classified as high risk by the NICE committee (HES data)
Year Brain 1a Brain 2b Brain 3c NE PE
2005–6 19,554 5346 1684 302 4629
2006–7 21,451 5317 1069 311 4098
2007–8 19,302 5517 1062 338 6164
2008–9 18,406 5557 1107 354 8415
2009–10 19,404 5706 1101 389 7660
2010–11 20,323 5755 1121 488 7796
2011–12 21,288 5889 1217 497 5081
2012–13 21,110 5887 1151 500 13,296
2013–14 22,497 5905 1110 539 13,060
2014–15 22,508 6013 1087 532 5378
2015–16 22,916 6106 1110 527 5226
2016–17 23,029 6114 968 518 5481
Numbers assumed subsequent to 2017d 22,818 6078 1055 526 5362
NE, neuroendoscopy; PE, posterior eye.
a Brain 1 denotes operations with assumed normal life expectancy.
b Brain 2 denotes operations with assumed death within 12 months.
c Brain 3 denotes operations with a 50% chance of death within 12 months and a 50% chance of normal
life expectancy.
d Estimated as an average of the numbers between 2014 and 2017.
Note
These data are inflated by 15% within the model to account for operations not coded as the main procedure and to
account for operations conducted privately at non-NHS hospitals.
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operations and thus it was assumed that the proportion of operations conducted in 2005 or later that
were observed for posterior eye surgery (10/24) were applicable to neurosurgery, which equates to a
possible five cases of stCJD since 2005 (rounding to the nearest integer). The sum of these calculations
implies that there could have been 15 cases of stCJD transmitted since 2005 that had been misdiagnosed
as another form of CJD, or just over one case per year on average.
Categorisation of surgical units, establishing probabilistic sensitivity
analysis configurations that are plausible and generating likelihood
functions for plausible probabilistic sensitivity analysis configurations
Categorisation of surgical units
Based on the heterogeneity in surgical units adhering to IPG196 and the analyses varying the
assumption of whether or not the P96 group (patients born after 1996) could be infectious from birth,
six categories of surgical units were defined (denoted S1 to S6). These were:
l S1 – a unit adheres to IPG196 and guidance on keeping instruments moist. The P96 group are
infectious from birth.
l S2 – a unit does not adhere to IPG196 but adheres to guidance on keeping instruments moist.
The P96 group are infectious from birth.
l S3 – a unit does not adhere to IPG196 nor does it adhere to guidance on keeping instruments
moist. The P96 group are infectious from birth.
l S4 – a unit adheres to IPG196 and guidance on keeping instruments moist. The P96 group are not
infectious from birth.
l S5 – a unit does not adhere to IPG196 but adheres to guidance on keeping instruments moist.
The P96 group are not infectious from birth.
l S6 – a unit does not adhere to IPG196 nor does it adhere to guidance on keeping instruments
moist. The P96 group are not infectious from birth.
Based on the opinion of members of the NICE committee it was assumed that, independent of whether
or not the P96 group was assumed to be infectious, 10% of units adhered to IPG196 and guidance
on keeping instruments moist, 30% of units adhered only to keeping instruments moist and 60% of
units neither followed IPG196 nor kept instruments moist. These probabilities were altered in a
scenario analysis.
Employing a heuristic to rule out probabilistic sensitivity analysis configurations that
would produce implausible results
Owing to the time required for each run [approximately 12 seconds per ‘plausible’ (defined later) PSA
configuration] and the number of PSA configurations, random number (RN) streams, scenarios and
PSA configurations that would not be compatible with the observed data, heuristics were used to
generate the cost-effectiveness results. At all stages, a cautious approach was employed to ensure
that potentially appropriate configurations were not prohibited. Appendix 7 describes the methodology
using formal mathematical notation, with a lay description provided in the main text.
The initial step was to develop a metric to exclude PSA draws that would clearly be discrepant to the
observed data (known cases of CJD that could potentially be attributed to surgical transmission),
without having to run these configurations.
Here, a factor to efficiently maximise the likelihood (FML) was established and any PSA configuration
with a value greater than the FML value was discarded.
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The FML was derived using a combination of parameters related to the infectious titre after a
decontamination cycle, the mass transferred to a patient and the prevalence of prion in tissue in
asymptomatic patients:
FML = 10A × B × C, (2)
in which
l A =mean infectious titre (in log-terms) × log-reduction in infectivity associated with the first
autoclaving cycle × log-reduction associated with detergent on the first cycle
l B = residual mass on an instrument × (1 – the proportion of residual mass transferred to the patient)
l C = the proportion of asymptomatic individuals with CJD prions in their tissue.
In order to generate the FML threshold value, 2000 PSA configurations were drawn from the
appropriate distributions and run using 12 RN streams for each of the following scenarios: S1, S2 and
S3. Having assessed the likelihood of each of the 2000 PSA configurations producing results consistent
with the observed data, it was decided that any draw with a FML value of > e12 would effectively have
zero weight and could be discarded without affecting the results. Any draw with a value ≤ e12 could
potentially be consistent with the observed data.
Running further analyses to remove probabilistic sensitivity analysis configurations that
are potentially consistent with the observed data but generate an implausible number of
transmissions when run through the model
In total, 2000 PSA configurations with a FML value of ≤ e12 were sampled. For each configuration, the
first RN stream was run, assuming a S3 surgical unit and determining whether or not there was a
violation of the permissible limit (VPL) of clinical transmissions for patients aged ≤ 60 years. It was noted
that the clinical experts had stated it was implausible that the correct detection rate of CJD was below
50% in this age group and that the assumed maximum number of clinically apparent cases potentially
transmitted via surgery, across all ages, was 15. If there was a VPL, the PSA configuration was deemed to
be inconsistent with the observed data and the PSA run was discarded. If there was not a VPL, the next
RN stream was run with this process repeated until a maximum of 27 RN streams had been run.
The VPL threshold was dynamic and changed as the number of RN streams increased. A large VPL
threshold was chosen to reduce the possibility of rejecting viable PSA configurations, while
acknowledging that there was also the probability that clinical transmissions had occurred in older
patients. The initial threshold for VPL was 36 transmissions, which was constant for the cumulative
total across the first six RN streams. From RN streams 7 to 13, the VPL threshold was increased to 40;
from RN streams 14 to 17, the VPL threshold was increased to 45; from RN streams 18 to 23, the VPL
threshold was increased to 55; and for RN streams 24 to 27 the VPL threshold was increased to 66.
This resulted in 509 out of the 2000 PSA runs that all had an FML ≤ e12 being potentially consistent
with the observed data. These are denoted ‘plausible’ PSA configurations.
Calculating the likelihood of each plausible probabilistic sensitivity analysis configuration
being consistent with the observed data
Approximate Bayesian computation methods were used to estimate the likelihood of a PSA
configuration being consistent with the observed data. Full details are provided in Appendix 7. A
likelihood ranges from 1, where the simulated number of transmissions that are clinically detected
are entirely consistent with the number of observed cases, to zero where the simulated number of
transmissions that are clinically detected cannot be consistent with the number of observed cases.
Within this decision problem, any PSA configuration that produces ≤ 15 transmissions that result in
clinical symptoms would have a likelihood of 1, whereas any PSA configuration that produced > 30
transmissions that result in clinical symptoms, in patients than < 60 years of age, would have a
likelihood of zero.
COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80
The likelihoods for each PSA configuration are shown in Figure 17. These have been ranked in
descending order and have been curtailed at 250 of the 509 PSA configurations. A large proportion of
the PSA configurations that were not rejected have likelihoods close to zero, which offers support to
the belief that it was unlikely that potentially appropriate PSA configurations were discarded. For
information, the lowest likelihood was 10–12 where the P96 group was assumed to be infectious and
10–13 where the P96 group was assumed not to be infectious.
Generating estimates of the expected numbers of future surgically transmitted
Creutzfeldt–Jakob disease, life-years lost and quality-adjusted life-years lost
The likelihoods associated with each PSA sample were multiplied by the results (future stCJD deaths,
life-years lost and QALYs lost) produced when using that PSA sample and these were added together
and divided by the sum of the likelihood to produce expectations for the combined results.
Exploring the uncertainty in the results produced within the base-case analyses
In order to explore more pessimistic scenarios, the maximum value across all of the 509 PSA
configurations of the number of QALYs simulated to be lost multiplied by the likelihood of the PSA
was also calculated. These values are necessarily greater than the expectations, which use the average
value multiplied by the likelihood of the PSA rather than the maximum value. Generating CIs around the
mean of each output was more complex owing to the use of likelihoods, as not all of the 509 scenarios
were weighted equally. In order to provide an indication of the width of the CI (which would need to be
halved if only looking at increasing or decreasing the value from the mean), an approximation was made,
which is detailed in Appendix 7, that involved simulation to translate each PSA likelihood into either zero
or 1 and then using statistical techniques to estimate a CI.
Exploring the probability that each type of surgical unit was the most cost-effective
Exploratory analyses were undertaken to provide indicative probabilities that each type of surgical unit
(one of S1, S2 and S3, or S4, S5 and S6) or moving to single-use instruments were most cost-effective
across a range of cost-per-QALY thresholds. This analysis assumed that a surgical centre was a S3 (S6),
meaning that expenditure was required to move to S1 or S2 (S4 or S5). The probabilities were calculated
assuming that the weight applied to each of the 509 PSA values would be provided to the surgical unit
or single-use instrument scenario that was most cost-effective at a chosen cost-per-QALY threshold.
The summated total of weights for each option was divided by the sum of the total weights to provide a
probability of being most cost-effective, which summate to 1.
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FIGURE 17 The likelihoods of the PSA configurations being compatible with the observed data (curves are drawn on top
of each other).
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Exploring the changes in the results produced with alternative assumptions relating to the
assumed distribution of surgical units between the assumed decontamination levels
In the base-case analyses, it was assumed that 10% of surgical units would both follow IPG196 and
keep instruments moist; 30% would not follow IPG196; and 60% of surgical units neither kept
instruments moist nor followed IPG196. The NICE committee requested that a scenario analysis be run
that changed these proportions to 50%; 30%; and 20%, respectively. Thus, in this scenario analysis half
of surgical units both followed IPG196 and kept instruments moist.
Strategies modelled
In consultation with the NICE committee, the following strategies were run:
1. Do nothing, assuming that the current situation is maintained with respect to surgical centres’
adherence to IPG196.
2. Full adherence to IPG196, and guidance on keeping instruments moist for those units where this is
not followed.
3. Full adherence to keeping instruments moist for those units where this is not followed.
4. Removal of the requirements to have separate instrument sets for the P96 group.
5. Modelling interventions that prohibit the possibility of stCJD. These are likely to take the form of
the introduction of single-use instruments or the introduction of a decontamination product during
the sterilisation process that is completely effective.
Within this report ‘adherence to IPG196’ is a slight misnomer, as the modelled scenario does not
assume that neuroendoscopy instruments are single-use. However, for brevity, we have used the term
‘adherence to IPG196’.
Based on advice provided by the NICE committee, it was assumed that the quality of single-use and
reusable instruments were equivalent.
Based on advice provided by the NICE committee, no modelling of decontamination products was
conducted other than that contained in strategy five. The reasons for this were multiple. First, there
was a lack of homogeneity in the identified studies of decontamination products in terms of prion
strains, drying times, infectious titre of the material used, time and temperature of the exposure to the
decontaminant, dose of the decontaminant, observation period, substrate used, assay and infectivity
detection method used. Second, the findings for some agents inevitably differed both within and
between studies, owing to the described heterogeneity (see results for Rely+On depending on the
assay or NaOH depending on the prion strain). Identifying the most ‘efficacious’ decontaminant,
requiring comparison across agents, was, therefore, not possible. Third, as far as we could tell, the
majority of the decontaminants (and combinations thereof) were not commercially available but had
been developed for the laboratory tests, whereas others that did exist as distinct products were few
and, in some cases, were no longer on the market, for example Rely+On. Fourth, uptake of additional
decontaminant solutions might be very low in practice owing to requiring an extra step in the sterilisation
process. Therefore, major concerns affected the certainty and generalisability of the evidence on
decontaminants for reducing the risk of prions in surgery. The authors wanted to provide an indication
of the potential prices that could be cost-effective if a completely effective decontamination product
was commercially available and so explored this in strategy 5.
Epidemiological results
For each PSA scenario the number of transmissions by age group that resulted in clinical symptoms
(whether correctly diagnosed as CJD or not), the number of life-years lost and the number of
discounted QALYs lost were simulated through the mathematical model. These results were then
weighted by the likelihood, with the sum of these values divided by the sum of the likelihoods.
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The epidemiological results presented are based on an individual surgical unit. Units are denoted S1 to
S6 (defined in Categorisation of surgical units) to represent the combinations of the unit’s adherence to
IPG196; whether or not instruments are kept moist; and whether or not it is assumed that the P96
group is infectious. It has been assumed that there are 27 units in England.
It is assumed that the answers produced will contain Monte Carlo sampling errors and that further RN
streams and PSA configurations would provide more accurate answers. However, we believe that the
results presented are sufficiently robust to draw conclusions. The base-case results assume that there
may have been up to 15 deaths attributable to stCJD between 2005 and 2018.
Base-case results
The base-case results are provided in Table 26 and relate to the period 2019–23, as agreed with the NICE
committee. The estimated values are presented in columns two to four; these are calculated using all PSA
configurations (n = 509) and all RN streams (n = 27). The values of simulated deaths as a result of CJD
infection, which were weighted by their likelihood that the transmissions of CJD modelled between 2005
and 2018, matched the observed data. The final column contains a value that represents the maximum
value across the PSA configurations of the simulated deaths in that PSA multiplied by the likelihood of that
PSA. Note that the maximum deaths across the P96 and the non-P96 group may not equal the maximum
values for both the P96 group and the non-P96 group individually. The values are per surgical unit and
need to be multiplied by 27 to represent values for England.
Interpretation of the base-case results
As anticipated, fewer deaths as a result of stCJD were estimated when IPG196 was followed and when
residual mass was reduced. Thus, in terms of future deaths as a result of stCJD, S1 had fewer deaths
than S2, which had fewer deaths than S3, and S4 had fewer deaths than S5, which had fewer deaths
than S6. Furthermore, as anticipated, when the P96 group was assumed not to be infectious there
were fewer projected deaths as a result of stCJD; that is, S1 had more deaths than S4, S2 had more
deaths than S5 and S3 had more deaths than S6.
Those units that followed IPG196 and kept instruments moist (S1 and S4) had 0.052 and 0.038 future
deaths caused by stCJD, respectively. Where IPG196 was not followed but instruments were kept moist,
there was an increase in future deaths as a result of stCJD of 0.035 when the P96 group was deemed
infectious from birth and 0.040 when the P96 group was not deemed infectious from birth. Assuming
IPG196 was not followed, failure to keep instruments moist was associated with an increase in the estimated
numbers of future deaths compared with not following IPG196 increased by 0.343 when the P96 group
TABLE 26 Base-case results per surgical unita
Surgical
unit
Average number of
future deaths caused
by infections between
2019 and 2023, total
(non-P96 group/
P96 group)b
Average number of
future undiscounted
life-years lost caused
by infections between
2019 and 2023
Average number of
future discounted
QALYs lost caused by
infections between
2019 and 2023
Maximum number of
future deaths across
the PSAs caused by
infections between 2019
and 2023 multiplied by
likelihood, total (non-P96
group/P96 group)b
S1 0.052 (0.036/0.016) 1.548 0.459 0.519 (0.519/0.000)
S2 0.087 (0.068/0.020) 2.699 0.874 1.741 (1.481/0.259)
S3 0.430 (0.339/0.091) 12.438 4.009 4.259 (3.704/0.556)
S4 0.038 (0.038/0.000) 0.741 0.275 0.519 (0.519/0.000)
S5 0.078 (0.036/0.015) 2.276 0.736 1.741 (1.481/0.259)
S6 0.389 (0.314/0.075) 10.809 3.485 4.259 (3.704/0.556)
a The values need to be multiplied by 27 to provide numbers for England rather than surgical units.
b Numbers may appear discrepant as a result of rounding.
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was deemed infectious from birth and 0.310 when the P96 group was not deemed infectious from birth.
From these results, it is apparent that ensuring that instruments are kept moist has a large impact on
the risk of future transmissions.
It is of note that the number of potential stCJD infections in the P96 group is not necessarily zero,
even when these patients are assumed not to be infectious. This can occur when a P96 patient is
infected via an operation prior to 2012, the date at which the new instrument sets for the P96
patients were introduced. Such a patient could then have a further high-risk operation while in the
subclinical but infectious period, which could have infected P96 patients.
The circumstances in which the maximum future deaths predicted within the model were explored. A
high number of future deaths were associated with the prevalence of CJD prions in their tissue being
very low: < 1 per 200,000 people had prions in their tissue. In these PSA runs, no infectious people
had entered the system between 2004 and 2018; this resulted in no infections and thus these PSA
runs have a likelihood of 1 of matching the observed data. In the 2019–23 period, infectious people
were simulated to have an operation in some RN streams, which resulted in infections and deaths. The
number of deaths was greater where IPG196 was not followed and where instruments were not kept
moist. The maximum number of future deaths multiplied by the likelihood is expected to be associated
with approximately 10 times more deaths than the expectation. For completeness, the best-case
scenario would be that there were no further deaths, which applies for all types of surgical unit.
Uncertainty in the mean number of QALYs gained was explored as described in Exploring the
uncertainty in the results produced within the base-case analyses and Appendix 7. The width of the CI
around the mean estimate of QALY loss was estimated to be 0.25 for S1 units, 0.58 for S2 units,
2.07 for S3 units, 0.19 for S4 units, 0.58 for S5 units and 1.89 for S6 units. To explore the relationship
between the number of PSA samples and the width of the CI, a randomly selected PSA was removed
with the remaining 508 split into two groups of 254. The widths of the CIs for each of the two groups
were 0.32 and 0.40 for S1; 0.87 and 0.78 for S2; 3.02 and 2.85 for S3; 0.25 and 0.29 for S4; 0.78 and
0.87 for S5; and 2.76 to 2.62 for S6. This indicated that approximately doubling the number of PSA
configurations had led to a reduction in the width of the CIs by approximately 30%. The CIs produced
from the 509 PSA configurations were not believed by the authors of this report to be large enough to
endanger the conclusions of the analyses are endangered. Given this, it was believed that further
reductions in the width of the CIs through running further PSAs were not required.
Scenario analyses using the base case as the foundation
Eight scenario analyses were run, with the change within a unit being assumed to happen instantly at
midnight on the 31st December 2018. These scenarios comprised strategies to follow IPG196 and/or
reduce the residual mass on instruments, and estimated the effect of removing the guidance on having
different instrument sets for the P96 group from the remaining patients. The results of the scenario
analyses are presented in Table 27. The results are presented in terms of surgical centres; these values
would be needed to be multiplied by 27 in order to form estimates for England.
Interpretation of the scenario analyses results using the base case as the foundation
These results are subject to Monte Carlo sampling error, particularly in relation to the RNs exhausted
within a simulation. For example, in the scenario analysis that changed a unit from S2 to S1, at the
start of 2019 this model run will have used significantly more RNs than a comparison with S1 alone.
This is a result of the RNs required in selecting from 2012 onwards, the SIs used in an operation and
the migration of instruments between sets (which is a feature of S2 but not of S1). This misalignment
of RNs between runs will result in different simulated outcomes.
Despite the presence of Monte Carlo sampling error, the results generated are broadly consistent
between comparable units, which offers support that the values are relatively robust. However, caution
is advised in trying to interpret differences in the results of the scenario analyses (see Table 27) and
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the base-case results (see Table 26), as these differences could be artefacts of the RNs selected.
Significantly more computational time would be required to provide an accurate comparison of the
scenario analyses and the base-case results; this was beyond the time scales of the project.
Scenario analyses using an alternative distribution of surgical unit compliance with
following IPG196 and keeping instruments moist
As described in Exploring the probability that each type of surgical unit was the most cost-effective, the
distribution that was assumed in relation to following IPG196 and guidance on keeping instruments
moist was changed to provide an indication of the sensitivity of the epidemiological results to these
parameters. The results for the expected number of QALYs lost as a result infections occurring
between 2019 and 2023 are shown for the base-case and the alternative scenario in Figure 18. The
results are very similar, as will be the costs associated with each strategy and, as such, no analyses of
the alternative scenario will be provided as these are highly comparable to those of the base case.
TABLE 27 Results of the scenario analyses per surgical unit using the base case as the foundation
Surgical
unit
Average number of
future deaths caused by
infections between 2019
and 2023, total (not P96
group/P96 group)a
Average number of
future undiscounted
life-years lost caused
by infections between
2019 and 2023
Average number of
future discounted
QALYs lost caused by
infections between
2019 and 2023
Maximum number of
future deaths across
the PSAs caused by
infections between 2019
and 2023 multiplied by
likelihood, total (non-P96
group/P96 group)a
S2 to S1 0.045 (0.037/0.008) 1.127 0.359 0.519 (0.519/0.000)
S3 to S1 0.047 (0.039/0.008) 1.159 0.371 0.519 (0.519/0.000)
S3 to S2 0.073 (0.073/0.000) 2.894 0.825 1.741 (1.481/0.259)
S5 to S4 0.038 (0.038/0.000) 0.744 0.271 0.519 (0.519/0.000)
S6 to S4 0.040 (0.040/0.000) 0.782 0.285 0.519 (0.519/0.000)
S6 to S5 0.058 (0.058/0.000) 2.238 0.627 1.741 (1.481/0.259)
S1b 0.041 (0.041/0.000) 1.661 0.484 0.556 (0.444/0.111)
S4b 0.037 (0.037/0.000) 1.543 0.451 0.556 (0.444/0.111)
a Numbers may appear discrepant as a result of rounding.
b Removing the necessity for the P96 group to have to use a different instrument set.
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FIGURE 18 Comparing the QALYs lost within the base case and when using an alternative assumption related to the
distribution of surgical units following IPG196 and in keeping instruments moist. The percentages in the figure key refer
to the proportion of units that are S1/S4, S2/S5 and S3/S6, respectively. S1 and S4 are assumed to follow both IPG196
and guidance on keeping instruments moist. S2 and S5 are assumed to keep instruments moist. S3 and S6 are assumed to
neither follow IPG196 nor keep instruments moist.
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Cost-effectiveness results
The presented results have been grouped by type of surgical unit (from S1 to S6). Within each
category, evaluated strategies are compared incrementally if appropriate. In addition to the base-case
results, sensitivity analyses have been run that change the values of parameters and threshold analyses
have been performed to determine at what price for a single-use kit, or cleaning solution that was
100% effective, the cost per QALY gained would equal the chosen cost-effectiveness threshold.
In all analyses, the additional costs have been calculated considering the following elements: the costs
of single-use sets; the disposal costs of reusable instruments; the costs of autoclaving reusable
instruments; and the costs associated with symptomatic stCJD.
When cost-per-QALY values have been calculated, these are compared with threshold values used
within common NICE evaluations. These are £30,000 within a standard technology appraisal, although
this can potentially be raised to approximately £50,000 if the end-of-life criteria are met,216 and
between £100,000 and £300,000 for highly specialised technologies.221
Parameter values within the base-case cost-effectiveness results
The parameter values used within the base-case estimate of the cost-effectiveness of various
strategies are shown in Table 28. It is noted that the number of operations were discounted such that
sensitivity analyses on the values could be performed without re-running the model. On completion of
the runs, it was discovered that the number of instruments disposed of within the run was not saved
to file. As such, an estimate of this was calculated rather than being directly taken from the model; it is
unlikely that this limitation will influence the results owing to the relatively small values involved.
TABLE 28 Parameter values used within the cost-effectiveness analyses
Parameter Base-case value
Intended values for use in
the sensitivity analyses
Discounted number of brain operations performed between
2019 and 2023
5199.84 Assumed fixed
Discounted number of posterior eye operations performed
between 2019 and 2023
904.92 Assumed fixed
Discounted number of neuroendoscopies performed between
2019 and 2023
58.7 Assumed fixed
Cost of an average single-use set, including disposal costs £425 £350; £500
Cost of a replacement reusable instrument £150 £100; £200
Assumed number of new instruments bought per surgical unit
between 2019 and 2023
32 Assumed fixed
Assumed cost associated with a clinically CJD transmission
(diagnosed correctly or not)
£50,000 £30,000; £70,000
Cost of an autoclaving cycle (per instrument) £0.60 Assumed fixed
Cost of keeping an instrument set moist £0.12 Assumed fixed
Cost of increasing standards to adhere to IPG196 – set-up costs £750,000 £500,000; £1,000,000
Assumed cost-effectiveness threshold (per QALY) £30,000 £50,000; £100,000; £300,000
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The base-case cost-effectiveness of strategies for reducing the likelihood of surgically
transmitted Creutzfeldt–Jakob disease
Results for S1 and S4 units
For surgical units that adhere to IPG196 and keep instruments moist, the only strategy currently
available to reduce the potential for stCJD is to use single-use instruments. Based on the values
reported in Table 28, it is estimated for a S1 unit that the additional net cost of single-use instruments
per unit would be £1,814,139, which would produce an expected 0.459 QALYs, thereby resulting in a
cost per QALY gained of £4.0M. For a S4 unit, the net cost was similar (£1,814,545) with fewer QALYs
gained (0.275), resulting in a cost per QALY gained of £6.7M. Both cost-per-QALY estimates are
markedly higher than the thresholds commonly used by NICE.
Results for S2 and S5 units
For surgical units that do not adhere to IPG196 but keep instruments moist, two strategies are
currently available to reduce the potential for stCJD: the use of single-use instruments and adhering
to IPG196.
Based on the values reported in Table 28, it is estimated for a S2 unit that the additional net cost of
single-use instruments per unit would be £2,562,829, which would produce an expected 0.874 QALYs,
thereby resulting in a cost per QALY gained of £2,933,530. For a S5 unit, the net costs were similar
(£2,563,238) with fewer QALYs gained (0.736), resulting in a cost per QALY gained of £3,484,476.
Both cost-per-QALY estimates are markedly higher than the thresholds commonly used by NICE.
For a S2 unit, adherence to IPG196 is estimated to have a net cost of approximately £750,000 and
provide an increase in QALYs of 0.415, resulting in a cost per QALY of approximately £1.8M. For a S5
unit, adherence to IPG196 is estimated to have a net cost of approximately £750,000, an increase in
QALYs of 0.461, resulting in a cost per QALY gained in the region of £1.6M. Both cost-per-QALY
estimates are markedly higher than the thresholds commonly used by NICE.
Results for S3 and S6 units
For surgical units that are neither adhering to IPG196 nor keeping instruments moist, three strategies
are currently available to reduce the potential for stCJD: the use of single-use instruments; adhering to
IPG196 and keeping instruments moist; and keeping instruments moist.
Based on the values reported in Table 28, it is estimated for a S3 unit that the additional costs of single-use
instruments per unit would be £2,550,760, which would produce an expected 4.009 QALYs, thereby
resulting in a cost per QALY gained of £636,292. For a S6 unit the costs were similar (£2,552,043) with
fewer QALYs gained (3.485), resulting in a cost per QALY of £732,364. Both cost-per-QALY estimates are
markedly higher than the thresholds commonly used by NICE.
For a S3 unit, keeping instruments moist is estimated to produce a cost saving (as the costs of potential
prevented CJD cases outweighed those associated with keeping the instruments moist) and to provide
an increase of 3.135 QALYs, suggesting that keeping instruments moist is dominant (lower costs and
more QALYs produced). For a S6 unit, there was also an expected cost saving of an increase in QALYs
of 2.749, resulting in keeping instruments moist being dominant.
For a S3 unit, having initially kept instruments moist, the cost-effectiveness of adhering to IPG196
would be similar to that of moving from S2 to S1, that is in the region of £1.8M per QALY gained. For a
S6 unit having moved to a S5, the cost per QALY gained of adhering to IPG196 would be in the region
of £1.6M.
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Estimating the probabilities that each type of surgical unit or using single-use
instruments are the most cost-effective strategies assuming that a centre does not
currently follow IPG196 nor keep instruments moist
The probabilities of each surgical unit and using single-use instruments being the most cost-effective
are provided in Figure 19 when it is assumed that the P96 group are infectious, and in Figure 20
when it is assumed the P96 group are not infectious. These results assume that all surgical units are
currently S3 or S6. Both figures have similar characteristics in that S2/S5 (units that keep instruments
moist but do not follow IPG196) have the highest probability of being cost-effective, followed by units
that continue to ignore IPG196 and those that do not keep instruments moist. Even at high cost-per-
QALY thresholds, the probability that single-use instruments are the most cost-effective is negligible.
The probability of being most cost-effective accord with the scenarios (S2 and S5) that are estimated
to be the most cost-effective.
Sensitivity analyses performed on the base-case results
Having observed the ICERs that were presented in terms of cost per QALY gained produced in the base
case, the sensitivity analyses that was performed explored a combination of all of the values that were
more favourable to single-use instruments. Thus, the cost of a CJD case was increased to £70,000; the
average cost of a reusable instrument was assumed to be £200; and the cost of a single-use set was
assumed to be £350. Note that these sensitivity analyses change the costs only and that the benefits in
QALYs are assumed to be constant.
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FIGURE 19 The probabilities that S1, S2, S3 and single-use instruments are the most cost-effective at a range of
cost-per-QALY thresholds. SUI, single-use instrument.
90
80
70
60
50
40
30
20
10
0
0 50 10
0
15
0
20
0
25
0
30
0
35
0
40
0
45
0
50
0
Cost-per-QALY threshold (£000)
P
ro
b
a
b
il
it
y
 (
%
)
SUI
S4
S5
S6
FIGURE 20 The probabilities that S4, S5, S6 and single-use instruments are the most cost-effective at a range of
cost-per-QALY thresholds. SUI, single-use instrument.
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Sensitivity analyses results for S1 and S4 units
The ICER for single-use instruments for a S1 unit became £2.9M, whereas the ICER for a S4 unit
became £4.9M. Neither value was below the commonly used NICE thresholds.
Sensitivity analyses results for S2 and S5 units
The ICER for single-use instruments for a S2 unit became £2.4M, whereas the ICER for a S5 unit
became £2.9M. Neither value was below the commonly used NICE thresholds.
For a S2 unit, adherence to IPG196 is estimated to have an ICER of approximately £1.2M, whereas
for a S5 unit this ICER was approximately £1.1M. Neither value was below the commonly used
NICE thresholds.
Sensitivity analyses results for S3 and S6 units
For a S3 unit, keeping instruments moist remains a dominant strategy. This is also the case for a S6 unit.
For a S3 unit, having initially kept instruments moist, the cost-effectiveness of adhering to IPG196
would be similar to that of moving from S2 to S1, that is in the region of £1.2M per QALY gained. For a
S6 unit, the cost-per-QALY of adhering to IPG196 would be in the region of £1.1M, which is similar to
moving from a S5 to a S4 unit. These values are similar rather than identical, as there may be more
infectious material on instruments in the S3 and S6 units than in S2 and S5 units.
Threshold analyses on the costs of single-use sets or a completely effective
cleaning solution
Analyses were performed to indicate the cost at which a single-use set (including disposal costs) would
be cost-effective at cost-per-QALY thresholds of £30,000, £50,000, £100,000 and £300,000. These
results are identical to the threshold cost of a cleaning solution that was 100% effective at removing
CJD prions, as both approaches (single-use instruments and the cleaning solution) are assumed to
prohibit CJD infection via surgery.
The results are presented for each unit type, by four cost-per-QALY thresholds, and for the base
case and for a scenario analysis that was more favourable to reusable instruments and a completely
effective cleaning solution. The results are presented in Table 29. Caution must be used in interpreting
these results, as options other than single-use instruments or a completely effective cleaning solution
exist. For example, moving from a S6 to a S5 (or S3 to a S2) is estimated to be a dominant strategy and
thus the thresholds for single-use sets for a S6 unit or a S3 unit are redundant, although these have
been presented for information.
It is seen that in units where instruments were kept moist, a single-use set price would need to be in
the region of £50 to have a cost per QALY below £300,000; to be below a cost per QALY of £30,000,
the cost of a single-use kit would need to be in the region of £10.
Threshold analyses on the costs of adhering to IPG196
For S2 and S5 units, analyses were performed to indicate the cost at which adhering to IPG196 would
produce an ICER equal to a chosen threshold. These results are presented for the S2 and S5 unit types,
by four cost-per-QALY thresholds, and for the base case and for the scenario more favourable to reusable
instruments and a completely effective cleaning solution. The results are presented in Table 30. The
estimated cost of implementing IPG196 is estimated to be £750,000, which is greater than the threshold
values provided in Table 30.
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Estimating the cost-effectiveness of removing the need for the P96 group to be operated
on with separate instrument sets
The data reported in Tables 26 and 27 indicate that there would be fewer deaths and marginally more
QALYs lost when the recommendation that the P96 group are operated on using different instrument
sets is removed and the P96 group is considered infectious on model entry. These results lack face
validity, particularly in relation to QALYs lost as younger patients can lose more QALYs, and is caused
by Monte Carlo sampling error as a result of the misalignment of RNs. Conversely, where the
requirement for different instrument sets is removed, given the assumption that the P96 group are not
infectious on model entry there are an additional 0.18 QALYs lost although marginally fewer deaths.
The computational time required to provide an accurate estimate for both the number of deaths
(which may be equal in both scenarios) and the QALYs lost is far beyond the resources assigned to this
work. As such, the results should be interpreted with caution, although currently there is no indication
that removing the recommendation related to separate instrument sets would greatly influence the
numbers of predicted CJD cases.
TABLE 29 Threshold analyses on the cost of single-use sets (including disposal costs) and a completely effective cleaning
solution
Surgical unit Assumptions
Cost-per-QALY threshold (£)
30,000 50,000 100,000 300,000
S1 Base case 11.21 12.70 16.43 31.32
Favourable 11.60 13.09 16.81 31.71
S2 Base case 13.44 16.28 23.36 51.71
Favourable 13.91 16.75 23.83 52.18
S3 Base case 30.66 43.67 76.19 206.27
Favourable 31.91 44.92 77.44 207.53
S4 Base case 10.25 11.14 13.37 22.30
Favourable 10.61 11.50 13.73 22.66
S5 Base case 12.70 15.09 21.06 44.93
Favourable 13.15 15.53 21.50 45.37
S6 Base case 27.90 39.21 67.48 180.55
Favourable 29.07 40.38 68.65 181.72
Favourable denotes assumptions that are more favourable to single-use and effective detergents.
TABLE 30 Threshold analyses on the cost of implementing IPG196
Surgical unit Assumptions
Cost-per-QALY threshold (£)
30,000 50,000 100,000 300,000
S2 Base case 13,746 22,038 42,766 125,678
Favourable 14,270 22,561 43,290 126,202
S5 Base case 15,122 24,333 47,360 139,466
Favourable 15,645 24,856 47,882 139,988
Favourable denotes assumptions that are more favourable to single-use and effective detergents.
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Chapter 4 Discussion and conclusions
The purpose of the systematic review was to summarise the most up-to-date published evidenceabout CJD with regards to the risk of transmission by surgery. As the reviews are largely
descriptive rather than summative, with no attempt to rank evidence, formal critical appraisal of study
quality was not deemed to be useful. Direct evidence to answer the literature review questions was
limited because of the rare nature of CJD. As a result, the eight systematic reviews are heavily reliant
on historical cases of stCJD, observational data, case–control study designs and animal data.
This review has included evidence from all forms of CJD, whereas the decision problem was focused
on vCJD in the previous work conducted by ScHARR in 2005.11 The apparent increase in sCJD cases
noted in several papers is speculated to be due to improved case ascertainment, population increases
and an ageing population. Although the vCJD epidemic appears to have subsided, with few recent
clinical cases observed, CJD remains an iatrogenic risk in surgery, mainly from sporadic and genetic
forms. Abnormal prion protein, detected using vCJD-specific immunostaining, has also been detected in
stored anonymised appendix tissue samples in cohorts of people considered not to have had significant
exposure to the BSE epidemic, as reported in the recent Appendix III study.16 Studies using advanced
detection assays also highlight wide vCJD accumulation in the peripheral tissues of a preclinical patient.
However, some studies indicate that prions can accumulate in peripheral tissues such as appendixes
without transmission to the CNS. Therefore, the assumption that a prevalence of non-clinical prion
accumulation in peripheral tissue represents disease that will go on to become clinical CJD has yet to be
substantiated. As CJD detection methods advance, more accurate confirmation of CJD pathology will be
possible from autopsy and excised tissue samples. Data on the likely incubation periods of CJD are limited
to retrospective data from iCJD, vCJD or kuru cases. These data indicate that very long incubation periods
that exceed life expectancy are possible. Although sCJD cannot be considered to have an incubation
period, as the precise time of disease onset cannot be ascertained, on the basis of having the highest
incidence, sCJD (rather than vCJD or gCJD) is likely to pose the greatest risk to surgery.
In the period covered by the reviews, to our knowledge no reports of observed cases of stCJD have
been published. Although many studies aim to retrospectively suggest a relationship between prior
surgery and risk of developing CJD, these case–control designs are known to be prone to bias and
confounding. Few data to supersede the original review conducted by ScHARR regarding infectious
dose required to transmit CJD were identified, but some animal studies using advanced detection
methods indicate that infectious doses greater than 108 ID50 per gram are possible.
Evidence on the decontamination of surgical instruments is fragmented with no single study assessing
the efficacy of all strategies, which include reducing residual mass, keeping instruments moist,
autoclaving and sterilisation. Comparison of included studies is also problematic as a result of these
being conducted under different conditions and in laboratory settings that limit their external validity
to the clinical setting. As empirical data on instrument set-keeping and single-use instruments were not
retrieved, no evidence to substantiate or refute anecdotal claims about the drawbacks and merits of
reusable versus single-use instruments is available. Data on the likelihood of future surgery in those
undergoing high-risk procedures are limited in their potential to inform the model, as these did not
focus solely on high-risk procedures and do not compare the risk of additional procedures with control
data for those who had not undergone an index high-risk procedure.
The decision problem was complex owing to the paucity of robust data on key modelling parameters
such as the efficacy of current decontamination methods and the incubation period associated with
stCJD; the lack of observed stCJD cases; the possibility for patients with stCJD to be misdiagnosed as
having a different neurodegenerative disease; and the number of model runs required to produce
accurate results for the scenarios evaluated. In order to provide additional data to populate the model,
output from elicitation sessions was used alongside heuristics that increased the efficiency of the
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available computational time. The results produced suggest that although there is a possibility that
stCJD cases are observed between 2019 and 2023, these are unlikely to be large in number. Based
on the analyses run to inform this report, the maximum number of cases of stCJD simulated that were
infected between 2019 and 2023 was 47 across England, although the mean estimate was 2.36 cases.
Not adhering to keeping instruments moist had a higher mean number of cases (approximately 11) and
a maximum among the simulations undertaken of 115. As such, keeping instruments moist should be
undertaken wherever possible.
Although simplifications were made in the modelling process, all decisions were made in consultation
with the NICE advisory committee meaning that it is likely that most key aspects were included, but
there remains the possibility that some were not identified by the committee and were therefore
omitted. The use of a distribution for prevalence data based on prions in lymphoid tissue rather than
just the central nervous system will overestimate the potential numbers used as prior distributions in
the model runs used for calibration. However, this will not restrict the posterior distribution formed in
the PSA that are consistent with observed information.
Given the large ICERs produced for the modelled strategies, the additional QALYs that would need to
be gained through improved public perception of infection control would have to be very large to bring
the ICERs for strategies below the thresholds commonly used by NICE. Similarly, the cost implications
related to a potential future public inquiry would need to be very large to alter the conclusions. Both
the affect of public perception of infection control and any future inquiry would need to be weighted
by the probability of a large number of cases being observed, which is expected to be small given the
expected number of potential stCJD deaths per unit (< 0.08; see Table 27) having kept instruments
moist, noting that these cases would appear in the future and may be misdiagnosed.
Running a greater number of PSA configurations would increase the accuracy in the ICER related to
uncertainty in parameter estimates, and running more RN streams would increase the accuracy for a
given PSA configuration. However, it is believed that the results are suitable for robust decision-making,
given that (1) the estimated uncertainty in the mean QALYs lost is relatively small and (2) that keeping
instruments moist is a dominant strategy compared with not, and (3) that all other ICERs are in excess
of £1 million per QALY gained; these values are greater than the cost-effectiveness thresholds reported
by NICE. Keeping instruments moist is also aligned with guidance from Department of Health and
Social Care.203
Threshold analyses undertaken indicate that the cost of single-use instruments (per cycle) or the cost
per set of using a completely effective decontamination method would need to be in the region of £50
to be cost-effective at a threshold of £300,000 per QALY. Assuming a lower cost-per-QALY threshold
of £30,000 meant that the single-use sets or the decontamination method would need to be in the
region of £10 per set. The current estimated cost of a single-use set is £425, thus it does not appear
likely that costs can be reduced to the threshold levels. The additional cost per set of using a
completely effective novel decontamination method is unknown and thus it is possible that standard
NICE threshold levels can be achieved, for a commercially available agent that is proven to be
completely effective at removing CJD prions.
Threshold analyses were also undertaken to determine the maximum cost to a unit, over a 5-year
period, of following IPG196. Assuming a cost-per-QALY threshold of £300,000 and £30,000, these
costs were approximately £125,000 and £15,000, respectively. Given that the estimated costs of
installing a system to track surgical instruments is estimated to be £750,000 per unit, it is not expected
that the prices would fall to the estimated threshold levels.
Furthermore, the analyses run indicated that there would be no marked increase in the risk of stCJD
cases when the requirement that P96 patients need to be operated on with separate instruments
were removed.
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Within this report the authors have presented ICERs on a number of strategies. Using a cost-per-QALY
gained threshold of either £30,000 or £300,000, it would appear that the following strategy would be
cost-effective: implementing measures to ensure that instruments are kept moist, which is estimated to
increase health and save money. Strategies to prevent instrument migration, to use different instrument
sets for the P96 group and the non-P96 group, or to use single-use instruments (at current prices) do
not appear cost-effective. These results appear robust to assumptions regarding the current standard of
decontamination among surgical units. If a decontamination solution became commercially available that
was proven to be perfectly effective at removing CJD prions, it is possible that it could be cost-effective
dependent on the acquisition price. The ultimate decision in terms of any strategy recommended is,
however, the responsibility of NICE.
Strengths and limitations of the work
There has been a comprehensive review of published literature of factors associated with stCJD. The
modelling work considered all of the aspects deemed important by the NICE advisory committee and
was calibrated to the potential number of stCJD cases that have been observed between 2005 and
2018. Limitations with the work are primarily due to the lack of evidence on key parameters, in
particular the number of stCJD cases that have actually occurred in England, which was used as
the calibration target. Elicitation sessions were conducted to provide an estimation of possible
values where there was little published evidence. Owing to the time scale of the project, it was only
possible to elicit opinion from four experts, which may be a limitation. It is highlighted that the model
focused only on brain surgery, posterior eye surgery and neuroendoscopy, based on the results of
previous work.
The approach was also selective on what to include in the model; these decisions were made in
conjunction with the NICE advisory committee, but it is possible that pertinent costs or changes in
utility have been omitted. It is acknowledged that gains that may be achieved in surgical procedures
unrelated to CJD have not been included within the model.
A further limitation is that novel decontaminant cleaning solutions could not be included, although
exploratory analyses were performed to estimate the maximum price that a completely effective
decontaminant could command to be cost-effective.
Although the work undertaken suggests that (1) keeping instruments moist is a dominant strategy
compared with not, and (2) that all other ICERs are in excess of £1 million per QALY gained, there remains
a possibility of future stCJD cases using this strategy due to the uncertainty in the calibration targets and
the estimated posterior distributions for each parameter. If there are multiple suspected or definite stCJD
cases observed in the near future, then re-assessing the decision problem promptly would be required.
Recommendations for future work
Clinical trials in this rare disease are not a feasible recommendation for research; however, future
investigations could take advantage of data from national surveillance programmes such as NCJDRSU and
HES to conduct and publish well-designed studies to provide an indication of the number of CJD cases that
could potentially be attributed to surgical transmission. Case–control studies using appropriately matched
controls and ascertaining surgical exposures through use of medical records are likely to be the best feasible
approach for identifying an association between surgery and CJD, at a population level. Considering the
methodological limitations and potential for bias in these studies, it is important that the conduct of each
individual case–control study is well planned, pre-registered and rigorously executed.
The accuracy of the results produced within the model can be improved through better knowledge
relating to the number of stCJD cases that have been observed in England. Historical data are unlikely
to provide further insight; however, prospectively assessing whether or not patients diagnosed with
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alternative neurodegenerative diseases have a history of high-risk surgery could improve the
ascertainment rates of stCJD. Furthermore, autopsy studies of patients dying with dementia could also
help to assess the extent of underdiagnoses of CJD.
It is acknowledged that surgical history data are gathered and assessed for patients with confirmed
CJD by the NCJDRSU. Where family consent is given following the death of suspected, or confirmed,
CJD cases, routine post-mortem analysis and publication of clinicopathological data may provide
further understanding on the transmissibility and infectivity of CJD. Additionally, seeking in-life
permission from those identified as being at risk of exposure to vCJD to perform an autopsy may also
improve the rate of CJD confirmation. Furthermore, increasing the number of future and stored
appendixes tested for prions may allow an improved estimate of the prevalence of asymptomatic CJD
in the UK population.
Further studies of the effectiveness of keeping surgical instruments moist in producing log-reductions
in prion load, and on reductions in transmission, would be informative to further validate understanding
of the efficacy of current decontamination procedures. Currently, the information used in the model is
indirect, as it assumes that reductions associated with protein residue translate to reductions in the
potential for transmission of vCJD.
The analyses undertaken did not exclude the possibility that a cleaning solution could be cost-effective
providing it was sufficiently efficacious at removing CJD prions, priced appropriately and was commercially
available. Further research into proving the efficacy of such products may be worthwhile. It is noted that
should a policy to prevent surgical instruments migrating between sets be put in place, then the threshold
costs for a completely effective cleaning solution would be approximately half that contained in Table 29,
as the QALYs likely to be gained are approximately halved (see Table 27).
In the event of identification of multiple stCJD cases, performing an urgent update of this review with
an amended calibration target is likely to be informative.
DISCUSSION AND CONCLUSIONS
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Appendix 1 Clinical effectiveness search
strategies
MEDLINE, MEDLINE Epub Ahead of Print, In-Process & Other
Non-Indexed Citations
Date range searched: 1946 to 2017 (via Ovid).
Date searched: 14 August 2017.
Search strategy
1. exp Creutzfeldt–Jakob Syndrome/
2. ((creutzfeldt jakob or creutzfeldt-jakob) adj (disease or syndrome)).tw.
3. (cjd or vcjd or v-cjd).tw.
4. exp Prion Diseases/
5. exp Prions/
6. ((transmissible or spong*) adj encephalopath*).tw.
7. (prion* or tse).tw.
8. prp.tw.
9. or/1-8
10. exp Incidence/
11. exp Prevalence/
12. incidence.tw.
13. prevalence.tw.
14. or/10-13
15. incubat*.tw.
16. 9 and (14 or 15)
17. limit 16 to yr=“2005 -Current”
18. exp Creutzfeldt–Jakob Syndrome/
19. ((creutzfeldt jakob or creutzfeldt-jakob) adj (disease or syndrome)).tw.
20. (cjd or vcjd or v-cjd).tw.
21. exp Prion Diseases/
22. exp Prions/
23. ((transmissible or spong*) adj encephalopath*).tw.
24. (prion* or tse).tw.
25. prp.tw.
26. or/18-25
27. ((transmission or transmit* or iatrogenic or transfer*) adj5 (creutzfeldt or cjd or vcjd or v-cjd or
encephalopath* or prion* or tse or prp)).tw.
28. exp Surgical Instruments/
29. exp Decontamination/
30. exp Sterilization/
31. 28 and (29 or 30)
32. ((surgery or surgical* or instrument* or device* or equipment*) adj5 (decontaminat* or reprocess*
or disinfect* or wash* or clean* or steril* or contaminat* or prerinse or pre-rinse or inactivat*)).tw.
33. 31 or 32
34. 26 and (27 or 33)
35. limit 34 to yr=“2005 -Current”
36. exp Surgical Instruments/
37. exp Decontamination/
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38. exp Sterilization/
39. 36 and (37 or 38)
40. ((surgery or surgical* or instrument* or device* or equipment*) adj5 (decontaminat* or reprocess*
or disinfect* or wash* or clean* or steril* or contaminat* or prerinse or pre-rinse or inactivat*)).tw.
41. 39 or 40
42. Neurosurgery/
43. Neurosurgical Procedures/
44. (neurosurgery or neurological surgery).tw.
45. exp Brain/su [Surgery]
46. exp Meninges/su [Surgery]
47. exp Pituitary Gland/su [Surgery]
48. Pineal Gland/su [Surgery]
49. ((brain or meninges or cerebral or pituitary or pineal) adj5 (surgery or surgical* or excision or
lesion or ablation or operation* or neurostimulation or connection or destruction)).tw.
50. exp Cranial Nerves/su [Surgery]
51. ((cranial or dura) adj5 (graft* or transection or destruction or lesion or repair* or decompress* or
neurostimulation or exploration or operation*)).tw.
52. Ophthalmologic Surgical Procedures/
53. ((eye or vitreous or retina) adj5 (surgery or surgical* or excision or operation* or photocoagulation
or destruction)).tw.
54. Eye/su [Surgery]
55. Vitreous Body/su [Surgery]
56. exp Retina/su [Surgery]
57. or/42-56
58. 41 and 57
59. limit 58 to yr=“2005 -Current”
60. (disposable or dispose* or nondispos* or non-dispos* or reus* or re-us* or “single use” or
“single-use”).mp.
61. Disposable Equipment/
62. exp Equipment Reuse/
63. (ultrasonic aspirator or aneurysm clip applicator or rhoton dissectors or microsurgical scissors or upcut
rongeurs or budde halo or retraction system or self-retaining retractors or neuroendoscope*).mp.
64. or/60-63
65. Neurosurgery/
66. Neurosurgical Procedures/
67. (neurosurgery or neurological surgery).tw.
68. exp Brain/su [Surgery]
69. exp Meninges/su [Surgery]
70. exp Pituitary Gland/su [Surgery]
71. Pineal Gland/su [Surgery]
72. ((brain or meninges or cerebral or pituitary or pineal) adj5 (surgery or surgical* or excision or
lesion or ablation or operation* or neurostimulation or connection or destruction)).tw.
73. exp Cranial Nerves/su [Surgery]
74. ((cranial or dura) adj5 (graft* or transection or destruction or lesion or repair* or decompress* or
neurostimulation or exploration or operation*)).tw.
75. Ophthalmologic Surgical Procedures/
76. ((eye or vitreous or retina) adj5 (surgery or surgical* or excision or operation* or photocoagulation
or destruction)).tw.
77. Eye/su [Surgery]
78. Vitreous Body/su [Surgery]
79. exp Retina/su [Surgery]
80. or/65-79
81. complication*.mp.
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82. co.fs.
83. exp Postoperative Complications/
84. exp Intraoperative Complications/
85. or/81-84
86. 64 and 80 and 85
87. limit 86 to yr=“2005 -Current”
88. *Reoperation/
89. reoperat*.tw.
90. ((repeat or revision) adj3 (surgery or surgical* or operat*)).tw.
91. or/88-90
92. Neurosurgery/
93. Neurosurgical Procedures/
94. (neurosurgery or neurological surgery).tw.
95. exp Brain/su [Surgery]
96. exp Meninges/su [Surgery]
97. exp Pituitary Gland/su [Surgery]
98. Pineal Gland/su [Surgery]
99. ((brain or meninges or cerebral or pituitary or pineal) adj5 (surgery or surgical* or excision or
lesion or ablation or operation* or neurostimulation or connection or destruction)).tw.
100. exp Cranial Nerves/su [Surgery]
101. ((cranial or dura) adj5 (graft* or transection or destruction or lesion or repair* or decompress* or
neurostimulation or exploration or operation*)).tw.
102. Ophthalmologic Surgical Procedures/
103. ((eye or vitreous or retina) adj5 (surgery or surgical* or excision or operation* or photocoagulation
or destruction)).tw.
104. Eye/su [Surgery]
105. Vitreous Body/su [Surgery]
106. exp Retina/su [Surgery]
107. or/92-106
108. 91 and 107
109. 17 or 35 or 59 or 87 or 108
EMBASE
Date range searched: 1974 to 11 August 2017.
Date searched: 14 August 2017.
Search strategy
1. exp Creutzfeldt Jakob disease/
2. ((creutzfeldt jakob or creutzfeldt-jakob) adj (disease or syndrome)).tw.
3. (cjd or vcjd or v-cjd).tw.
4. exp prion disease/
5. exp prion/
6. ((transmissible or spong*) adj encephalopath*).tw.
7. (prion* or tse).tw.
8. prp.tw.
9. or/1-8
10. exp incidence/
11. exp prevalence/
12. incidence.tw.
13. prevalence.tw.
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14. or/10-13
15. incubat*.tw.
16. 9 and (14 or 15)
17. limit 16 to yr=“2005 -Current”
18. ((transmission or transmit* or iatrogenic or transfer*) adj5 (creutzfeldt or cjd or vcjd or v-cjd or
encephalopath* or prion* or tse or prp)).tw.
19. exp surgical equipment/
20. instrument sterilization/
21. 19 and 20
22. ((surgery or surgical* or instrument* or device* or equipment*) adj5 (decontaminat* or reprocess*
or disinfect* or wash* or clean* or steril* or contaminat* or prerinse or pre-rinse or inactivat*)).tw.
23. 21 or 22
24. 9 and (18 or 23)
25. limit 24 to yr=“2005 -Current”
26. exp surgical equipment/
27. instrument sterilization/
28. 26 and 27
29. ((surgery or surgical* or instrument* or device* or equipment*) adj5 (decontaminat* or reprocess*
or disinfect* or wash* or clean* or steril* or contaminat* or prerinse or pre-rinse or inactivat*)).tw.
30. 28 or 29
31. neurosurgery/
32. (neurosurgery or neurological surgery).tw.
33. exp brain/su [Surgery]
34. exp meninx/su [Surgery]
35. exp hypophysis/su [Surgery]
36. pineal body/su [Surgery]
37. ((brain or meninges or cerebral or pituitary or pineal) adj5 (surgery or surgical* or excision or
lesion or ablation or operation* or neurostimulation or connection or destruction)).tw.
38. exp cranial nerve/su [Surgery]
39. ((cranial or dura) adj5 (graft* or transection or destruction or lesion or repair* or decompress* or
neurostimulation or exploration or operation*)).tw.
40. eye surgery/
41. ((eye or vitreous or retina) adj5 (surgery or surgical* or excision or operation* or photocoagulation
or destruction)).tw.
42. eye/su [Surgery]
43. vitreous body/su [Surgery]
44. exp retina/su [Surgery]
45. or/31-44
46. 30 and 45
47. limit 46 to yr=“2005 -Current”
48. (disposable or dispose* or nondispos* or non-dispos* or reus* or re-us* or “single use” or “single-use”).mp.
49. disposable equipment/
50. exp recycling/
51. (ultrasonic aspirator or aneurysm clip applicator or rhoton dissectors or microsurgical scissors
or upcut rongeurs or budde halo or retraction system or self-retaining retractors or
neuroendoscope*).mp.
52. or/48-51
53. neurosurgery/
54. (neurosurgery or neurological surgery).tw.
55. exp brain/su [Surgery]
56. exp meninx/su [Surgery]
57. exp hypophysis/su [Surgery]
58. pineal body/su [Surgery]
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59. ((brain or meninges or cerebral or pituitary or pineal) adj5 (surgery or surgical* or excision or
lesion or ablation or operation* or neurostimulation or connection or destruction)).tw.
60. exp cranial nerve/su [Surgery]
61. ((cranial or dura) adj5 (graft* or transection or destruction or lesion or repair* or decompress* or
neurostimulation or exploration or operation*)).tw.
62. eye surgery/
63. ((eye or vitreous or retina) adj5 (surgery or surgical* or excision or operation* or photocoagulation
or destruction)).tw.
64. eye/su [Surgery]
65. vitreous body/su [Surgery]
66. exp retina/su [Surgery]
67. or/53-66
68. complication*.mp.
69. co.fs.
70. exp postoperative complication/
71. exp peroperative complication/
72. or/68-71
73. 52 and 67 and 72
74. limit 73 to yr=“2005 -Current”
75. *reoperation/
76. reoperat*.tw.
77. ((repeat or revision) adj3 (surgery or surgical* or operat*)).tw.
78. or/75-77
79. neurosurgery/
80. (neurosurgery or neurological surgery).tw.
81. exp brain/su [Surgery]
82. exp meninx/su [Surgery]
83. exp hypophysis/su [Surgery]
84. pineal body/su [Surgery]
85. ((brain or meninges or cerebral or pituitary or pineal) adj5 (surgery or surgical* or excision or
lesion or ablation or operation* or neurostimulation or connection or destruction)).tw.
86. exp cranial nerve/su [Surgery]
87. ((cranial or dura) adj5 (graft* or transection or destruction or lesion or repair* or decompress* or
neurostimulation or exploration or operation*)).tw.
88. eye surgery/
89. ((eye or vitreous or retina) adj5 (surgery or surgical* or excision or operation* or photocoagulation
or destruction)).tw.
90. eye/su [Surgery]
91. vitreous body/su [Surgery]
92. exp retina/su [Surgery]
93. or/79-92
94. 78 and 93
95. 17 or 25 or 47 or 74 or 94
96. 96 remove duplicates from 95
Science Citation Index (SCI-E) and Conference Proceedings Citation Index (CPCI)
Date range searched: 1990 to 2017 (via Web of Science).
Date searched: 14 August 2017.
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Search strategy
1. TS=(creutzfeldt jakob NEAR/1 disease) OR TS=(creutzfeldt jakob NEAR/1 syndrome) OR
TS=(creutzfeldt-jakob NEAR/1 disease) OR TS=(creutzfeldt-jakob NEAR/1 syndrome)
2. TS=((cjd or vcjd or v-cjd))
3. TS=(transmissible NEAR/1 encephalopath*) OR TS=(spong* NEAR/1 encephalopath*)
4. TS=(prion* or tse or prp)
5. #4 OR #3 OR #2 OR #1
6. TS= (incidence)
7. TS= (prevalence)
8. TS= (incubat*)
9. #8 OR #7 OR #6
10. #9 AND #5 Timespan=2005-2017
11. TS=(creutzfeldt jakob NEAR/1 disease) OR TS=(creutzfeldt jakob NEAR/1 syndrome) OR
TS=(creutzfeldt-jakob NEAR/1 disease) OR TS=(creutzfeldt-jakob NEAR/1 syndrome)
12. TS=((cjd or vcjd or v-cjd))
13. TS=(transmissible NEAR/1 encephalopath*) OR TS=(spong* NEAR/1 encephalopath*)
14. TS=(prion* or tse or prp)
15. #14 OR #13 OR #12 OR #11
16. TS=(((transmission or transmit* or iatrogenic or transfer*) NEAR/5 (creutzfeldt or cjd or vcjd or
v-cjd or encephalopath* or prion* or tse or prp)))
17. TS=(((surgery or surgical* or instrument* or device* or equipment*) NEAR/5 (decontaminat* or
reprocess* or disinfect* or wash* or clean* or steril* or contaminat* or prerinse or pre-rinse
or inactivat*)))
18. #17 OR #16
19. #18 AND #15 Timespan=2005-2017
20. TS=(((surgery or surgical* or instrument* or device* or equipment*) NEAR/5 (decontaminat* or
reprocess* or disinfect* or wash* or clean* or steril* or contaminat* or prerinse or pre-rinse
or inactivat*)))
21. TS=((neurosurgery or neurological surgery))
22. TS=(((brain or meninges or cerebral or pituitary or pineal) NEAR/5 (surgery or surgical* or excision
or lesion or ablation or operation* or neurostimulation or connection or destruction)))
23. TS=(((cranial or dura) NEAR/5 (graft* or transection or destruction or lesion or repair* or
decompress* or neurostimulation or exploration or operation*)))
24. TS=(((eye or vitreous or retina) NEAR/5 (surgery or surgical* or excision or operation* or
photocoagulation or destruction)))
25. #24 OR #23 OR #22 OR #21
26. #25 AND #20 Timespan=2005-2017
27. TS=((disposable or dispose* or nondispos* or non-dispos* or reus* or re-us* or “single use” or
“single-use”))
28. TS=((ultrasonic aspirator or aneurysm clip applicator or rhoton dissectors or microsurgical
scissors or upcut rongeurs or budde halo or retraction system or self-retaining retractors
or neuroendoscope*))
29. #28 OR #27
30. TS=((neurosurgery or neurological surgery))
31. TS=(((brain or meninges or cerebral or pituitary or pineal) NEAR/5 (surgery or surgical* or excision
or lesion or ablation or operation* or neurostimulation or connection or destruction)))
32. TS=(((cranial or dura) NEAR/5 (graft* or transection or destruction or lesion or repair* or
decompress* or neurostimulation or exploration or operation*)))
33. TS=(((eye or vitreous or retina) NEAR/5 (surgery or surgical* or excision or operation* or
photocoagulation or destruction)))
34. #33 OR #32 OR #31 OR #30
35. #34 AND #29
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36. TS=(complication*)
37. #36 AND #35 Timespan=2005-2017
38. TS=(reoperat*)
39. TS=(((repeat or revision) NEAR/3 (surgery or surgical* or operat*)))
40. #39 OR #38
41. TS=((neurosurgery or neurological surgery))
42. TS=(((brain or meninges or cerebral or pituitary or pineal) NEAR/5 (surgery or surgical* or excision
or lesion or ablation or operation* or neurostimulation or connection or destruction)))
43. TS=(((cranial or dura) NEAR/5 (graft* or transection or destruction or lesion or repair* or
decompress* or neurostimulation or exploration or operation*)))
44. TS=(((eye or vitreous or retina) NEAR/5 (surgery or surgical* or excision or operation* or
photocoagulation or destruction)))
45. #44 OR #43 OR #42 OR #41
46. #45 AND #40
47. #46 OR #37 OR #26 OR #19 OR #10
Supplementary searches
Supplementary searches were carried out in October 2017.
MEDLINE, MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations
Date range searched: 1946 to 2017 (via Ovid).
Date searched: 2 October 2017.
Search strategy
1. exp Creutzfeldt–Jakob Syndrome/
2. ((creutzfeldt jakob or creutzfeldt-jakob) adj (disease or syndrome)).tw.
3. (cjd or vcjd or v-cjd).tw.
4. exp Prion Diseases/
5. exp Prions/
6. ((transmissible or spong*) adj encephalopath*).tw.
7. (prion* or tse).tw.
8. prp.tw.
9. or/1-8
10. (surgery or surgical* or operat*).tw.
11. risk*.mp.
12. 9 and 10 and 11
13. limit 12 to yr=“2005 –Current”
EMBASE
Date range searched: 1974 to 2017 October.
Date searched: 2 October 2017.
Search strategy
1. exp Creutzfeldt Jakob disease/
2. ((creutzfeldt jakob or creutzfeldt-jakob) adj (disease or syndrome)).tw.
3. (cjd or vcjd or v-cjd).tw.
4. exp prion disease/
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5. exp prion/
6. ((transmissible or spong*) adj encephalopath*).tw.
7. (prion* or tse).tw.
8. prp.tw.
9. or/1-8
10. (surgery or surgical* or operat*).tw.
11. risk*.mp.
12. 9 and 10 and 11
13. limit 12 to yr=“2005 -Current”
Science Citation Index (SCI-E) and Conference Proceedings Citation Index (CPCI)
Date range searched: 1990 to 2017 (via Web of Science).
Date searched: 2 October 2017.
Search strategy
1. # TS=(creutzfeldt jakob NEAR/1 disease) OR TS=(creutzfeldt jakob NEAR/1 syndrome) OR
TS=(creutzfeldt-jakob NEAR/1 disease) OR TS=(creutzfeldt-jakob NEAR/1 syndrome)
2. # TS=((cjd or vcjd or v-cjd))
3. # TS=(transmissible NEAR/1 encephalopath*) OR TS=(spong* NEAR/1 encephalopath*)
4. # TS=(prion* or tse or prp)
5. # #4 OR #3 OR #2 OR #1
6. # TOPIC: ((surgery or surgical* or operat*))
7. # TOPIC: ((risk*))
8. # #7 AND #6 AND #5
9. # #7 AND #6 AND #5 Refined by: PUBLICATION YEARS: (2006 OR 2012 OR 2016 OR 2015 OR
2007 OR 2013 OR 2005 OR 2009 OR 2010 OR 2017 OR 2014 OR 2011 OR 2008)
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Appendix 2 Cost-effectiveness
search strategies
MEDLINE, MEDLINE Epub Ahead of Print, In-Process & Other Non-Indexed Citations
Date range searched: 1946 to 2017 (via Ovid).
Date searched: 7 June 2017.
Search strategy
1. exp Creutzfeldt–Jakob Syndrome/
2. ((creutzfeldt jakob or creutzfeldt-jakob) adj (disease or syndrome)).tw.
3. (cjd or vcjd or v-cjd).tw.
4. exp Prion Diseases/
5. exp PRIONS/
6. ((transmissible or spong*) adj encephalopath*).tw.
7. (prion* or tse).tw.
8. prp.tw.
9. or/1-8
10. exp “Costs and Cost Analysis”/
11. Economics/
12. exp Economics, Hospital/
13. exp Economics, Medical/
14. Economics, Nursing/
15. exp models, economic/
16. Economics, Pharmaceutical/
17. exp “Fees and Charges”/
18. exp Budgets/
19. budget$.tw.
20. ec.fs.
21. cost$.ti.
22. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimi$)).ab.
23. (economic$ or pharmacoeconomic$ or pharmaco-economic$).ti.
24. (price$ or pricing$).tw.
25. (financial or finance or finances or financed).tw.
26. (fee or fees).tw.
27. (value adj2 (money or monetary)).tw.
28. quality-adjusted life years/
29. (qaly or qalys).af.
30. (quality adjusted life year or quality adjusted life years).af.
31. or/10-30
32. 9 and 31
33. limit 32 to yr=“2004 –Current”
EMBASE 1974 to 2017 June 6
Date range searched: 1974 to 6 June 2017.
Date searched: 7 June 2017.
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Search strategy
1. exp Creutzfeldt Jakob disease/
2. ((creutzfeldt jakob or creutzfeldt-jakob) adj (disease or syndrome)).tw.
3. (cjd or vcjd or v-cjd).tw.
4. exp prion disease/
5. exp prion/
6. ((transmissible or spong*) adj encephalopath*).tw.
7. (prion* or tse).tw.
8. prp.tw.
9. or/1-8
10. Socioeconomics/
11. Cost benefit analysis/
12. Cost effectiveness analysis/
13. Cost of illness/
14. Cost control/
15. Economic aspect/
16. Financial management/
17. Health care cost/
18. Health care financing/
19. Health economics/
20. Hospital cost/
21. (fiscal or financial or finance or funding).tw.
22. Cost minimization analysis/
23. (cost adj estimate$).mp.
24. (cost adj variable$).mp.
25. (unit adj cost$).mp.
26. or/10-25
27. 9 and 26
28. limit 27 to yr=“2004 -Current”
Science Citation Index (SCI-E) and Conference Proceedings Citation Index (CPCI)
Date range searched: 1990 to 2017 (via Web of Science).
Date searched: 11 July 2017.
Search strategy
1. # TS=(creutzfeldt jakob NEAR/1 disease) OR TS=(creutzfeldt jakob NEAR/1 syndrome) OR
TS=(creutzfeldt-jakob NEAR/1 disease) OR TS=(creutzfeldt-jakob NEAR/1 syndrome)
2. # TS=((cjd or vcjd or v-cjd))
3. # TS=(transmissible NEAR/1 encephalopath*) OR TS=(spong* NEAR/1 encephalopath*)
4. # TS=(prion* or tse or prp)
5. # #4 OR #3 OR #2 OR #1
6. # TS=((cost* and (effective* or utilit* or benefit* or minimi*))) OR TI=((cost*)) OR TS=((economic*
or pharmacoeconomic* or pharmaco-economic*)) OR TS=((price* or pricing*)) OR TS=((financial
or finance or finances or financed)) OR TS=((economic* and (hospital or medical or nursing or
pharmaceutical))) OR TS=((“quality adjusted life year” or “quality adjusted life years”)) OR TS=((qaly
or qalys)) OR TS=((budget*))
7. # #6 AND #5 Refined by: PUBLICATION YEARS: ( 2015 OR 2017 OR 2011 OR 2014 OR 2016 OR
2008 OR 2013 OR 2007 OR 2009 OR 2005 OR 2012 OR 2004 OR 2010 OR 2006 )
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Appendix 3 Excluded studies from the
clinical reviews with reasons for exclusion
Reference
Primary reason for
exclusion
Adam AM, Akuku O. Creutzfeldt–Jakob disease in Kenya. Trop Med Int Health 2005;10:710–12 Data from pre 2005
Allen CT, Sonnen J, Leslie MJ, Kidoguchi L, Harris C, Gambetti P, Montine TJ. Washington
statewide pathology surveillance for prion disease. Ann Neurol 2007;61:371–72
Superceded data
Amour J. Comparison of single-use and reusable metal laryngoscope blades for orotracheal
intubation during rapid sequence induction of anaesthesia: a multicenter cluster randomised
study. Anaesthesiology 2010;112:325–32
Not high-risk surgery
Brandel JP, Salomon D, Capek I, Vaillant V, Alperovitch A. Epidemiological surveillance of
Creutzfeldt–Jakob in France. Rev Neurol 2009;165:684–93
Review with no
original data
Chandra SR, Issac TG, Philip M, Gadad V. Creutzfeldt–Jakob disease phenotype and course:
our experience from a tertiary centre. Indian J Psychol Med 2016;38:438–42
No usable data for
any review question
Checchi M, Hewitt PE, Bennett P, Ward HJ, Will RG, Mackenzie JM, Sinka K. Ten-year
follow-up of two cohorts with an increased risk of variant CJD: donors to individuals who
later developed variant CJD and other recipients of these at-risk donors. Vox Sang
2016;111:325–32
No usable data for
any review question
Chen CC, Wang YH, Wu KY. Consumption of bovine spongiform encephalopathy (BSE)
contaminated beef and the risk of variant Creutzfeldt–Jakob disease. Risk Anal
2013;33:1958–68
No usable data for
any review question
de Pedro-Cuesta J, Bleda MJ, Rabano A, Cruz M, Laursen H, Molbak K, Siden A. Classification
of surgical procedures for epidemiologic assessment of sporadic Creutzfeldt–Jakob disease
transmission by surgery. Eur J Epidemiol 2006;21:595–604
Wrong outcome
Frontzek K, Moos R, Schaper E, Jann L, Herfs G, Zimmermann DR, et al. Iatrogenic and
sporadic Creutzfeldt–Jakob disease in 2 sisters without mutation in the prion protein gene.
Prion 2015;9:444–8
No usable data for
any review question
Graziano S and Pocchiari M. Management and prevention of human prion diseases. Curr Neurol
Neurosci Rep 2009;9:423–9
Review with no
original data
Gregori L, Yang H, Anderson S. Estimation of variant Creutzfeldt–Jakob disease infectivity
titres in human blood. Prion 2012;6:139
No usable data for
any review question
Gubbels S, Bacci S, Laursen H, Hogenhaven H, Cowan S, Molbak K, Christiansen M. Description
and analysis of 12 years of surveillance for Creutzfeldt–Jakob disease in Denmark, 1997 to 2008.
Euro Surveill 2012;17:12
Superceded data
Hamaguchi T. Clinical manifestations and epidemiology of prion diseases in Japan. Rinsho
Shinkeigaku 2013;23:1246–8
Superceded data
Ironside JW, Head MW, Peden A, Ward H. Asymptomatic vCJD infection detected at autopsy
in a UK haemophilic patient. Haemophilia 2010;16:29
Superceded data
Karhade AV, Vasudeva VS, Dasenbrock HH, Lu Y, Gormley WB, Groff MW, et al. Thirty-day
readmission and reoperation after surgery for spinal tumours: a National Surgical Quality
Improvement Program analysis. Neurosurg Focus 2016;41(2)
Wrong outcome
Klug GM, Boyd A, Lewis V, McGlade A, Stehmann C, Masters CL, Collins SJ. Surveillance of
Creutzfeldt–Jakob disease in Australia: 2009 update. Commun Dis Intell Q Rep 2019;33:188–91
Superceded data
Kobayashi A, Matsuura Y, Iwaki T, Iwasaki Y, Yoshida M, Takahashi H, et al. Sporadic
Creutzfeldt–Jakob disease MM1 + 2C and MM1 are identical in transmission properties.
Brain Pathol 2016;26:95–101
Review with no
original data
Kobayashi A, Teruya K, Matsuura Y, Shirai T, Nakamura Y, Yamada M, et al. The influence of
PRNP polymorphisms on human prion disease susceptibility: an update. Acta Neuropathol
2015;130:159–70
Review with no
original data
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Reference
Primary reason for
exclusion
Kovacs GG, Majtenyi K. Creutzfeldt–Jakob disease in Hungary. Folia Neuropathol 2005;43:279–85 Superceded data
Maddox RA, Person MK, Minino AM, Blevins JE, Schonberger LB, Belay ED. Unusually young
prion disease cases in the United States, 1979–2014. Prion 2016;10:S98–S99
No usable data for
any review question
Maheshwari A, Fischer M, Gambetti P, Parker A, Ram A, Soto C, Hussein HM. Recent us case
of variant Creutzfeldt–Jakob disease-global implications. Emerg Infect Dis 2015;21:750–9
Superceded data
Mei LL, Sin HF, Suk ML, Wai CL. Effectiveness of 2D barcode tracking in recording instrument
sterilisation & avoiding spread of infection in operating theatre. J Microbiol Immunol Infection
2015;48:S68
Wrong outcome
Mikol J, Deslys JP, Zou WQ, Xiao W, Brown P, Budka H, Goutieres F. Creutzfeldt–Jakob
disease with unusually extensive neuropathology in a child treated with native human growth
hormone. Clin Neuropathol 2012;31:127–34
Superceded data
Papacostas S, Malikides A, Petsa M, Kyriakides T. Ten-year mortality from Creutzfeldt–Jakob
disease in Cyprus. East Mediterr Health J 2008;14:715–19
Data from pre-2005
Parchi P. Molecular-phenotypic correlation in sporadic and genetic Creutzfeldt–Jakob disease:
Insights from recent studies. Clin Neuropathol 2009;28:235–36
Review with no
original data
Ritchie DL, Lowrie S, Le Grice M, Burns K, Ironside JW. Amyloid-beta accumulation in human
growth hormone related iatrogenic CJD patients in the UK. Neuropathol Appl Neurobiol
2017;43:39
Not CJD related
Rohan Z, Rusina R, Maresova M, Matej R. Human prion diseases in the Czech Republic.
Epidemiol Mikrob Im 2015;64:115–20
No usable data for
any review question
Saba R, Booth SA. The genetics of susceptibility to variant Creutzfeldt–Jakob disease.
Public Health Genomics 2013;16:17–24
No usable data for
any review question
Sawyer EB, Edgeworth JA, Thomas C, Collinge J, Jackson GS. Preclinical detection of infectivity
and disease-specific PrP in blood throughout the incubation period of prion disease. Sci Rep
2015;5:17742
No usable data for
any review question
Takeuchi A, Kobayashi A, Ironside JW, Mohri S, Kitamoto T. Characterization of variant
Creutzfeldt–Jakob disease prions in prion protein-humanised mice carrying distinct codon 129
genotypes. J Biol Chem 2013;288:21659–66
No usable data for
any review question
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Appendix 4 Elicitation exercise relating to
epidemiological parameters (conducted
18 January 2018)
List of participants
Participating experts: in alphabetical order of surname
l Dr David Hilton: Consultant Neuropathologist, University Hospitals Plymouth NHS Trust.
l Professor Simon Mead: Professor of Neurology, University College London.
l Professor Graham Medley: Professor of Infectious Disease Modelling, London School of Hygiene &
Tropical Medicine.
l Dr Katy Sinka: Creutzfeldt-Jacob disease Section Head, Public Health England.
Note that this order does not correspond to experts A, B, C and D: we have chosen to anonymise
individual responses and comments in this record.
Facilitator
l Professor Jeremy E Oakley: Professor of Statistics, University of Sheffield.
Parameters related to misdiagnoses of the cause of death in patients who
die as a result of Creutzfeldt–Jakob disease
The quantity of interest is the percentage of patients whose death was due to CJD who were
misdiagnosed as having died from another neurodegenerative disease, since 2005.
A separate percentage is considered for each of three age categories:
1. aged < 60 years
2. aged 60–79 years
3. aged ≥ 80 years.
It was decided to elicit distributions for age categories (1) and (3), and assume that the percentage for
age category (2) would be the mean of these two.
Parameter 1 definition: the percentage of patients, aged less than 60 years, whose death
was because of Creutzfeldt–Jakob disease, that are misdiagnosed as having died from
another neurodegenerative disease, since 2005
Individual judgements
Without conferring, the experts made the probability judgements for parameter 1 as shown in Table 31.
Group discussion and consensus judgements
Expert C argued that correct diagnosis would be dependent on whether or not the patient was referred
to Neurology; a higher misdiagnosis rate could occur if the referral rate were lower. Where patients
were misdiagnosed, a possible diagnosis would be early-onset dementia.
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Expert A was willing to revise their own judgements upwards somewhat, but thought that expert C’s
view was pessimistic.
It was agreed that expert C’s arguments were valid, but not overwhelming; for the consensus
distribution, the experts agreed on quartiles supporting higher values, but set somewhat lower than
those originally proposed by expert C. Agreed percentiles for parameter 1 are provided in Table 32.
Fitted distribution for parameter 1
A beta (0.952, 2.71) distribution, scaled to the interval (0, 50%), was fitted to the consensus
judgements. This is shown in Figure 21. The blue shaded region indicates that, given this choice of
distribution, a probability of about 0.99 has been assumed that the percentage misdiagnosed will be
< 40%. Percentiles from the fitted distribution for parameter 1 are shown in Table 33.
TABLE 31 The probability judgements for each expert for parameter 1
Expert
Plausible
lower limit (%) 25th percentile (%) Median (%) 75th percentile (%)
Plausible
upper limit (%)
A 0 0.5 1 3 10
B 0 2.5 5 7.5 15
C 0 10 20 30 50
D 0 1 5 10 20
6.0
4.0
2.0
0.0
0 10 20 30 40 50
Percentage misdiagnosed
D
e
n
si
ty
FIGURE 21 The distribution chosen to represent the experts’ consensus judgements for parameter 1: the percentage
of patients aged < 60 years whose death was due to CJD who are misdiagnosed as having died from another
neurodegenerative disease, since 2005.
TABLE 32 Consensus percentiles for parameter 1
Plausible lower limit (%) 25th percentile (%) Median (%) 75th percentile (%) Plausible upper limit (%)
0 5 10 20 50
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Parameter 2 definition: the percentage of patients aged ≥ 80 years whose death was
because of Creutzfeldt–Jakob disease who are misdiagnosed as having died from another
neurodegenerative disease, since 2005.
Individual judgements
Without conferring, the experts made the probability judgements for parameter 2 as shown in Table 34.
Group discussion and consensus judgements
Expert C argued for higher values of parameter 2, based on figures 2 and 3 from the 25th Annual
Report on CJD surveillance in the UK.2 The argument was that mortality rates from sCJD have been
observed to increase over time in the higher age categories and that this is a consequence of changes
in diagnostics; it is plausible that this trend will continue, suggesting that the current percentage of
misdiagnoses could be high. The remaining experts accepted a higher median and 25th percentile as
consensus judgements, but thought that percentages close to 100% would be unlikely, agreeing a 75th
percentile closer to the median. The consensus judgements are given in Table 35.
Fitted distribution for parameter 2
A beta (3.36, 2.75) distribution was fitted to the consensus judgements, as is shown in Figure 22.
The blue shaded region indicates that, given this choice of distribution, a probability of about 0.98 has
been assumed that the percentage misdiagnosed will be between 14% and 92%. Percentiles from the
distribution fitted to parameter 2 are provided in Table 36.
Parameter 3 definition: the percentage of patients aged 60–79 years whose death was
because of Creutzfeldt–Jakob disease who are misdiagnosed as having died from another
neurodegenerative disease, since 2005
This parameter is assumed to be the mean of Parameters 1 and 2 (the percentages for the two age
groups: aged < 60 years and ≥ 80 years). Its implied distribution can be obtained by simulation and is
shown in Figure 23. Percentiles of this distribution are estimated by simulation and are provided in
Table 37.
TABLE 33 Percentiles from the fitted distribution for parameter 1
Percentile 1st 5th 95th 99th
Parameter value 0.1% 0.8% 33.0% 40.6%
TABLE 34 The probability judgements for each expert for parameter 2
Expert
Plausible
lower limit (%) 25th percentile (%) Median (%) 75th percentile (%)
Plausible
upper limit (%)
A 5 30 50 60 70
B 10 25 50 75 90
C 20 50 80 90 100
D 0 20 50 60 75
TABLE 35 Consensus percentiles for parameter 1
Plausible lower limit 25th percentile Median 75th percentile Plausible upper limit
0% 40% 60% 65% 100%
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FIGURE 22 The distribution chosen to represent the experts’ consensus judgements for parameter 2: the percentage
of patients aged ≥ 80 years whose death was due to CJD who are misdiagnosed as having died from another
neurodegenerative disease, since 2005.
TABLE 36 Percentiles from the fitted distribution for parameter 2
Percentile 1st 5th 95th 99th
Parameter value 14% 23% 85% 92%
3.0
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Percentage misdiagnosed
FIGURE 23 The distribution chosen to represent the experts’ consensus judgements for parameter 3: the percentage
of patients aged 60–79 years, whose death was due to CJD who are misdiagnosed as having died from another
neurodegenerative disease, since 2005.
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Distributions related to incubation periods
Previous analysis had used different incubation periods for different recipient genotypes. It was
thought that incubation period would depend on the genotypes of both host and recipient and also the
infecting prion, and that a more manageable elicitation task would be to consider a single distribution
of incubation periods, for genotype unspecified.
Distribution definition
The uncertain object of interest here is not a single parameter, but instead a distribution of incubation
periods: the distribution of incubation period in years, in all patients, following infection with prion via
surgery (i.e. posterior eye, brain, neuroendoscopy, and intradural spinal surgery), genotype unknown for
each patient.
Individual estimates of the uncertain distribution
Without conferring, each expert gave estimates of three quantiles of the uncertain distribution,
together with suggested lower and upper limits. These values are provided in Table 38.
Group discussion and quantifying uncertainty about the distribution
It was proposed to quantify uncertainty about the distribution of incubation periods as follows. First,
four intervals were specified based on the estimates provided at the individual stage. These intervals
are provided in Table 39.
As a central estimate, it was proposed that each interval describes incubation periods for 25% of the
population. Incubation periods would be assumed to be uniform in each interval, giving the estimated
distribution shown in Figure 24. The blue shaded region indicates that, given this choice of distribution,
98% of incubation periods will lie between 0.32 years and 48.8 years.
To allow for uncertainty in the estimated distribution, it was proposed to allow the percentages in each
interval to vary by up to 15% in intervals 1–3 and up to 10% in interval 4. For example, an alternative
distribution would be as shown in Table 40 and Figure 25. The blue shaded region indicates that, given
this choice of distribution, 98% of incubation periods will lie between 0.37 years and 48 years.
TABLE 37 Simulated percentiles from parameter 3
Percentile 1st 5th 95th 99th
Parameter value 10% 16% 51% 58%
TABLE 38 The probability judgements for each expert related to incubation periods
Expert
Plausible lower
limit (years)
25th percentile
(years)
Median
(years)
75th percentile
(years)
Plausible upper
limit (years)
A 0.5 2 4 10 50
B 0.25 3 7.5 10 40
C 0.2 1 12 20 50
D 0.5 3 12 30 70
TABLE 39 Consensus quartile intervals related to incubation periods. As a central estimate, it was assumed that 25% of
incubation period would occur within each interval
Interval 1 Interval 2 Interval 3 Interval 4
0.25–2 years 2–10 years 10–20 years 20–50 years
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Susceptibility of patients to Creutzfeldt–Jakob disease: prion infection
The experts agreed that all patients would be susceptible to infection if a sufficient infectious load was
received. This differed from the previous modelling undertaken where it was assumed that proportions
of MV genotype and VV genotype at codon 129 patients were non-susceptible.
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FIGURE 24 An estimate of the distribution of incubation periods for all patients the distribution of incubation period in
years, in all patients, following infection with prion via surgery (posterior eye, brain, neuroendoscopy, and intradural
spinal surgery), genotype unknown for each patient.
TABLE 40 An illustrative alternative distribution of patients between incubation intervals
Incubation period
Interval 1 Interval 2 Interval 3 Interval 4
0.25–2 years 2–10 years 10–20 years 20–50 years
Percentage of patients 15% 35% 35% 15%
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FIGURE 25 Alternative the distribution of incubation periods, constructed by perturbing the proportions of the
population in each interval from the central estimates.
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The prevalence of Creutzfeldt–Jakob disease prions in central nervous
system tissue
The experts suggested that there is uncertainty in this parameter but that using different prevalence
distributions for different age bands, which resulted in increased prevalence in the 16- to 39-year-old
band, was not appropriate. It was commented that because sCJD increases with age but vCJD
incubation could be greatest in younger ages, using the same distribution independent of age would be
appropriate. The previous distribution used for 16- to 39 year-olds for prevalence per million people
was a beta (1.24, 2225.393). This distribution is shown in Figure 26. The blue shaded region indicates
that, given this choice of distribution, a probability of about 0.99 has been assumed that number per
million will be less than 2300. Percentiles from the distribution are shown in Table 41. The experts
commented that this may produce pessimistic numbers as the original elicitation was for all tissue, and
not just CNS tissue, but thought that the use of the distribution was reasonable, and this was assumed
appropriate for all ages. This prevalence was assumed to apply from 2005 onwards.
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FIGURE 26 The distribution chosen to represent the experts’ consensus judgements for the number of patients per million
with CJD-prions in central nervous system tissue.
TABLE 41 Percentiles from the fitted distribution for the prevalence of CJD in the central nervous system
Percentile 1st 5th 95th 99th
Prevalence (patients per million) 12 46 1547 2304
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Appendix 5 The assumed age profile of
patients receiving each operation
The assumed age profiles for patients undergoing brain surgery (conditional on survival category),posterior eye surgery and neuroendoscopy are contained in Figures 27–31.
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FIGURE 27 The assumed age profile of patients undergoing brain surgery who are assumed to have normal life expectancy.
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FIGURE 28 The assumed age profile of patients undergoing brain surgery assumed to die at 18 months.
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FIGURE 29 The assumed age profile of patients undergoing brain surgery who are assumed to have a 50% chance of
death at 18 months otherwise who are assumed to have normal life expectancy.
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FIGURE 30 The assumed age profile of patients undergoing neuroendoscopy.
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FIGURE 31 The assumed age profile of patients undergoing posterior eye operations.
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Appendix 6 The operations considered to
be at high risk
The operations considered to be high risk are contained in Tables 42–46, conditional on the type ofoperation and expected prognosis.
TABLE 42 Brain operations: patients modelled to die within 12 months
National code Operation
A01.1 Hemispherectomy
A01.2 Total lobectomy of brain
A01.3 Partial lobectomy of brain
A01.8 Other specified major excision of tissue of brain
A01.9 Unspecified major excision of tissue of brain
A02.1 Excision of lesion of tissue of frontal lobe of brain
A02.2 Excision of lesion of tissue of temporal lobe of brain
A02.3 Excision of lesion of tissue of parietal lobe of brain
A02.4 Excision of lesion of tissue of occipital lobe of brain
A02.5 Excision of lesion of tissue of cerebellum
A02.6 Excision of lesion of tissue of brain stem
A02.7 Excision of transcranial dermoid cyst
A02.8 Other specified excision of lesion of tissue of brain
A02.9 Unspecified excision of lesion of tissue of brain
A04.1 Open biopsy of lesion of tissue of frontal lobe of brain
A04.2 Open biopsy of lesion of tissue of temporal lobe of brain
A04.3 Open biopsy of lesion of tissue of parietal lobe of brain
A04.4 Open biopsy of lesion of tissue of occipital lobe of brain
A04.5 Open biopsy of lesion of tissue of cerebellum
A04.6 Open biopsy of lesion of tissue of brain stem
A04.8 Other specified open biopsy of lesion of tissue of brain
A04.9 Unspecified open biopsy of lesion of tissue of brain
A08.1 Biopsy of lesion of tissue of frontal lobe of brain NEC
A08.2 Biopsy of lesion of tissue of temporal lobe of brain NEC
A08.3 Biopsy of lesion of tissue of parietal lobe of brain NEC
A08.4 Biopsy of lesion of tissue of occipital lobe of brain NEC
A08.5 Biopsy of lesion of tissue of cerebellum NEC
A08.6 Biopsy of lesion of tissue of brain stem NEC
A08.8 Other specified other biopsy of lesion of tissue of brain
A08.9 Unspecified other biopsy of lesion of tissue of brain
NEC, not elsewhere classified.
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TABLE 43 Brain operations: patients modelled to have a 50% chance of death within 12 months, otherwise normal life
expectancy
National code Operation
A03.1 Stereotactic leucotomy
A03.2 Stereotactic ablation of tissue of thalamus
A03.3 Stereotactic ablation of tissue of globus pallidus
A03.8 Other specified stereotactic ablation of tissue of brain
A03.9 Unspecified stereotactic ablation of tissue of brain
A05.1 Drainage of abscess of tissue of brain
A05.2 Evacuation of haematoma from temporal lobe of brain
A05.3 Evacuation of haematoma from cerebellum
A05.4 Evacuation of intracerebral haematoma NEC
A05.8 Other specified drainage of lesion of tissue of brain
A05.9 Unspecified drainage of lesion of tissue of brain
A07.1 Open division of tissue of brain
A07.2 Removal of foreign body from tissue of brain
A07.3 Exploration of tissue of brain
A07.4 Excision of abscess of tissue of brain
A07.6 Complete callosotomy
A07.7 Partial callosotomy
A07.8 Other specified other open operations on tissue of brain
A10.2 Aspiration of abscess of tissue of brain
A10.3 Aspiration of haematoma of tissue of brain
A10.4 Aspiration of lesion of tissue of brain NEC
A10.5 Puncture of tissue of brain NEC
A10.8 Other specified other operations on tissue of brain
NEC, not elsewhere classified.
TABLE 44 Brain operations: patients modelled to have normal life expectancy
National code Operation
A06.1 Excision of basal encephalocele
A06.2 Excision of occipital encephalocele
A06.3 Excision of syncipital encephalocele
A06.4 Repair of post-traumatic meningoencephalocele
A06.8 Other specified other excision of lesion of tissue of brain
A06.9 Unspecified other excision of lesion of tissue of brain
A09.1 Implantation of neurostimulator into brain
A09.2 Maintenance of neurostimulator in brain
A09.3 Removal of neurostimulator from brain
A09.4 Operation on neurostimulator in brain NEC
A09.5 Insertion of neurostimulator electrodes into the brain
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TABLE 44 Brain operations: patients modelled to have normal life expectancy (continued )
National code Operation
A09.8 Other specified neurostimulation of brain
A09.9 Unspecified neurostimulation of brain
A11.1 Placement of depth electrodes for electroencephalography
A11.2 Placement of surface electrodes for electroencephalography
A11.3 Monitoring of pressure in tissue of brain
A11.4 Cortical mapping
A11.8 Other specified operations on tissue of brain
A12.1 Ventriculocisternostomy
A12.2 Creation of ventriculovascular shunt
A12.3 Creation of ventriculopleural shunt
A12.4 Creation of ventriculoperitoneal shunt
A12.5 Creation of subcutaneous cerebrospinal fluid reservoir
A12.8 Other specified creation of connection from ventricle of brain
A13.1 Maintenance of proximal catheter of cerebroventricular shunt
A13.2 Maintenance of distal catheter of cerebroventricular shunt
A13.3 Insertion of antisyphon device into cerebroventricular shunt
A13.4 Renewal of valve of cerebroventricular shunt
A13.8 Other specified attention to component of connection from ventricle of brain
A13.9 Unspecified attention to component of connection from ventricle of brain
A14.1 Renewal of cerebroventricular shunt
A14.2 Revision of cerebroventricular shunt NEC
A14.3 Removal of cerebroventricular shunt
A14.4 Irrigation of cerebroventricular shunt
A14.5 Attention to cerebroventricular shunt NEC
A14.8 Other specified other operations on connection from ventricle of brain
A14.9 Unspecified other operations on connection from ventricle of brain
A16.1 Open drainage of ventricle of brain NEC
A16.8 Other specified other open operations on ventricle of brain
A20.1 Drainage of ventricle of brain NEC
A20.2 Ventriculography of brain
A20.3 Monitoring of pressure in ventricle of brain
A20.8 Other specified other operations on ventricle of brain
A20.9 Unspecified other operations on ventricle of brain
A22.1 Drainage of subarachnoid space of brain
A22.2 Puncture of cistern of brain
A22.3 Isotopic cisternography
A22.8 Other specified operations on subarachnoid space of brain
A25.1 Intracranial transection of optic nerve (ii)
A25.2 Intracranial transection of oculomotor nerve (iii)
A25.3 Intracranial transection of trigeminal nerve (v)
A25.4 Intracranial transection of facial nerve (vii)
continued
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TABLE 44 Brain operations: patients modelled to have normal life expectancy (continued )
National code Operation
A25.5 Intracranial transection of acoustic nerve (viii)
A25.6 Intracranial transection of glossopharyngeal nerve (ix)
A25.7 Intracranial transection of vagus nerve (x)
A25.8 Intracranial transection of specified cranial nerve NEC
A26.1 Intracranial destruction of optic nerve (ii)
A26.2 Intracranial destruction of oculomotor nerve (iii)
A26.3 Intracranial destruction of trigeminal nerve (v)
A26.4 Intracranial destruction of facial nerve (vii)
A26.6 Intracranial destruction of glossopharyngeal nerve (ix)
A26.8 Intracranial destruction of specified cranial nerve NEC
A26.9 Unspecified other intracranial destruction of cranial nerve
A29.1 Excision of lesion of optic nerve (ii)
A29.8 Excision of lesion of specified cranial nerve NEC
A29.9 Unspecified excision of lesion of cranial nerve
A31.3 Intracranial stereotactic neurolysis of trigeminal nerve (v)
A31.5 Intracranial stereotactic neurolysis of acoustic nerve (viii)
A31.8 Intracranial stereotactic neurolysis of specified cranial nerve NEC
A32.1 Decompression of optic nerve (ii)
A33.1 Introduction of neurostimulator into cranial nerve
A33.2 Maintenance of neurostimulator in cranial nerve
A33.3 Removal of neurostimulator from cranial nerve
A33.4 Insertion of neurostimulator electrodes into the cranial nerve
A33.8 Other specified neurostimulation of cranial nerve
A33.9 Unspecified neurostimulation of cranial nerve
A34.1 Exploration of optic nerve (ii)
A34.3 Exploration of trigeminal nerve (v)
A34.4 Exploration of facial nerve (vii)
A34.5 Exploration of acoustic nerve (viii)
A34.7 Exploration of vagus nerve (x)
A34.8 Exploration of specified cranial nerve NEC
A34.9 Unspecified exploration of cranial nerve
A36.8 Other specified other operations on cranial nerve
A38.1 Extirpation of lesion of meninges of cortex of brain
A38.2 Extirpation of lesion of meninges of sphenoidal ridge of cranium
A38.3 Extirpation of lesion of meninges of subfrontal region of brain
A38.4 Extirpation of lesion of meninges of parasagittal region of brain
A38.5 Extirpation of lesion of falx cerebri
A38.6 Extirpation of lesion of tentorium cerebelli
A38.8 Other specified extirpation of lesion of meninges of brain
A38.9 Unspecified extirpation of lesion of meninges of brain
A39.1 Repair of meningoencephalocele
A39.2 Repair of dura of anterior fossa of cranium
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TABLE 44 Brain operations: patients modelled to have normal life expectancy (continued )
National code Operation
A39.3 Repair of dura of middle fossa of cranium
A39.4 Repair of dura of posterior fossa of cranium
A39.5 Repair of dura of vault of cranium
A39.8 Other specified repair of dura
A39.9 Unspecified repair of dura
A41.1 Evacuation of subdural haematoma
A41.2 Drainage of abscess of subdural space
A41.8 Other specified drainage of subdural space
A41.9 Unspecified drainage of subdural space
A42.1 Creation of anastomosis of dura
A42.2 Biopsy of lesion of meninges of brain
A42.8 Other specified other operations on meninges of brain
A43.1 Extirpation of lesion of meninges of skull base
A43.2 Extirpation of lesion of meninges of skull clivus
A43.8 Other specified other extirpation of lesion of meninges of brain
A43.9 Unspecified other extirpation of lesion of meninges of brain
A44.1 Chordectomy of spinal cord
A44.2 Extirpation of lesion of spinal cord NEC
A44.3 Excision of lesion of intradural intramedullary spinal cord
A44.4 Excision of lesion of extradural spinal cord
A44.5 Excision of lesion of intradural extramedullary spinal cord
A44.8 Other specified partial extirpation of spinal cord
A44.9 Unspecified partial extirpation of spinal cord
A45.1 Stereotactic chordotomy of spinal cord
A45.2 Open chordotomy of spinal cord NEC
A45.3 Myelotomy of spinal cord
A45.4 Open biopsy of lesion of spinal cord
A45.5 Removal of foreign body from spinal cord
A45.6 Open aspiration of lesion of spinal cord
A45.8 Other specified other open operations on spinal cord
A47.1 Needle destruction of substantia gelatinosa of cervical spinal cord
A47.2 Radiofrequency controlled thermal destruction of spinothalamic tract
A47.3 Percutaneous chordotomy of spinal cord
A47.8 Other specified other destruction of spinal cord
A48.1 Biopsy of lesion of spinal cord NEC
A48.2 Aspiration of lesion of spinal cord
A48.3 Insertion of neurostimulator adjacent to spinal cord
A48.4 Attention to neurostimulator adjacent to spinal cord NEC
A48.6 Removal of neurostimulator adjacent to spinal cord
A48.7 Insertion of neurostimulator electrodes into the spinal cord
A48.8 Other specified other operations on spinal cord
continued
DOI: 10.3310/hta24110 Health Technology Assessment 2020 Vol. 24 No. 11
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
141
TABLE 44 Brain operations: patients modelled to have normal life expectancy (continued )
National code Operation
A49.1 Freeing of spinal tether NEC
A49.2 Closure of spinal myelomeningocele
A49.3 Closure of spinal meningocele
A49.4 Complex freeing of spinal tether
A49.8 Other specified repair of spina bifida
A49.9 Unspecified repair of spina bifida
A51.1 Extirpation of lesion of meninges of spinal cord
A51.2 Freeing of adhesions of meninges of spinal cord
A51.3 Biopsy of lesion of meninges of spinal cord
A51.8 Other specified other operations on meninges of spinal cord
A51.9 Unspecified other operations on meninges of spinal cord
A53.1 Cerebrospinal syringostomy
A53.3 Creation of syringoperitoneal shunt
A57.1 Extirpation of lesion of spinal nerve root
A57.6 Reimplantation of spinal nerves into spinal cord
A57.8 Other specified operations on spinal nerve root
A57.9 Unspecified operations on spinal nerve root
B01.1 Transethmoidal hypophysectomy
B01.2 Trans-sphenoidal hypophysectomy
B01.4 Transcranial hypophysectomy
B01.8 Other specified excision of pituitary gland
B02.2 Implantation of radioactive substance into pituitary gland
B04.1 Excision of lesion of pituitary gland
B04.2 Biopsy of lesion of pituitary gland
B04.3 Decompression of pituitary gland
B04.4 Exploration of pituitary gland
B04.5 Operations on pituitary stalk
B04.8 Other specified other operations on pituitary gland
B06.1 Excision of pineal gland
B06.8 Other specified operations on pineal gland
B06.9 Unspecified operations on pineal gland
L33.1 Excision of aneurysm of cerebral artery
L33.2 Clipping of aneurysm of cerebral artery
L33.3 Ligation of aneurysm of cerebral artery NEC
L33.4 Obliteration of aneurysm of cerebral artery NEC
L33.8 Other specified operations on aneurysm of cerebral artery
L34.1 Reconstruction of cerebral artery
L34.2 Anastomosis of cerebral artery
L34.3 Open embolectomy of cerebral artery
L34.4 Open embolisation of cerebral artery
L34.8 Other specified other open operations on cerebral artery
NEC, not elsewhere classified.
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TABLE 45 Neuroendoscopy operations
National code Operation
A17.1 Endoscopic extirpation of lesion of ventricle of brain
A17.2 Endoscopic third ventriculostomy
A17.8 Other specified therapeutic endoscopic operations on ventricle of
brain
A17.9 Unspecified therapeutic endoscopic operations on ventricle of brain
A18.1 Diagnostic endoscopic examination of ventricle of brain and biopsy of
lesion of ventricle of brain
A18.9 Unspecified diagnostic endoscopic examination of ventricle of brain
TABLE 46 Posterior eye operations
National code Operation
C85.1 Retinopexy using cryotherapy
C84.5 Drainage of subretinal fluid through retina
C84.6 Retinotomy NEC
C89.2 Injection of steroid into posterior segment of eye
C85.5 Retinopexy NEC
C84.1 Epiretinal dissection
C85.2 Retinopexy using diathermy
C89.3 Injection of therapeutic substance into posterior segment of eye NEC
C84.8 Other specified other operations on retina
C82.8 Other specified destruction of lesion of retina
C89.1 Insertion of sustained release device into posterior segment of eye
C85.8 Other specified fixation of retina
C01.1 Exenteration of orbit
C84.3 Biopsy of lesion of retina
C84.2 Excision of lesion of retina NEC
C84.9 Unspecified other operations on retina
C01.2 Enucleation of eye
C01.3 Evisceration of eye
C82.9 Unspecified destruction of lesion of retina
C89.8 Other specified operations on posterior segment of eye
C83.3 Limited macular translocation
C85.4 Retinopexy using tissue adhesive
C85.9 Unspecified fixation of retina
C01.8 Other specified excision of eye
C01.9 Unspecified excision of eye
C85.3 Retinopexy using mechanical tacks
C89.9 Unspecified operations on posterior segment of eye
C88.9 Unspecified destruction of subretinal lesion
NEC, not elsewhere classified.
DOI: 10.3310/hta24110 Health Technology Assessment 2020 Vol. 24 No. 11
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Stevenson et al. under the terms of a commissioning contract issued by the Secretary of State
for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
143
Appendix 7 The calibration methodology
Notation
We define the following:
l θ – the simulation model inputs. The true values of these inputs are uncertain; following various
expert elicitation sessions, we have constructed a prior distribution p(θ) for θ.
l T(i) – the number of transmissions of CJD via surgery that result in clinical symptoms in age category
i, over the period 2005–18. The age categories are i = 1: ≤ 59 years; i = 2: 60–79 years; and i = 3:
≥ 80 years. We write T = [T(1),T(2),T(3)].
l R(i) – the number of transmissions of CJD via surgery that result in clinical symptoms, in age category
i, over the period 2005–18, that resulted in deaths recorded as being due to CJD. Note that for each
i, we have R(i) ≤ T(i).
l C – the data available for calibrating the simulation model. We know that over the period 2005–18,
there were 15 recorded deaths from CJD, where the individuals were known to have had surgery.
Hence, any number between 0 and 15 of these individuals could have acquired CJD from surgery.
The age categories for these 15 recorded deaths are unavailable to us, so the calibration data C is
the observation of the event that:
0≤R(1) + R(2) + R(3) ≤15: (3)
l ϕ(i) – the percentage of patients, in age category i, whose death was due to CJD, that are
misdiagnosed as having died from another neurodegenerative disease, since 2005. These
percentages are unknown, and we have elicited probability distributions for them. Note that we
treat these as elicited ‘posterior distributions’ p(ϕ(i)|C).
We suppose that:
R(i) |T(i), ϕ(i) ∼Binomial½T(i), 1−ϕ(i) (4)
We collect the ϕ(i) parameters into vector ϕ and write:
ϕ = ½ϕ(1),ϕ(2),ϕ(3). (5)
M(i) the maximum number of transmissions of CJD via surgery that result in clinical symptoms, in age
category i, over the period 2005–2018, that resulted in deaths recorded as being due to CJD. We have:
M(1) +M(2) +M(3) = 15, (6)
and that:
R(i) ≤M(i), (7)
for i = 1, 2, 3. Defining:
M = ½M(1),M(2),M(3), (8)
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we make the assumption that:
M|C∼Multinomial 15; 1
3
, 1
3
, 1
3
 
, (9)
that is, that each of the 15 potential cases were equally likely to be in any age category. This is likely
to give too much weight to the oldest age category, but the assumption is conservative in the sense
of minimising the risk of underestimating numbers of transmissions of CJD via surgery that result in
clinical symptoms; patients in the oldest age category are judged the most likely to be misdiagnosed as
having died from another neurodegenerative disease. Allocating a higher number of the 15 cases into
the oldest age category will ‘permit’ higher numbers of transmissions of CJD via surgery that result in
clinical symptoms, as more can be undetected.
‘S’ and ‘Y’ can be defined as follows:
l S = (s1, . . . s27) – a vector of scenario values for each surgical centre. Two separate analyses are
performed. In the first, each si is coded as an integer from 1 to 3 inclusive, and in the second, each si
is coded as an integer from 4 to 6 inclusive. These correspond to the six scenarios S1 to S6 defined
in Chapter 3, Categoristation of surgical units. (The P96 group are infectious from birth in scenarios S1
to S3 only.)
l Y – the number of discounted QALYs that would be lost, as a result of transmission of CJD via
surgery that result in clinical symptoms, due to surgery that took place between 2019 and 2023.
Estimating the number of quality-adjusted life-years lost owing to surgically
transmitted Creutzfeld–Jakob disease caused by an operation between
2019 and 2023
The aim is to draw a sample of values Y1, . . . ,YN from the probability distribution of p(Y:C), from which
we can provide an estimate of the expected value E(Y:C). This distribution can be expressed as:
p(Y |C) = ∫ p(Y |C, θ)p(θ|C)dθ. (10)
Hence, we can obtain a sample Y1, . . . ,YN by obtaining a sample θ1, . . . , θN from p(θ|C), and then
sampling Y1 from p(Y|θi,C). In essence, we are:
1. Calibrating the simulation model by updating the model inputs from p(θ) to p(θ|C) – we update what
we know about the model inputs in light of the calibration data C.
2. Running the simulation model forward to predict Y, at input values θ sampled from p(θ|C) – input
values identified to be consistent with the calibration data C.
Sampling from p(θ|C)
The method we use to sample from p(θ|C) is known as approximate Bayesian computation (ABC). This
is a standard technique when we have a simulation model that can generate a random value of C given
an input θ, but no formula can be obtained for the likelihood function p(C|θ). The basic ABC algorithm is
as follows:
1. Generate one random value θ* from the elicited prior p(θ).
2. Given the model input θ*, run the model, and observe whether or not the event C has occurred
within the model simulation.
3. If the event C has occurred within the model simulation, accept θ* as a valid draw from p(θ|C).
Otherwise, reject, and return to step 1. Repeat until a candidate value θ* is accepted.
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The process is repeated as many times as required to produce a sample θ1, . . . , θN from p(θ|C). For each
accepted θ value, the model can be run forward to produce the desired sample Y1, . . . ,YN. We refer to
this as the ‘simple rejection ABC algorithm’.
Implementing the simple rejection approximate Bayesian computation algorithm
The output quantities produced by the simulation model are T(1), T(2), T(3). To determine from these
whether or not the event C has occurred, we additionally sample M, S and ϕ, so that we are in effect
sampling from the joint distribution p(θ, M, S, ϕ|C). We write:
p(θ,M, S,ϕjC) = p(M,ϕjC)p(θ, SjM,ϕ,C), (11)
and we assume:
p(M,ϕ|C) = p(M|C)p(ϕ|C). (12)
We have the multinomial distribution for M|C and the elicited distribution for ϕ|C, from which we can
simulate values easily.
Note that:
p(θ, S|M,ϕ,C) = p(θ, S|M,ϕ), (13)
since given:
M = ½M(1),M(2),M(3), (14)
we already know C – the total of M(1), M(2), M(3).
The ABC algorithm is then, in effect, used to sample from p(θ, S|M, ϕ), where the ‘prior’ distribution is
p(θ, S|ϕ) and we assume independence between θ, S and ϕ:
p(θ, S|ϕ) = p(θ|ϕ)p(S|ϕ) = p(θ)P(S) (15)
1. Sample θ* from p(θ|ϕ) = p(θ).
2. Sample S* from p(S|ϕ) = p(S).
3. Run the simulation model to generate outputs T.
4. Given the outputs T, sample R, where:
R(i) |T(i), ϕ(i) ∼Binomial½T(i), 1−ϕ(i). (16)
5. Observe whether or not, within the simulation model, the event:
R(i) ≤M(i), (17)
for i = 1, 2, 3 has occurred. If it has, we accept θ*, S* as a sample from p(θ,S|M,ϕ). Otherwise, we
reject and return to step 1.
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Estimation of E(Y|C)
Applying the ABC algorithm would give a sample θ(1), . . . , θ(M). Running the simulation model forward at
these inputs only, we obtain an independent sample Y(1), . . . , Y(M) from the distribution of p(Y|C), from
which we can estimate E(Y|C) via:
Y =
1
M
∑M
i=1Y
(i), (18)
and an approximate 95% CI for E(Y|C) can be calculated as:
Y±2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
S2Y /M
q
, (19)
with:
S2Y =
1
M−1
∑M
i=1½Y
(i) − Y
2
. (20)
We actually use a slightly different estimator for E(Y|C) which has a lower variance, but we retain the
CI given above. Note also that there is a computational bottleneck in step 3 of this algorithm; running
the model to observe whether or not C has occurred can be computationally expensive.
Speeding up the computation
We can speed up the computation by noting that, in some cases, it will not be necessary to simulate
outcomes for all 27 surgical centres. Based on the number of simulated transmissions of CJD via surgery
that result in clinical symptoms for a single surgical centre, an upper bound can be placed on the
probability that the parameter value will ultimately be accepted. For example, if there were T(1) = 65
simulated transmissions of CJD via surgery that result in clinical symptoms in the age < 60 years
category, no more than 50 of these could result in undetected CJD cases, and the probability of this
occurring would be of the order of 10–9; the final probability of acceptance could be no more than this,
regardless of what other events are simulated. (Under such a scenario, almost certainly, there would be
transmissions of CJD via surgery that result in clinical symptoms in the other age groups, which would
reduce the probability of acceptance by further orders of magnitude.)
Based on an understanding of the model’s behaviour and some preliminary analysis of the model outputs,
we can determine parameter combinations that are guaranteed to be rejected. Specifically, we consider
the term:
γ = 10θM × θR × θP, (21)
where θM is the mean infectious titre (in log-terms) × log-reduction in infectivity associated with the
first autoclaving cycle × log-reduction associated with detergent on the first cycle; θR is the residual
mass on an instrument × (1– the proportion of residual mass transferred to the patient); θP is the
proportion of asymptomatic individuals with CJD prions in their tissue.
2000 parameter sets θ1, . . . , θ2000 were drawn from the appropriate distributions. Y1, . . . , Y2000 was
calculated in each case, and 12 RN streams (corresponding to 12 surgical centres) were simulated for
each of the following scenarios: S1, S2 and S3. We identified that for γ > e12, the final probability of
acceptance would be negligible (too many transmissions of CJD via surgery that result in clinical
symptoms would be simulated), and so the corresponding parameter set could be rejected without
running the full simulation to produce R.
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For γ > e12, it would still be possible for the candidate θ to be rejected. In other cases, we can be certain
that a candidate value θ* will be rejected, based on a ‘partial’ simulation run: we do not have to simulate
the full calibration output R. We used the following approach:
1. Generate a candidate value θ*, for which γ > e12.
2. Under scenario S3, first simulate the number of transmissions of CJD via surgery that result in
clinical symptoms for six RN streams (six surgical centres).
3. If the total number of transmissions of CJD via surgery that result in clinical symptoms for the first
six RN streams for the aged < 60 years category exceeds 36, reject θ* and return to step 1.
4. Continue simulating RN streams in batches: reject θ* if in streams 7 to 13 the rejection threshold
was increased to 40; to 45 for RN streams 14 to 17; to 55 for RN streams 18 to 23; and 66 for RN
streams 24 to 27.
A weighted ABC scheme
Instead of using the estimator Y , we can instead calculate a weight wi: the probability that the model
will simulate the event T to have occurred. The estimate for E(Y|C) will then be of the form:
E^(Y |C) =∑509
i=1
~wiY i, (22)
with:
~wi =
wi
∑509
i=1wi
. (23)
This approach instead generates (weighted) samples directly from the marginal distribution p(θ|T),
rather than joint samples from p(θ, M, S, ϕ|T). Each weight wi is estimated using the following Monte
Carlo procedure. For each candidate value θi, the model simulates numbers of transmissions of CJD via
surgery that result in clinical symptoms in each age band, under all scenarios for each surgical centre.
The transmissions of CJD via surgery that result in clinical symptoms corresponding to the scenarios in
S can then be selected.
For k = 1, . . . , 100,000:
1. Randomly sample S from its prior distribution, and denote this value by Sk. Given the model
simulation run for input value θj and scenario set Sk, extract the number of transmissions of CJD
via surgery that result in clinical symptoms in each age band. Denote these by:
T(i)j, k for i = 1, 2, 3. (24)
2. Randomly sample M from its multinomial distribution. Denote the sampled values by:
M(1)k ,M
(2)
k ,M
(3)
k . (25)
3. Randomly sample ϕ(1),ϕ(2),ϕ(3) from the three elicited prior distributions. Denote these values by:
ϕ
(1)
k ,ϕ
(2)
k ,ϕ
(3)
k . (26)
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4. Given the sampled values in step 2, we now have:
R(i) |T(i)j, k, ϕ
(i)
k ∼Binomial½T
(i)
j, k, 1−ϕ
(i)
k . (27)
5. Compute, from the corresponding binomial distributions in step 3:
w j, k =∏
3
i=1Pr½R
(i) ≤M(i)k . (28)
6. The weight wi is estimated as:
w^ j =
1
100,000
∑100,000
k=1 w j, k . (29)
Implementation
We started with a sample of 2000 parameter values. Applying the screening based on the calculated
γ1, . . . , γ2000 values, we obtained a set θ1, . . . , θ509 that were not rejected. The weighted ABC algorithm
was used to estimate E(Y|C), and the (conservative) CI using the simple rejection ABC algorithm was
calculated for this estimate. Applying the simple rejection ABC algorithm reduces the sample size from
509 candidate parameter values to 119, when it was assumed that the P96 group could be infectious
from birth, and 134, when it was assumed that the P96 group were not infectious from birth; the
estimator Y would be based on 119 and 134 model runs, respectively.
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